# Patent

## Title
Diagnostic autoantibody profiles for the detection and diagnosis of neurodegenerative diseases

## Abstract

The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles.

## Background
CROSS-REFERENCE TO RELATED APPLICATION
This application is the U.S. National Phase of International Patent Application Serial No. PCT/US11/30883, filed on Apr. 1, 2011, which claims the benefit of U.S. Provisional Application Nos. 61/334,466 filed May 13, 2010 and 61/444,932 filed Feb. 21, 2011, the disclosures of which are incorporated herein by reference in their entireties.


BACKGROUND OF THE INVENTION
An autoantibody is an antibody manufactured by an individual's immune system that is directed against an antigen of the individual's own proteins. Antibodies are normally produced in response to a foreign protein or substance within the body, typically a pathogen, which is an infectious organism. Normally, the immune system is able to recognize and ignore the body's own cells and not overreact to non-threatening substances in the environment, such as foods. Sometimes, however, the immune system ceases to recognize one or more of the body's normal constituents as “self”, leading to production of autoantibodies. These autoantibodies attack the body's own cells, tissues, and/or organs, causing inflammation and damage.
Serum autoantibodies have been implicated in a wide variety of neurological diseases and syndromes. Neuron-binding autoantibodies have been detected in sera from individuals exhibiting obsessive compulsive disorder, Sydenham's chorea, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (“PANDAS”), and Hashimoto's encephalopathy. Schizophrenia has also been linked to the appearance of autoantibodies, including several directed against neuronal surface receptors. Systemic lupus erythematosus (“SLE”), known to be caused by antinuclear antibodies, appears to have cognitive and memory loss components consistent with the presence of a subset of anti-DNA antibodies that cross-react with the N-methyl-D-aspartate receptor (“NMDAR”). Also, brain-reactive antibodies in mothers of autistic children elicit behavioral abnormalities in progeny when administered to pregnant mammals.
Moreover, among neurodegenerative diseases, autoantibodies have been found in Parkinson's disease, Autism spectrum disorders, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, and Alzheimers disease (“AD”). In the case of AD, there have been numerous reports of patients having high titers of autoantibodies to both non-brain and brain-associated targets, including neuron-binding autoantibodies. Moreover, several specific autoantibody targets have been identified, including aldolase, heavy neurofilament subunit, histone, tubulin, glial fibrillary acid protein, and S-100.
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder of the elderly that is highlighted by a dramatic reduction of memory and cognition and linked to loss of neurons and synapses (Selkoe (2002) Science 298, 789-91). Additional key pathological features include the deposition of amyloid beta (Aβ), especially the 42-amino acid peptide (Aβ42), within neurons, amyloid plaques and in the walls of brain blood vessels, as well as the appearance of neurofibrillary tangles, glial activation and widespread inflammation (Schwab et al. (2008) J Alzheimers Dis 13, 359-69; Thal et al. (2008) Acta Neuropathol 115, 599-609; Weisman et al. (2006) Vitam Horm 74, 505-30). Aβ42 deposition within neurons is initiated early in the course of the disease, precedes amyloid plaque and tangle formation, and temporally and spatially coincides with loss of synapses in human AD and transgenic mouse brains (D'Andrea et al. (2001) Histopathology 38, 120-134; Nagele et al. (2002) J Neurosci 110, 199-211; Gouras et al. (2000) Am J Patho. 156, 15-20). This has led to the proposal that the gradual growth of Aβ deposits may progressively impair the ability of neurons to support their extensive dendritic arbors, thereby contributing to early synaptic loss that eventually becomes apparent through telltale symptoms.
Studies have reported the presence of immunoglobulin (Ig)-immunopositive neurons in histological sections of post-mortem AD brains, which were only rarely observed in comparable brain regions of non-demented, age-matched controls (Stein et al. (2002) J Neuropathol Exp Neurol 61, 1100-8; Bouras et al. (2005) Brain Res Brain Res Rev 48, 477-87; D'Andrea (2003) Brain Res Brain Res Rev 982, 19-30). The presence of specific brain-reactive autoantibodies in the serum of AD patients has also been reported. (Bouras et al. (2005) Brain Res Brain Res Rev 48, 477-87; Kulmala et al. (1987) Exp Aging Res 13, 67-72; Mecocci et al. (1993) Biol Psychiatry 34, 380-5; Mecocci et al. (1995) J Neuroimmunol 57, 165-70; Weksler et al. (2002) Exp Gerontol 37, 971-979).
Autism spectrum disorders (“ASDs”) are a group of disorders in brain development that includes autism, Asperger's syndrome, Rett's disorder, and childhood disintegrative disorder. ASDs are characterized by impairments in social behavior and communication that are usually expressed within the first 36 months of childhood (American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (2000)). A substantial fraction (20-30%) of autism patients undergo a period of autistic regression during which they experience a loss of previously acquired milestones in language and behavioral skills (Fombonne (2003) JAMA 289, 87-89). Inexplicably, the prevalence of ASD has recently increased dramatically, a finding not due to improved diagnostics, but rather suggesting some environmental causal factor(s). ASDs now affect 1:150 children, and the etiology is largely unknown but likely to be multifactorial (Fombonne, 2003).
Neuropathological and neuroimaging studies of autistic patients have reported increased brain size and weight (Bailey et al. (1998) Psychol Med 25, 63-77; Kemper and Bauman (1998) Neurol Clinic 1, 175-87; Palmen et al. (2004) Brain 127, 2572-2583). Many studies of autistic brains have reported an overall reduction in neuron size and an increased neuron packing density, especially in the hippocampus, subiculum and amygdala (Kemper and Bauman, 1993).
ASDs have been linked to specific brain abnormalities. Neurological observations and neuroimaging studies have provided evidence that many brain regions can be affected in autism, including the cerebellum, cerebral cortex, amygdala, hippocampus, basal ganglia and the brain stem (Akshoomoff et al., 2002; Acosta and Pearl (2004) Semin Pediatr Neurol 11, 205-213). Cerebellar abnormalities are also common in ASD, hallmarked by a scarcity of Purkinje and granule cells (Courchesne et al., 2001).
Autoimmunity and autoantibodies are involved in the pathogenesis of ASDs (Ashwood et al. (2006) J Leukocyte Biol 80, 1-11; Wills et al. (2007) Ann N.Y. Acad Sci 1107, 79-91; Zimmerman et al. (2007) Brain Behav Immun 21, 351-357). The binding of autoantibodies to neurons can disrupt the normal pattern of neurodevelopment at critical stages. Autoantibodies reactive to the brain have been reported in autistic children, and several autoimmune factors including brain-specific autoantibodies, impaired lymphocyte function, abnormal cytokine regulation, and viral associations have been implicated (Singh and Rivas (2004) Neurosci Lett 355, 53-56). For example, Singh and Rivas (2004) have shown that the serum of autistic children contains brain-specific autoantibodies. In a study of 68 autistic children at 4-12 years of age, antibodies to the caudate nucleus, cerebral cortex and cerebellum were detected in 49%, 18% and 9%, respectively, of autistic children, but not in normal children. Another study has shown that children with Tourette syndrome possess anti-striatal antibodies, and influsion of these antibodies into the rat striatum caused neuronal dysfunction similar to Tourette syndrome (Hallet et al. (2000) J Neuroimmunol 111, 195-202). Other anti-brain antibodies have also been found in autistic patients, including antibodies to serotonin receptor, myelin basic protein, axon filament protein, cerebellar neurofilaments, nerve growth factor, brain endothelial proteins and antibodies directed against other unidentified brain proteins.
A strong link between the presence of anti-neuronal autoantibodies and neurological disease has been shown in children in cases following streptococcal infections, such as in obsessive compulsive disorder (OCD), Sydenham's chorea, Tourette syndrome, PANDAS, and paraneoplasia, and in elderly patients with SLE that show both cognitive and memory loss (Swedo et al. (1989) Am J Psychiatry 154, 110-2; Kalume et al. (2004) J Neurosci Res 77, 82-89; Tanaka et al. (2004) J Neurological Sci 217, 25-30). DeGeorgio et al. (2001) Nature Med 11, 1189-1193 and Kowal et al. (2004) Immunity 21, 179-188, report that a subset of anti-DNA antibodies in SLE patients cross-reacts with the NMDA (N-methyl-D-aspartate) subtype of glutamate receptors (NR2a and NR2b) by means of molecular mimicry and induces neuronal injury and death both in vivo and in vitro.
SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a method for detecting neurodegenerative disease diagnostic autoantibodies in a subject comprising obtaining a biological sample from the subject, and performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample.
In another embodiment, the present invention provides a method for diagnosing a neurodegenerative disease in a subject comprising obtaining a biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and diagnosing said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.
In another embodiment, the present invention provides a method of identifying a subject at risk for developing a neurodegenerative disease comprising obtaining a biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and identifying the subject as at risk for developing said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.
In another embodiment, the present invention provides a method of generating a subject-specific, neurodegenerative disease diagnostic autoantibody profile comprising obtaining a biological sample from a subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and generating a subject-specific neurodegenerative disease diagnostic autoantibody profile of the disease diagnostic autoantibodies present in the sample.
Another embodiment of this invention provides a substrate on which one or more autoantigens that are specific for one or more neurodegenerative disease diagnostic autoantibodies are immobilized.
Another embodiment of this invention provides a microarray comprising a substrate on which one or more autoantigens that are specific for one or more neurodegenerative disease diagnostic autoantibodies are immobilized.
Another embodiment of this invention provides a kit for detecting neurodegenerative disease diagnostic autoantibodies.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graphical representation of a diagnostic logic exemplified in Example 8.



DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, it has been discovered that autoantibodies, also known as self-reactive antibodies, are both abundant and ubiquitous in human sera, regardless of age or the presence or absence of disease. Some are brain-reactive; others are reactive to targets in other organs throughout the body. Although some autoantibodies may be vestiges of past diseases and immunological activity, it has been discovered in accordance with the present invention that many autoantibodies are also present in the blood and cerebrospinal fluid as a result of existing or ongoing diseases. It is this latter group that is useful for the early detection and diagnosis of existing diseases.
It has been discovered herein that the presence of active neurodegenerative disease, including both long- and short-term diseases, causes the production and release of cellular products as a result of cell damage related to ongoing pathology, some of which are both cell type- and organ-specific. These released cellular products (many of which are proteins), their break-down fragments and disease-related post-translational modifications enter the blood and lymph circulation, act as antigens, and elicit an immune response. This immune response leads to the production and appearance of a relatively large number of self-reactive autoantibodies in the blood. Cells throughout the body share a vast number of proteins in common, but only a relatively small subset of autoantibodies are specifically reactive to the cells, tissues and organs involved in a particular disease. It has been discovered in accordance with the present invention that this response leads to a disease-specific autoantibody profile that is characteristic for each disease and the specific cell types involved. In addition, in individuals with concurrent diseases, it has been discovered herein that a specific pattern of autoantibodies reflects each of these concurrent, ongoing disease processes.
Additionally, it has been discovered herein that autoantibodies capable of binding to brain-specific targets, including neurons and their supportive glial cells, are common in the blood; in fact they appear to be ubiquitous. Binding of these autoantibodies to neurons and/or glial cells in the brain is harmful to these cells and the functions in which they participate. It not only disrupts normal cellular functions, but also eventually leads to neuron and glial cell death and permanent loss from the brain.
Once inside the brain tissue, autoantibodies are free to bind selectively to any cells within the brain that possess and display the proper target antigens on their surfaces. If the autoantibody target is particularly abundant on a cell surface, the binding of many molecules of autoantibody can crosslink and immobilize this protein. If the target is an important receptor, the target and the cell can be rendered nonfunctional, leading to more global brain functional impairments. When the target cells are neurons, autoantibody binding may lead to neuronal dysfunction that can eventually manifest itself as behavioral, cognitive, memory and motor impairments. When the target is a glial cell that supports neurons, the loss of this support may indirectly compromise the function of neurons. Thus, specific brain-reactive autoantibodies in human sera can put one at risk for specific neurodegenerative diseases. The invention described herein provides a method for the detection of these autoantibodies in human biological samples.
Thus in one embodiment, the present invention provides a method of identifying a subject at risk for developing a neurodegenerative disease comprising obtaining an immunoglobulin-containing biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and identifying the subject as at risk for developing said neurodegenerative disease if one or more of the disease diagnostic autoantibodies is present.
In another embodiment of this invention provides a method for detecting neurodegenerative disease diagnostic autoantibodies in a subject comprising obtaining an immunoglobulin-containing biological sample from the subject, and performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample.
In a preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (“PANDAS”), Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a preferred embodiment of the invention, the subject is a human.
In a preferred embodiment of the invention, the immunoglobulin-containing biological sample is serum, whole blood, CSF, saliva, or sputum. A blood sample may be obtained by methods known in the art including venipuncture or a finger stick. CSF may be obtained by methods known in the art including a lumbar spinal tap. To obtain serum from blood, a sample of blood is received and centrifuged at a speed sufficient to pellet all cells and platelets, and the serum to be analyzed is drawn from the resulting supernatant. Sputum and saliva samples may be collected by methods known in the art. The biological samples may be diluted with a suitable buffer.
In a preferred embodiment of the invention, the assay used to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample is performed by contacting the biological sample with one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody under conditions that allow an immunocomplex of the autoantigen and the autoantibody to form, and detecting the presence of the immunocomplex.
Autoantibodies that are specific for a neurodegenerative disease diagnostic autoantibody may be identified by comparing the autoantibodies present in a immunoglobulin-containing sample from a subject having a neurodegenerative disease with autoantibodies present in an immunoglobulin-containing sample from an age-matched disease-free control subject. The target autoantigens for the autoantibodies present in the sample from the subject having the disease but not present in the sample from the control subject provide the identification of the disease diagnostic autoantibodies. The sample is preferably serum.
For example, protein microarrays containing thousands of full-sized or nearly full-sized human proteins spotted on a single specimen slide may be used to identify autoantibodies in a patient sample that are reactive with the antigen targets on the microarray. Autoantibodies in a control sample may be similarly identified. The patient autoantibody profile may be compared with the control autoantibody profile to determine the disease specific autoantibodies and corresponding autoantigens.
Protein microarrays useful for identifying neurodegenerative disease diagnostic autoantibodies and autoantigens may be made by methods known in the art and are also commercially available. Commercially available protein microarrays include, for example, Invitrogen's Prot® Array® Human Protein Microarray v5.0, which is preferably used in accordance with the Invitrogen ProtoArray® protocol and Immune Response Biomarker Profiling application.
Methods for probing and scanning such protein microarrays, and for determining the diagnostic significance of the resulting data, are known to those of skill in the art and disclosed, for example, by Tibshirani et al. (2002) Proc Natl Acad Sci USA 99, 6567-6572. Once the autoantibodies that are diagnostic for the neurodegenerative disease are identified by the foregoing methods, the corresponding autoantigens are identified and selected for use in the methods of detection and diagnosis.
An autoantigen may comprise a protein antigen, a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the disease diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the disease diagnostic autoantibody. The autoantigens may be purified from natural sources, or produced recombinantly or synthetically by methods known in the art, and may be in the form of fusion proteins. The autoantigens may be produced in vitro using cell-free translation systems. In one preferred embodiment, the autoantigens are produced in a mammalian or insect expression system to ensure correct folding and function. All of these methods may be automated for high throughput production.
Assays and conditions for the detection of immunocomplexes are known to those of skill in the art. Such assays include, for example, competition assays, direct reaction assays and sandwich-type assays. The assays may be quantitative or qualitative. In one preferred embodiment, the assay utilizes a solid phase or substrate to which the autoantigens are directly or indirectly attached, such as a microtiter or microassay plate, slide, magnetic bead, non-magnetic bead, column, matrix, membrane, dipstick, filter, membrane, pin, or sheet, and may be composed of a synthetic material such as polystyrene, polyvinyl chloride, polyamide, or other synthetic polymers, natural polymers such as cellulose, derivatized natural polymers such as cellulose acetate or nitrocellulose, and glass, for example glass fibers. The substrate preferably comprises a plurality of individually addressable autoantigens immobilized on the surface. The individually addressable autoantigens are preferably immobilized on the surface to form an array. The substrates may be used in suitable shapes, such as films, sheets, or plates, or may be coated onto or bonded or laminated to appropriate inert carriers, such as paper, glass, plastic films, or fabrics. In a preferred embodiment, the substrate is a slide or a bead.
Methods for attaching the autoantigens to the support or substrate are known in the art and include covalent and noncovalent interactions. For example, diffusion of applied proteins into a porous surface such a hydrogel allows noncovalent binding of unmodified protein within hydrogel structures. Covalent coupling methods provide a stable linkage and may be applied to a range of proteins. Biological capture methods utilising a tag (e.g., hexahistidine/Ni-NTA or biotin/avidin) on the protein and a partner reagent immobilized on the surface of the substrate provide a stable linkage and bind the protein specifically and in reproducible orientation. In one preferred embodiment, the autoantigens are coated or spotted onto the support or substrate such as chemically derivatized glass. In a more preferred embodiment, nitrocellulose-coated glass slides are used
In one preferred embodiment the autoantigens are provided in the form of an array, and preferably a microarray. Protein microarrays are known in the art and reviewed for example by Hall et al. (2007) Mech Ageing Dev 128:161-167 and Stoevesandt et al (2009) Expert Rev Proteomics 6:145-157, the disclosures of which are incorporated herein by reference in their entireties. Microarrays may be prepared by immobilizing purified autoantigens on a substrate such as a treated microscope slide using a contact spotter or a non-contact microarrayer. Microarrays may also be produced through in situ cell-free synthesis directly from corresponding DNA arrays.
Suitable methods for external production and purification of autoantigens to be spotted on arrays include expression in bacteria, as disclosed for example by Venkataram et al. (2008) Biochemistry 47:6590-6601, in yeast, as disclosed for example by Li et al. (2007) Appl Biochem Biotechnol. 142:105-124, in insect cells, as disclosed for example by Altman et al. (1999) Glycoconj J 16:109-123, and in mammalian cells, as disclosed for example by Spampinato et al. (2007) Curr Drug Targets 8:137-146.
Suitable methods for in situ (“on-chip”) protein production are disclosed, for example, by Ramachandran et al. (2006) Methods Mol. Biol. 2328:1-14 and He et al. (2008) Curr. Opin Biotechnol 19:4-9.
Other methods by which proteins are simultaneously expressed and immobilized in parallel on an array surface are also known in the art and may be used in accordance with the present invention. For example, in the Protein In Situ Arrays (PISA) method (He et al. (2001) Nucleic Acids Res 29:e73), proteins are made directly from DNA, either in solution or immobilized, and become attached to the array surface as they are made through recognition of a tag sequence. The proteins are expressed in parallel in vitro utilizing a cell free system, commonly rabbit reticulocyte or E. coli S30, to perform coupled transcription and translation. In this method, protein expression is performed on a surface which is precoated with an immobilizing agent capable of binding to the tag. Thus after each protein is translated, it becomes fixed simultaneously and specifically to the adjacent surface, while the other materials can subsequently be washed away. Microarrays may be produced directly onto glass slides, either by mixing the DNA with the cell free lysate system before spotting or by a multiple spotting technique (MIST) in which DNA is spotted first followed by the expression system.
In the system known as Nucleic Acid Programmable Protein Array (NAPPA) (Ramachandran et al. (2004) Science 305:86-90), transcription and translation from an immobilized (as opposed to a solution) DNA template allow conversion of DNA arrays to protein arrays. In this method, biotinylated cDNA plasmids encoding the proteins as GST fusions are printed onto an avidin-coated slide, together with an anti-GST antibody acting as the capture entity. The cDNA array is then covered with rabbit reticulocyte lysate to express the proteins, which become trapped by the antibody adjacent to each DNA spot, the proteins thereby becoming immobilized with the same layout as the cDNA. This technology generates a protein array in which the immobilized proteins are present together with DNA and a capture agent.
Another suitable method for generating a protein array is the DNA Array to Protein Array (DAPA) method. This method for in situ protein arraying uses an immobilized DNA array as the template to generate ‘pure’ protein arrays on a separate surface from the DNA, and also can produce multiple copies of a protein array from the same DNA template (He et al. (2008) Nature Methods, 5:175-7). Cell-free protein synthesis is performed in a membrane held between two surfaces (e.g., glass slides), one of which is arrayed with DNA molecules while the other surface carries a specific reagent to capture the translated proteins. Individual, tagged proteins are synthesized in parallel from the arrayed DNA, diffuse across the gap and are subsequently immobilized through interaction with the tag-capturing reagent on the opposite surface to form a protein array. Discrete spots which accurately reflect the DNA in position and quantity are produced. Replicate copies of the protein array can be obtained by reuse of the DNA.
Array fabrication methods include robotic contact printing, ink-jetting, piezoelectric spotting and photolithography. For example, purified autoantigens of the invention that are produced and purified externally may be spotted onto a microarray substrate using a flexible protein microarray inkjet printing system (e.g., ArrayJet, Roslin, Scotland, UK) to provide high quality protein microarray production. The precise rows and columns of autoantigens may be converted to detectable spots denoting both the presence and amount of diagnostic autoantibodies that have been bound.
The production of the microarrays is preferably performed with commercially available printing buffers designed to maintain the three-dimensional shape of the autoantigens. In one preferred embodiment, the substrate for the microarray is a nitrocellulose-coated glass slide.
The assays are performed by methods known in the art in which the one or more autoantigens are contacted with the biological sample under conditions that allow the formation of an immunocomplex of an autoantigen and an antibody, and detecting the immunocomplex. The presence and amount of the immunocomplex may be detected by methods known in the art, including label-based and label-free detection. For example, label-based detection methods include addition of a secondary antibody that is coupled to an indicator reagent comprising a signal generating compound. The secondary antibody may be an anti-human IgG antibody. Indicator reagents include chromogenic agents, catalysts such as enzyme conjugates, fluorescent compounds such as fluorescein and rhodamine, chemiluminescent compounds such as dioxetanes, acridiniums, phenanthridiniums, ruthenium, and luminol, radioactive elements, direct visual labels, as well as cofactors, inhibitors and magnetic particles. Examples of enzyme conjugates include alkaline phosphatase, horseradish peroxidase and beta-galactosidase. Methods of label-free detection include surface plasmon resonance, carbon nanotubes and nanowires, and interferometry. Label-based and label-free detection methods are known in the art and disclosed, for example, by Hall et al. (2007) and by Ray et al. (2010) Proteomics 10:731-748. Detection may be accomplished by scanning methods known in the art and appropriate for the label used, and associated analytical software.
In one preferred embodiment of the present invention, fluorescence labeling and detection methods are used to detect the immunocomplexes. Commericially available slide scanners (e.g. the Genepix 4000B slide scanner (Molecular Devices, Inc.) with associated analytical software may be used. In one preferred embodiment, the immunocomplex is probed with fluorescent-labeled (e.g., Alexa-Fluor (Invitrogen)) anti-human antibody and the intensity of fluorescence at each protein spot is measured using a microarray scanner. Commercially available software (e.g. GenePix Pro 5.0 software (Axon instruments)) may be used to extract the net median pixel intensities for individual features from the digital images produced by the scanner. Data may be normalized by comparing median values of multiple identical control spots in different regions of the same array.
Detection of immunocomplexes is indicative of the presence of neurodegenerative disease diagnostic autoantibodies in the biological sample, and thus a positive diagnosis of neurodegenerative disease.
Another embodiment of this invention provides a method for diagnosing a neurodegenerative disease in a subject comprising obtaining an immunoglobulin-containing biological sample from the subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in a biological sample, and diagnosing said disease if one or more of the disease diagnostic autoantibodies is present.
In a preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, PANDAS, Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a preferred embodiment of the invention, the subject is a human.
In a preferred embodiment of the invention, the immunoglobulin-containing biological sample is serum, whole blood, CSF, saliva, or sputum. A blood sample may be obtained by methods known in the art including venipuncture or a finger stick. CSF may be obtained by methods known in the art including a lumbar spinal tap. To obtain serum from blood, a sample of blood is received and centrifuged at a speed sufficient to pellet all cells and platelets, and the serum to be analyzed is drawn from the resulting supernatant. Sputum and saliva samples may be collected by methods known in the art. The biological samples may be diluted with a suitable buffer.
In a preferred embodiment, the assay used for diagnosing a neurodegenerative disease in a subject is performed by contacting the sample with one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody under conditions that allow an immunocomplex of the autoantigen and the autoantibody to form, and detecting the presence of the immunocomplex, and is described in detail hereinabove. Autoantigens may provided in the form of an array, or preferably, a microarray.
Another embodiment of this invention includes a method of generating an subject-specific, neurodegenerative disease specific autoantibody profile comprising obtaining an immunoglobulin-containing biological sample from a subject, performing an assay to determine the presence or absence of one or more neurodegenerative disease diagnostic autoantibodies in the biological sample, and generating a subject-specific neurodegenerative disease diagnostic autoantibody profile of the disease diagnostic autoantibodies present in the sample.
In a more preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, PANDAS, Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a preferred embodiment of the invention, the subject is a human.
In a preferred embodiment of the invention, the immunoglobulin-containing biological sample is serum, whole blood, CSF, saliva, or sputum. A blood sample may be obtained by methods known in the art including venipuncture or a finger stick. CSF may be obtained by methods known in the art including a lumbar spinal tap. To obtain serum from blood, a sample of blood is received and centrifuged at a speed sufficient to pellet all cells and platelets, and the serum to be analyzed is drawn from the resulting supernatant. Sputum and saliva samples may be collected by methods known in the art. The biological samples may be diluted with a suitable buffer.
In a preferred embodiment, the assay used to diagnose a neurodegenerative disease in a subject is performed by contacting the sample with one or more autoantigens that are specific for a neurodegenerative disease-specific autoantibody under conditions that allow an immunocomplex of the autoantigen and the antibody to form, and detecting the presence of the immunocomplex, and is described in detail hereinabove. Autoantigens may be provided in the form of an array, or preferably, a microarray.
Another embodiment of this invention provides a substrate on which one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody are immobilized. The present invention also provides, in another embodiment, a microarray comprising a substrate on which one or more autoantigens that are specific for a neurodegenerative disease diagnostic autoantibody are immobilized. The substrates and microarrays may be made as described hereinabove and are useful for creating neurodegenerative disease diagnostic autoantibody profiles and for the diagnosis of a neurodegenerative disease. An autoantigen may comprise a protein antigen, or a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the disease diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the disease diagnostic autoantibody. The substrates and microarrays contain at least one autoantigen specific for each neurodegenerative disease, and preferably contain from about two to about thirty autoantigens specific for each neurodegenerative disease.
The substrates and microarrays may contain a plurality of panels of autoantigens wherein each panel contains autoantigens that are diagnostic for a particular neurodegenerative disease. Such multi-substrates and multi-arrays allow the diagnosis of more than one neurodegenerative disease in the same assay, and also allow the differentiation of neurodegenerative diseases.
In a preferred embodiment, the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barre syndrome, chronic peripheral neuropathy, optic neuritis, vascular dementia, obsessive compulsive disorder, Sydenham's chorea, PANDAS, Hashimoto's encephalopathy, schizophrenia, systemic lupus erythematosus, vascular cognitive disorders, stroke, Huntington's disease, neuromyelitis optica, paraneoplastic syndromes, limbic encephalitis, Rasmussen encephalitis, Hashimoto's encephalitis, encephalitis lethargica, stiff person syndrome, post-streptococcal movement disorders, rheumatic fever, gluten enteropathy, ASD, dyslexia, HTLV-1-associated myelopathy/tropical spastic paraparesis, myasthenia gravis, Lambert-Eaton syndrome, and arthrogryposis multiplex congenita.
In a further embodiment, the present invention provides a kit for detecting neurodegenerative disease specific autoantibodies in a sample. The kit comprises one or more autoantigens that are specific for a neurodegenerative disease specific autoantibody and means for determining binding of the autoantigen to an autoantibody in the sample. The kit may also comprise packaging material comprising a label that indicates that the one or more autoantigens of the kit can be used for the identification of a neurodegenerative disease. Other components such as buffers, controls, detection reagents, and the like known to those of ordinary skill in art may be included in such the kits. The kits are useful for detecting neurodegenerative disease specific autoantibodies and for diagnosing neurodegenerative diseases.
Alzheimer's Disease
Alzheimer's disease (AD)-diagnostic autoantibodies are defined herein as antibodies that specifically bind to protein or peptide antigens and are diagnostic indicators that can be used to differentiate Alzheimer's Disease from control subjects without AD. Protein antigens that have been identified as being potentially useful diagnostic indicators are set forth in the following Table 1. The protein antigens in Table 1 are identified by art-accepted names as well as database identification numbers. The database identification numbers refer to the publically available protein databases of the National Center for Biotechnology Information (NCBI), which are well-known and accessible to those of ordinary skill in the art.








TABLE 1





Database ID
Description







NM_024754.2
pentatricopeptide repeat domain 2 (PTCD2)


BC051695.1
FERM domain containing 8 (FRMD8)


NM_014280.1
DnaJ homolog subfamily C member 8


BC064984.1
additional sex combs like 1 (Drosophila) (ASXL1)


NM_003384.1
vaccinia related kinase 1 (VRK1)


NM_001544.2
intercellular adhesion molecule 4 (Landsteiner-Wiener blood



group) (ICAM4), transcript variant 1


NM_001896.2
casein kinase 2, alpha prime polypeptide (CSNK2A2)


NM_021104.1
ribosomal protein L41 (RPL41), transcript variant 1


BC016380.1
cDNA clone MGC: 27376 IMAGE: 4688477, complete cds


NM_012387.1
peptidyl arginine deiminase, type IV (PADI4)


NM_003135.1
Signal recognition particle 19 kDa protein


BC022524.1
fibroblast growth factor 12 (FGF12)


BC000758.1
Coiled-coil domain-containing protein 28A


NM_021032.2
fibroblast growth factor 12 (FGF12), transcript variant 1


NM_022343.2
Golgi-associated plant pathogenesis-related protein 1


BC004236.2
ubiquitin-conjugating enzyme E2S (UBE2S)


NM_000983.3
60S ribosomal protein L22


NM_017588.1
WD repeat domain 5 (WDR5), transcript variant 1


NM_018956.2
chromosome 9 open reading frame 9 (C9orf9)


BC033178.1
immunoglobulin heavy constant gamma 3 (G3m marker) (IGHG3)


NM_006628.4
cyclic AMP phosphoprotein, 19 kD (ARPP-19)


BC022098.1
cDNA clone MGC: 31944 IMAGE: 4878869, complete cds


NM_001641.2
APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1),



transcript variant 1


NM_003668.2
mitogen-activated protein kinase-activated protein kinase 5



(MAPKAPK5), transcript variant 1


NM_015933.1
coiled-coil domain containing 72 (CCDC72)


PHC1244
chemokine (C-C motif) ligand 19 (CCL19)


BC007782.2
immunoglobulin lambda constant 1 (Mcg marker) (IGLC1)


BC006423.1
Serine/threonine-protein kinase 6


BC042628.1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator



inhibitor type 1), member 2 (SERPINE2)


BC021561.1
FACT complex subunit SPT16


BC005248.1
eukaryotic translation initiation factor 1A, Y-linked (EIF1AY)


NM_006223.1
protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4



(parvulin) (PIN4)


NM_032377.2
elongation factor 1 homolog (S. cerevisiae) (ELOF1)


BC057774.1
RNA (guanine-9-)-methyltransferase domain-containing



protein 3


NM_004196.2
Cyclin-dependent kinase-like 1


BC001662.1
MAP kinase-activated protein kinase 3


NM_015920.3
40S ribosomal protein S27-like protein


NM_001031.4
40S ribosomal protein S28


NM_003688.1
Peripheral plasma membrane protein CASK


BC048970.1
tubulin tyrosine ligase-like family, member 7 (TTLL7)


NM_000984.2
ribosomal protein L23a (RPL23A)


NM_018439.1
Impact homolog (mouse) (IMPACT)


NM_002305.2
lectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1)


BC056508.1
variable charge, Y-linked 1B (VCY)


BC090938.1
Ig gamma-1 chain C region


NM_002013.2
FK506 binding protein 3, 25 kDa (FKBP3)


NM_007278.1
GABA(A) receptor-associated protein (GABARAP)


BC007228.1
CSAG family, member 3A (CSAG3A)


BC033758.1
centaurin, alpha 2 (CENTA2)


BC092518.1
Ig gamma-1 chain C region


BC019598.1
Zinc finger matrin-type protein 4


NM_145909.1
Zinc finger protein 323


NM_003516.2
histone cluster 2, H2aa3 (HIST2H2AA3)


NM_006838.1
methionyl aminopeptidase 2 (METAP2)


BC026038.1
Ig gamma-1 chain C region


NM_002129.2
high-mobility group box 2 (HMGB2)


NM_002677.1
peripheral myelin protein 2 (PMP2)


BC001132.1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 (DDX54)


NM_001001794.1
family with sequence similarity 116, member B (FAM116B)


NM_001997.2
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)



ubiquitously expressed (FAU)


BC021174.1
Small EDRK-rich factor 1


NM_001028.2
ribosomal protein S25 (RPS25)


NM_003512.3
Histone H2A type 1-C


NM_002095.1
general transcription factor IIE, polypeptide 2, beta 34 kDa



(GTF2E2)


NM_005720.1
actin related protein 2/3 complex, subunit 1B, 41 kDa



(ARPC1B)


NM_003868.1
fibroblast growth factor 16 (FGF16)


NM_004214.3
fibroblast growth factor (acidic) intracellular binding protein



(FIBP), transcript variant 2


NM_021079.2
N-myristoyltransferase 1 (NMT1)


NM_015833.1
adenosine deaminase, RNA-specific, B1 (RED1 homolog rat)



(ADARB1), transcript variant 2


PHR5001
Recombinant human CTLA-4/Fc


BC030983.1
immunoglobulin lambda locus (IGL@)


BC030984.1
cDNA clone MGC: 32654 IMAGE: 4701898, complete cds


NM_133494.1
NIMA (never in mitosis gene a)-related kinase 7 (NEK7)


BC010467.1
cDNA clone MGC: 17410 IMAGE: 4156035, complete cds


NM_014060.1
malignant T cell amplified sequence 1 (MCTS1)


NM_016167.3
nucleolar protein 7, 27 kDa (NOL7)


BC015833.1
cDNA clone MGC: 27152 IMAGE: 4691630, complete cds


NM_145063.1
chromosome 6 open reading frame 130 (C6orf130)


BC040106.1
hypothetical protein HSPC111 (HSPC111)


BC010947.1
signal recognition particle 19 kDa (SRP19)


NM_014065.2
Protein asteroid homolog 1


BC012760.2
Glycogen synthase kinase-3 beta


NM_004088.1
deoxynucleotidyltransferase, terminal (DNTT), transcript variant 1


BC019337.1
immunoglobulin heavy constant gamma 1 (G1m marker) (IGHG1)


NM_002938.2
ring finger protein 4 (RNF4)


NM_006620.2
HBS1-like (S. cerevisiae) (HBS1L)


NM_000992.2
60S ribosomal protein L29


NM_024668.2
ankyrin repeat and KH domain containing 1 (ANKHD1),



transcript variant 3


NM_031445.1
AMME chromosomal region gene 1-like (AMMECR1L)


NM_003517.2
histone cluster 2, H2ac (HIST2H2AC)


BC072419.1
Ig gamma-1 chain C region


NM_145174.1
DnaJ (Hsp40) homolog, subfamily B, member 7 (DNAJB7)


BC022361.1
rRNA-processing protein FCF1 homolog


BC006376.1
N-myristoyltransferase 2 (NMT2)


NM_001895.1
casein kinase 2, alpha 1 polypeptide (CSNK2A1), transcript



variant 2


NM_003524.2
Histone H2B type 1-H


BC027951.1
Cas scaffolding protein family member 4


NM_134427.1
regulator of G-protein signaling 3 (RGS3), transcript variant 4


NM_052969.1
ribosomal protein L39-like (RPL39L)


NM_023080.1
chromosome 8 open reading frame 33 (C8orf33)


NM_138779.1
chromosome 13 open reading frame 27 (C13orf27)


BC026030.1
zinc finger protein 239 (ZNF239)


BC029760.1
OTU domain containing 6B (OTUD6B)


PHC1475
C-C motif chemokine 21


NM_133336.1
Wolf-Hirschhorn syndrome candidate 1 (WHSC1), transcript



variant 9


BC034142.1
immunoglobulin kappa variable 1-5 (IGKV1-5)


NM_020235.2
bobby sox homolog (Drosophila) (BBX)


NM_198829.1
Ras-related C3 botulinum toxin substrate 1


BC098112.1
Histone H2B type 1-N


NM_032359.1
chromosome 3 open reading frame 26 (C3orf26)


NM_001966.2
Peroxisomal bifunctional enzyme


BC032451.1
cDNA clone MGC: 40426 IMAGE: 5178085, complete cds


XM_379117.1
PREDICTED: Homo sapiens hypothetical protein LOC150568



(LOC150568)


BC033159.1
DnaJ (Hsp40) homolog, subfamily C, member 8 (DNAJC8)


NM_006756.2
transcription elongation factor A (SII), 1 (TCEA1), transcript



variant 1


NM_016940.1
RWD domain containing 2B (RWDD2B)


NM_177559.2
casein kinase 2, alpha 1 polypeptide (CSNK2A1), transcript



variant 1


NM_004178.3
TAR (HIV-1) RNA binding protein 2 (TARBP2), transcript



variant 3


NM_032338.2
chromosome 12 open reading frame 31 (C12orf31)


BC005955.1
chromosome 8 open reading frame 53 (C8orf53)


NM_001009613.1
Sperm protein associated with the nucleus on the X



chromosome N4


BC036723.1
Fc fragment of IgG, low affinity IIIa, receptor (CD16a)



(FCGR3A)


NM_003690.3
Interferon-inducible double stranded RNA-dependent protein



kinase activator A


NM_014473.2
DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)



(DIMT1L)


NM_032855.1
hematopoietic SH2 domain containing (HSH2D)


NM_001167.2
baculoviral IAP repeat-containing 4 (BIRC4)


NM_178571.2
hypothetical protein MGC51025 (MGC51025)


NM_003600.1
aurora kinase A (AURKA), transcript variant 2


NM_006912.3
Ras-like without CAAX 1 (RIT1)


NM_005307.1
G protein-coupled receptor kinase 4


BC001280.1
Serine/threonine-protein kinase 6


NM_182970.2
regulating synaptic membrane exocytosis 4 (RIMS4)


NM_153332.2
three prime histone mRNA exonuclease 1 (THEX1)


NM_139016.2
chromosome 20 open reading frame 198 (C20orf198)


NM_003677.3
Density-regulated protein


NM_013293.1
Transformer-2 protein homolog


BC033856.1
La ribonucleoprotein domain family, member 1 (LARP1)


NM_000939.1
proopiomelanocortin (adrenocorticotropin/beta-lipotropin/



alpha-melanocyte stimulating hormone/beta-melanocyte



stimulating hormone/beta-endorphin) (POMC), transcript



variant 2


BC009348.2
cirrhosis, autosomal recessive 1A (cirhin) (CIRH1A)


NM_014508.2
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-



like 3C (APOBEC3C), mRNA.


NM_080659.1
chromosome 11 open reading frame 52 (C11orf52)


NM_022755.2
inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPPK)


NM_002690.1
polymerase (DNA directed), beta (POLB)


BC011668.1
Casein kinase II subunit alpha


NM_002128.2
high-mobility group box 1 (HMGB1)


BC012472.1
ubiquitin D (UBD)


BC030020.2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 55 (DDX55)


BC018060.1
Ras-like without CAAX 2 (RIT2)


NM_003141.2
tripartite motif-containing 21 (TRIM21)


NM_007054.1
kinesin family member 3A (KIF3A)


NM_006924.3
splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate



splicing factor) (SFRS1), transcript variant 1


NM_032563.1
late cornified envelope 3D (LCE3D)


NM_173080.1
small proline-rich protein 4 (SPRR4)


NM_003527.4
Histone H2B type 1-O


BC009762.2
Tripartite motif-containing protein 41


NM_006861.2
RAB35, member RAS oncogene family (RAB35)


NM_002136.1
heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1),



transcript variant 1


BC009623.1
nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1)


NM_021063.2
Histone H2B type 1-D


BC054021.1
pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of



hepatocyte nuclear factor 1 alpha (TCF1) 2 (PCBD2)


NM_012108.1
signal transducing adaptor family member 1 (STAP1)


NM_023937.1
mitochondrial ribosomal protein L34 (MRPL34), nuclear gene



encoding mitochondrial protein


XM_088679.2
Spermatid nuclear transition protein 4


NM_022720.5
DiGeorge syndrome critical region gene 8 (DGCR8)


NM_016073.2
hepatoma-derived growth factor, related protein 3 (HDGFRP3)


NM_018105.1
THAP domain containing, apoptosis associated protein 1



(THAP1), transcript variant 1


NM_005371.2
methyltransferase like 1 (METTL1), transcript variant 1


BC029427.1
coiled-coil domain containing 23 (CCDC23)


NM_032476.1
mitochondrial ribosomal protein S6 (MRPS6), nuclear gene



encoding mitochondrial protein


NM_003089.4
small nuclear ribonucleoprotein 70 kDa polypeptide (RNP antigen)



(SNRP70)


BC020972.1
Casein kinase I isoform gamma-2


BC000381.2
TBP-like 1 (TBPL1)


NM_007285.5
GABA(A) receptor-associated protein-like 2 (GABARAPL2)


NM_004060.2
cyclin G1 (CCNG1), transcript variant 1


BC001780.1
Uncharacterized methyltransferase WBSCR22


NM_022048.1
casein kinase 1, gamma 1 (CSNK1G1)


BC035256.1
Putative adenylate kinase 7


NM_175887.2
proline rich 15 (PRR15)


BC010919.1
ribosomal protein L35 (RPL35)


NM_016207.2
cleavage and polyadenylation specific factor 3, 73 kDa (CPSF3)


BC000784.1
baculoviral IAP repeat-containing 5 (survivin) (BIRC5)


NM_002364.1
melanoma antigen family B, 2 (MAGEB2)


NM_022839.2
mitochondrial ribosomal protein S11 (MRPS11), nuclear gene



encoding mitochondrial protein, transcript variant 1


NM_014370.2
SFRS protein kinase 3 (SRPK3)


NM_016505.2
zinc finger, CCHC domain containing 17 (ZCCHC17)


BC030813.1
cDNA clone MGC: 22645 IMAGE: 4700961, complete cds


BC020803.1
developmentally regulated GTP binding protein 1 (DRG1)


NM_205848.1
synaptotagmin VI (SYT6)


NM_006398.2
Ubiquitin D


NM_017646.3
tRNA isopentenyltransferase 1 (TRIT1)


NM_006925.2
Splicing factor, arginine/serine-rich 5


NM_153822.1
proteasome (prosome, macropain) 26S subunit, non-ATPase, 4



(PSMD4), transcript variant 2


NM_014321.2
origin recognition complex, subunit 6 like (yeast) (ORC6L)


BC012876.1
Ig lambda chain C regions


NM_021967.1
small EDRK-rich factor 1A (telomeric) (SERF1A)


NM_003295.1
tumor protein, translationally-controlled 1 (TPT1)


NM_017503.2
surfeit 2 (SURF2)


BC018137.1
TATA box binding protein (TBP)-associated factor, RNA



polymerase I, B, 63 kDa (TAF1B)


BC005004.1
family with sequence similarity 64, member A (FAM64A)


NM_152373.2
zinc finger protein 684 (ZNF684)


NM_000989.2
ribosomal protein L30 (RPL30)


NM_000800.2
fibroblast growth factor 1 (acidic) (FGF1), transcript variant 1


NM_000975.2
ribosomal protein L11 (RPL11)


PHC1695
C—X—C motif chemokine 11


NM_022140.2
Band 4.1-like protein 4A


NM_016287.2
heterochromatin protein 1, binding protein 3 (HP1BP3)


BC015586.2
laminin, gamma 1 (formerly LAMB2) (LAMC1)


NM_023931.1
zinc finger protein 747 (ZNF747)


NM_153207.2
AE binding protein 2 (AEBP2)


NM_007079.2
Protein tyrosine phosphatase type IVA 3


NM_004397.3
Probable ATP-dependent RNA helicase DDX6


NM_012424.2
Ribosomal protein S6 kinase delta-1


NM_020239.2
CDC42 small effector 1 (CDC42SE1), transcript variant 2


BC029378.1
telomeric repeat binding factor (NIMA-interacting) 1 (TERF1)


BC000306.1
hydroxyacyl-Coenzyme A dehydrogenase (HADH)


NM_182692.1
Serine/threonine-protein kinase SRPK2


NM_032350.3
Uncharacterized protein C7orf50


NM_001022.3
ribosomal protein S19 (RPS19)


NM_001002913.1
peptidyl-tRNA hydrolase 1 homolog (S. cerevisiae) (PTRH1)


BC000535.1
Suppressor of SWI4 1 homolog


NM_017692.1
aprataxin (APTX), transcript variant 4


NM_000993.2
ribosomal protein L31 (RPL31), transcript variant 1


NM_152653.1
ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog,



yeast) (UBE2E2)


NM_014891.1
PDGFA associated protein 1 (PDAP1)


NM_012148.1
double homeobox, 3 (DUX3)


NM_024046.1
CaM kinase-like vesicle-associated (CAMKV)


NM_022063.1
chromosome 10 open reading frame 84 (C10orf84)


BC036434.1
Serine/threonine-protein kinase VRK2


NM_001396.2
Dual specificity tyrosine-phosphorylation-regulated kinase 1A


NM_004939.1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 (DDX1)


NM_001039724.1
Nostrin


NM_138551.1
thymic stromal lymphopoietin (TSLP), transcript variant 2


XM_379194.1
PREDICTED: Homo sapiens hypothetical LOC401068



(LOC401068)


BC007401.2
cell division cycle 25 homolog A (S. pombe) (CDC25A)


BC008902.2
GRIP and coiled-coil domain-containing protein 1


BC019039.2
Regulator of G-protein signaling 3


NM_016050.1
mitochondrial ribosomal protein L11 (MRPL11), nuclear gene



encoding mitochondrial protein, transcript variant 1


NM_002927.3
regulator of G-protein signaling 13 (RGS13), transcript variant 1


NM_207430.1
FLJ46266 protein (FLJ46266), mRNA.


NM_016508.2
Cyclin-dependent kinase-like 3


NM_197964.1
chromosome 7 open reading frame 55 (C7orf55)


BC021930.1
KIAA1530 protein (KIAA1530)


NM_145043.1
nei like 2 (E. coli) (NEIL2)


BC030586.2
signal transducing adaptor molecule (SH3 domain and ITAM



motif) 1 (STAM)


BC004292.1
PHD finger protein 15 (PHF15)


BC022378.1
zinc finger with KRAB and SCAN domains 1 (ZKSCAN1)


NM_003792.1
endothelial differentiation-related factor 1 (EDF1), transcript



variant alpha


BC070154.1
Non-histone chromosomal protein HMG-14


BC010074.2
FUS interacting protein (serine/arginine-rich) 1 (FUSIP1)


NM_002201.3
interferon stimulated exonuclease gene 20 kDa (ISG20)


BC033621.2
Pseudouridylate synthase 7 homolog-like protein


NM_004114.2
fibroblast growth factor 13 (FGF13), transcript variant 1A


NM_012420.1
interferon-induced protein with tetratricopeptide repeats 5 (IFIT5)


NM_016203.2
protein kinase, AMP-activated, gamma 2 non-catalytic subunit



(PRKAG2), transcript variant a, mRNA.


NM_014878.2
Pumilio domain-containing protein KIAA0020


NM_018664.1
Jun dimerization protein p21SNFT (SNFT)


NM_002402.1
mesoderm specific transcript homolog (mouse) (MEST), transcript



variant 1


NM_003769.2
splicing factor, arginine/serine-rich 9 (SFRS9)


NM_018132.3
centromere protein Q (CENPQ)


NM_006072.4
chemokine (C-C motif) ligand 26 (CCL26)


NM_021029.3
ribosomal protein L36a (RPL36A)


NM_000978.2
ribosomal protein L23 (RPL23)


NM_001023.2
ribosomal protein S20 (RPS20)


BC013366.2
UNC-112 related protein 2 (URP2)


BC001327.1
interferon-related developmental regulator 2 (IFRD2)


BC000522.1
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment



epithelium derived factor), member 1 (SERPINF1)


NM_019067.1
guanine nucleotide binding protein-like 3 (nucleolar)-like



(GNL3L)


NM_152634.1
TFS2-M domain-containing protein 1 (MGC17403)


BC011842.2
hypothetical protein FLJ11184 (FLJ11184)


BC068514.1
NF-kappaB repressing factor (NKRF)


NM_018063.3
helicase, lymphoid-specific (HELLS)


NM_198467.1
round spermatid basic protein 1-like (RSBN1L)


NM_198517.2
TBC1 domain family, member 10C (TBC1D10C)


NM_001564.1
inhibitor of growth family, member 2 (ING2)


NM_002930.1
GTP-binding protein Rit2


NM_019058.1
DNA-damage-inducible transcript 4 protein


NM_020661.1
activation-induced cytidine deaminase (AICDA)


NM_173822.1
family with sequence similarity 126, member B (FAM126B)


BC056887.1
chromosome 5 open reading frame 5 (C5orf5)


BC070334.1
immunoglobulin kappa constant (IGKC)


NM_004071.1
Dual specificity protein kinase CLK1


NM_005801.2
eukaryotic translation initiation factor 1 (EIF1)


BC001487.2
TAR DNA-binding protein 43


NM_006790.1
myotilin (MYOT)


NM_175923.2
hypothetical protein MGC42630 (MGC42630)


NM_000122.1
excision repair cross-complementing rodent repair deficiency,



complementation group 3 (xeroderma pigmentosum group B



complementing) (ERCC3)


BC010501.1
Catenin delta-1


BC005298.1
cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis,



cdk-activating kinase) (CDK7)


PHC0076
interleukin 7 (IL7)


NM_138349.2
Tumor protein p53-inducible protein 13


BC000044.1
Spindlin-2B


NM_014747.2
regulating synaptic membrane exocytosis 3 (RIMS3)


NM_001014.2
ribosomal protein S10 (RPS10)


NM_005678.3
SNRPN upstream reading frame (SNURF), transcript variant 1


BC010876.1
nei endonuclease VIII-like 1 (E. coli) (NEIL1)


BC025281.1
RNA binding motif protein 9 (RBM9)


NM_001013.2
ribosomal protein S9 (RPS9)


NM_015414.2
ribosomal protein L36 (RPL36), transcript variant 2


NM_017566.2
kelch domain containing 4 (KLHDC4)


BC015818.1
lectin, galactoside-binding, soluble, 8 (galectin 8) (LGALS8)


BC036109.1
SECIS binding protein 2 (SECISBP2)


NM_005738.1
ADP-ribosylation factor-like 4A (ARL4A), transcript variant 1


BC022816.1
NA


NM_024303.1
zinc finger and SCAN domain containing 5 (ZSCAN5)


BC018823.2
splicing factor, arginine/serine-rich 5 (SFRS5)


NM_024319.1
chromosome 1 open reading frame 35 (C1orf35)


PV3359
Ephrin receptor A3 (EPHA3), transcript variant 1


NM_145899.1
high mobility group AT-hook 1 (HMGA1), transcript variant 1


NM_021158.1
tribbles homolog 3 (Drosophila) (TRIB3)


NM_005794.2
dehydrogenase/reductase (SDR family) member 2 (DHRS2),



transcript variant 2


BC005807.2
stearoyl-CoA desaturase (delta-9-desaturase) (SCD)


NM_006374.2
serine/threonine kinase 25 (STE20 homolog, yeast) (STK25)


NM_152757.1
Putative uncharacterized protein C20orf200


NM_001009880.1
chromosome 22 open reading frame 9 (C22orf9), transcript



variant 2


NM_138558.1
protein phosphatase 1, regulatory (inhibitor) subunit 8



(PPP1R8), transcript variant 2


BC007852.1
Serine/threonine-protein kinase 25


NM_012396.1
pleckstrin homology-like domain, family A, member 3



(PHLDA3)


NM_012437.2
SNAP-associated protein (SNAPAP)


PHC0205
interleukin 20 (IL20)


NM_016093.2
ribosomal protein L26-like 1 (RPL26L1)


NM_005902.1
SMAD family member 3 (SMAD3)


XM_375456.2
Ataxin-7-like protein 3


NM_006275.2
splicing factor, arginine/serine-rich 6 (SFRS6)


BC011600.1
cDNA clone IMAGE: 3050953, **** WARNING: chimeric clone ****


NM_014570.2
ADP-ribosylation factor GTPase activating protein 3 (ARFGAP3)


NM_022551.2
ribosomal protein S18 (RPS18)


BC063275.1
eukaryotic translation initiation factor 2C, 1 (EIF2C1)


BC062423.1
chromosome 7 open reading frame 41 (C7orf41)


BC096708.1
Wilms tumor-associated protein


NM_199123.1
SET domain containing 3 (SETD3), transcript variant 2


BC010907.1
PAK1 interacting protein 1 (PAK1IP1)


NM_004217.1
aurora kinase B (AURKB)


NM_005737.3
ADP-ribosylation factor-like 4C (ARL4C)


NM_020467.2
small trans-membrane and glycosylated protein (LOC57228), transcript



variant 2


BC021180.2
high-mobility group box 4 (HMGB4)


NM_004728.2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 (DDX21)


BC030702.1
microcephaly, primary autosomal recessive 1 (MCPH1)


NM_003724.1
jerky homolog (mouse) (JRK), transcript variant 1


NM_016077.1
peptidyl-tRNA hydrolase 2 (PTRH2), nuclear gene encoding



mitochondrial protein


NM_014955.2
KIAA0859 (KIAA0859), transcript variant 2


NM_003503.2
Cell division cycle 7-related protein kinase


BC017212.2
PHD finger protein 11 (PHF11)


NM_019069.3
WD repeat domain 5B (WDR5B)


BC094719.1
Rho GTPase-activating protein 12


BC021187.1
DKFZP434K028 protein (DKFZP434K028)


NM_003948.2
Cyclin-dependent kinase-like 2


BC040183.2
Rap guanine nucleotide exchange factor (GEF) 4 (RAPGEF4)


NM_014061.3
melanoma antigen family H, 1 (MAGEH1)


BC032587.1
tubby like protein 3 (TULP3)


BC005332.1
cDNA clone MGC: 12418 IMAGE: 3934658, complete cds


BC033710.2
RAD54 homolog B (S. cerevisiae) (RAD54B)


BC010425.1
acyl-Coenzyme A oxidase 1, palmitoyl (ACOX1)


NM_021138.2
TNF receptor-associated factor 2 (TRAF2)


BC093990.1
Sin3 histone deacetylase corepressor complex component SDS3


NM_014288.2
Centromere protein R


NM_024826.1
Microtubule-associated protein 9


BC035968.1
chloride intracellular channel 5 (CLIC5)


BC096165.1
Troponin I, cardiac muscle


BC012105.1
nuclear VCP-like (NVL)


BC011924.1
unkempt homolog (Drosophila)-like (UNKL)


NM_001311.2
Cysteine-rich protein 1


NM_014445.2
stress-associated endoplasmic reticulum protein 1 (SERP1)


NM_005979.1
S100 calcium binding protein A13 (S100A13), transcript variant 2


BC036923.1
chromosome 9 open reading frame 150 (C9orf150)


NM_033671.1
cyclin B3 (CCNB3), transcript variant 2


BC014441.1
NOL1/NOP2/Sun domain family, member 4 (NSUN4)


BC031549.1
CDC-like kinase 1 (CLK1)


NM_194290.1
cDNA FLJ42001 fis, clone SPLEN2029912 (LOC153684 protein)



[Source: UniProtKB/TrEMBL; Acc: Q6ZVW3]


BC053984.1
immunoglobulin heavy variable 4-31 (IGHV4-31)


BC050563.1
hypothetical protein LOC202051 (LOC202051)


BC050718.1
polymerase (DNA directed) kappa (POLK)


BC000896.1
RAB10, member RAS oncogene family (RAB10)


NM_006252.2
AMP-activated protein_kinase A2/B1/G1: PRKAA2/B1/G1 sequences



are seperated by -- (in protein list file).


BC013630.1
JTV1 gene (JTV1)


BC009108.1
cDNA clone IMAGE: 3451214 (MCM10)


BC002645.1
syntaxin 5 (STX5)


NM_138414.1
coiled-coil domain containing 101 (CCDC101)


NM_002740.1
protein kinase C, iota (PRKCI)


NM_002822.3
twinfilin, actin-binding protein, homolog 1 (Drosophila) (TWF1)


BC003566.1
zinc finger protein 24 (ZNF24)


NM_022756.2
Uncharacterized protein C1orf149


NM_153035.1
chromosome 1 open reading frame 83 (C1orf83)


NM_177524.1
mesoderm specific transcript homolog (mouse) (MEST), transcript



variant 2


NM_004635.2
mitogen-activated protein kinase-activated protein kinase 3



(MAPKAPK3)


NM_005607.1
Focal adhesion kinase 1


BC010697.1
RNA-binding protein 40


NM_174942.1
GAS2-like protein 3


BC038976.1
Rho GTPase-activating protein 15


NM_012117.1
chromobox homolog 5 (HP1 alpha homolog, Drosophila) (CBX5)


NM_013313.3
yippee-like 1 (Drosophila) (YPEL1)


NM_148179.1
chromosome 9 open reading frame 23 (C9orf23), transcript variant 2


BC038105.2
membrane protein, palmitoylated 7 (MAGUK p55 subfamily



member 7) (MPP7)


BC091489.1
zinc finger, MYND domain containing 11, mRNA (cDNA clone



MGC: 111056 IMAGE: 6186814), complete cds


BC034435.1
zinc finger CCCH-type containing 3 (ZC3H3)


NM_152736.2
Zinc finger protein 187


NM_015014.1
RNA binding motif protein 34 (RBM34)


NM_003137.2
SFRS protein kinase 1 (SRPK1)


BC016486.1
lectin, galactoside-binding, soluble, 8 (galectin 8) (LGALS8)


BC000238.1
ankyrin repeat and zinc finger domain containing 1 (ANKZF1)


NM_002904.4
RD RNA binding protein (RDBP)


BC009046.1
neurogenic differentiation 1 (NEUROD1)


NM_198965.1
Parathyroid hormone-related protein


BC047776.2
coiled-coil domain containing 43 (CCDC43)


NM_001004306.1
similar to hypothetical protein FLJ36492 (MGC87631)


NM_006800.2
male-specific lethal 3-like 1 (Drosophila) (MSL3L1), transcript



variant 3


NM_006038.1
spermatogenesis associated 2 (SPATA2)


NM_014477.2
chromosome 20 open reading frame 10 (C20orf10)


BC027612.2
EP300-interacting inhibitor of differentiation 3


NM_017411.2
survival of motor neuron 2, centromeric (SMN2), transcript variant d


BC004876.1
Protein MCM10 homolog


NM_201516.1
H2A histone family, member V (H2AFV), transcript variant 4


NM_022156.3
dihydrouridine synthase 1-like (S. cerevisiae) (DUS1L)


BC015742.1
polymerase (DNA directed), eta (POLH)


NM_001015509.1
Peptidyl-tRNA hydrolase 2, mitochondrial


NM_014366.1
guanine nucleotide binding protein-like 3 (nucleolar) (GNL3),



transcript variant 1


NM_018357.2
La ribonucleoprotein domain family, member 6 (LARP6), transcript



variant 1


BC020221.1
SH3 and cysteine rich domain (STAC)


NM_005307.1
G protein-coupled receptor kinase 4


NM_017785.2
coiled-coil domain containing 99 (CCDC99)


BC026101.2
nudE nuclear distribution gene E homolog (A. nidulans)-like 1



(NDEL1)


NM_175571.2
GTPase, IMAP family member 8 (GIMAP8)


NM_004286.2
GTP binding protein 1 (GTPBP1)


BC072461.1
Cysteine and histidine-rich domain-containing protein 1


BC047945.1
tripartite motif-containing 69 (TRIM69)


BC005858.1
fibronectin 1 (FN1)


NM_001722.2
polymerase (RNA) III (DNA directed) polypeptide D, 44 kDa



(POLR3D)


NM_024333.1
Fibronectin type III and SPRY domain-containing protein 1


NM_144595.1
SLAIN motif family, member 1 (SLAIN1), transcript variant 2


NM_002469.1
myogenic factor 6 (herculin) (MYF6)


BC053866.1
endothelin 3 (EDN3)


NM_001319.5
casein kinase 1, gamma 2 (CSNK1G2)


BC006124.1
IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2)


NM_014667.1
vestigial like 4 (Drosophila) (VGLL4)


NM_031465.2
chromosome 12 open reading frame 32 (C12orf32)


NM_182612.1
Parkinson disease 7 domain containing 1 (PDDC1)


PV4803
epidermal growth factor receptor (erythroblastic leukemia viral



(verb-b) oncogene homolog, avian) (EGFR); see catalog number for



detailed information on wild-type or point mutant status


NM_152266.1
chromosome 19 open reading frame 40 (C19orf40)


NM_000997.2
ribosomal protein L37 (RPL37)


BC001728.1
TCF3 fusion partner


BC007015.1
cyclin E2 (CCNE2)


NM_022347.1
interferon responsive gene 15 (IFRG15)


BC031821.1
Secernin-3


NM_016304.2
chromosome 15 open reading frame 15 (C15orf15)


BC069677.1
Regulator of G-protein signaling 8


BC013331.1
H2A histone family, member Y (H2AFY)


NM_017838.2
nucleolar protein family A, member 2 (H/ACA small nucleolar



RNPs) (NOLA2), transcript variant 1


BC013796.1
adaptor-related protein complex 2, mu 1 subunit (AP2M1)


NM_080743.2
serine-arginine repressor protein (35 kDa) (SRrp35)


BC000190.1
zinc finger, C3HC-type containing 1 (ZC3HC1)


BC036089.1
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,



Drosophila); translocated to, 3 (MLLT3)


NM_018215.2
hypothetical protein FLJ10781 (FLJ10781), transcript variant 1


BC095401.1
AKT-interacting protein


NM_001008572.1
tubulin tyrosine ligase-like family, member 1 (TTLL1), transcript



variant 2


BC103812.1
Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3


BC036365.1
PH domain-containing protein C10orf81


NM_016047.1
splicing factor 3B, 14 kDa subunit (SF3B14)


BC014949.1
DEXH (Asp-Glu-X-His) box polypeptide 58 (DHX58)


BC047690.1
Ras-related protein M-Ras


NM_001894.2
casein kinase 1, epsilon (CSNK1E), transcript variant 2


NM_006482.1
Dual specificity tyrosine-phosphorylation-regulated kinase 2


NM_025104.2
Protein DBF4 homolog B


NM_017819.1
RNA (guanine-9-)-methyltransferase domain-containing protein 1,



mitochondrial


NM_199139.1
XIAP associated factor-1 (XAF1), transcript variant 2


NM_003910.2
BUD31 homolog (S. cerevisiae) (BUD31)


BC000442.1
Serine/threonine-protein kinase 12


BC028711.2
cancer/testis antigen CT45-3 (CT45-3)


NM_018158.1
solute carrier family 4 (anion exchanger), member 1, adaptor protein



(SLC4A1AP)


BC034692.1
anillin, actin binding protein (ANLN)


NM_173605.1
potassium channel regulator (KCNRG), transcript variant 1


NM_014047.1
chromosome 19 open reading frame 53 (C19orf53)


BC073791.1
immunoglobulin kappa constant, mRNA (cDNA clone MGC: 88809



IMAGE: 6279986), complete cds


BC014928.1
MYC-induced nuclear antigen


BC053656.1
EGF-like repeats and discoidin I-like domains 3 (EDIL3)


XM_378879.2
PREDICTED: Homo sapiens hypothetical LOC400763



(LOC400763)


NM_017817.1
RAB20, member RAS oncogene family (RAB20)


BC031608.1
REST corepressor 3 (RCOR3)


BC047722.1
hypothetical protein MGC52110 (MGC52110)


BC020726.1
sciellin (SCEL)


NM_024039.1
MIS12, MIND kinetochore complex component, homolog (yeast)



(MIS12)


BC026213.1
F-box/WD repeat-containing protein 11


NM_002135.3
nuclear receptor subfamily 4, group A, member 1 (NR4A1),



transcript variant 1


NM_015939.2
tRNA methyltransferase 6 homolog (S. cerevisiae) (TRMT6)


NM_018039.2
jumonji domain containing 2D (JMJD2D)


NM_007373.2
soc-2 suppressor of clear homolog (C. elegans) (SHOC2)


BC067120.1
protein tyrosine phosphatase domain containing 1, mRNA (cDNA



clone MGC: 70358 IMAGE: 5539182), complete cds


NM_015918.2
processing of precursor 5, ribonuclease P/MRP subunit (S. cerevisiae)



(POP5), transcript variant 1


NM_152677.1
zinc finger and SCAN domain containing 4 (ZSCAN4)


BC008902.2
GRIP and coiled-coil domain-containing protein 1


NM_001008239.1
chromosome 18 open reading frame 25 (C18orf25), transcript



variant 2


NM_183397.1
peroxisomal membrane protein 4, 24 kDa (PXMP4), transcript



variant 2


NM_006337.3
microspherule protein 1 (MCRS1), transcript variant 1


BC034401.1
cDNA clone IMAGE: 5172086, partial cds


NM_006755.1
transaldolase 1 (TALDO1)


NM_004853.1
syntaxin 8 (STX8)


BC036910.1
hypothetical LOC388882 (LOC388882)


BC094687.1
Elongation factor 1-alpha 1


NM_144608.1
hexamthylene bis-acetamide inducible 2 (HEXIM2)


NM_003831.1
RIO kinase 3 (yeast) (RIOK3)


BC009250.1
guanine nucleotide binding protein-like 2 (nucleolar) (GNL2)


BC032598.1
NHL repeat containing 2 (NHLRC2)


NM_018697.3
LanC lantibiotic synthetase component C-like 2 (bacterial) (LANCL2)


NM_024104.1
chromosome 19 open reading frame 42 (C19orf42)


BC030665.1
Sulfotransferase 4A1


BC004955.1
ATPase inhibitory factor 1 (ATPIF1)


BC009010.1
Uncharacterized protein C6orf142 homolog


BC012887.1
Nucleolar and spindle-associated protein 1


BC015066.1
core-binding factor, runt domain, alpha subunit 2; translocated to, 2



(CBFA2T2)


BC052303.1
Rho GTPase activating protein 4 (ARHGAP4)


NM_080414.1
vacuolar protein sorting 16 homolog (S. cerevisiae) (VPS16), transcript



variant 2


NM_001790.2
cell division cycle 25 homolog C (S. pombe) (CDC25C), transcript



variant 1


PHC0045
interleukin 4 (IL4), transcript variant 1


NM_145041.1
transmembrane protein 106A (TMEM106A)


NM_021639.2
GC-rich promoter binding protein 1-like 1 (GPBP1L1)


BC028295.1
peptidase D (PEPD)


PV3612
aurora kinase A (AURKA), transcript variant 2


NM_032321.1
hypothetical protein MGC13057 (MGC13057), transcript variant 4


BC010033.1
quinolinate phosphoribosyltransferase (nicotinate-nucleotide



pyrophosphorylase (carboxylating)) (QPRT)


NM_001064.1
Transketolase


NM_017572.2
MAP kinase-interacting serine/threonine-protein kinase 2


NM_022650.1
RAS p21 protein activator (GTPase activating protein) 1 (RASA1),



transcript variant 2


NM_020781.2
zinc finger protein 398 (ZNF398), transcript variant 2


NM_002391.1
midkine (neurite growth-promoting factor 2) (MDK), transcript variant 3


NM_006298.2
zinc finger protein 192 (ZNF192)


BC047536.1
sciellin (SCEL)


NM_139062.1
casein kinase 1, delta (CSNK1D), transcript variant 2


NM_005639.1
synaptotagmin I (SYT1)


BC006811.1
peroxisome proliferator-activated receptor gamma (PPARG)


BC008364.1
heterogeneous nuclear ribonucleoprotein C (C1/C2) (HNRPC)


NM_032345.1
within bgcn homolog (Drosophila) (WIBG)


BC016825.1
spire homolog 1 (Drosophila) (SPIRE1)


NM_020664.3
2,4-dienoyl CoA reductase 2, peroxisomal (DECR2)


NM_017542.3
pogo transposable element with KRAB domain (POGK)


NM_003160.1
Serine/threonine-protein kinase 13


BC026346.1
family with sequence similarity 84, member A (FAM84A)


BC041037.1
immunoglobulin heavy constant mu (IGHM)


BC033677.1
Uncharacterized protein C9orf114


BC055427.1
TRAF2 and NCK interacting kinase (TNIK)


NM_016648.1
La ribonucleoprotein domain family, member 7 (LARP7), transcript



variant 1


BC064145.1
CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1)


NM_138565.1
cortactin (CTTN), transcript variant 2


NM_022823.1
fibronectin type III domain containing 4 (FNDC4)


BC006104.1
RIO kinase 1 (yeast) (RIOK1)


BC014975.1
family with sequence similarity 136, member A (FAM136A)


NM_138730.1
high mobility group nucleosomal binding domain 3 (HMGN3),



transcript variant 2


NM_025004.1
Coiled-coil domain-containing protein 15


NM_004092.2
Enoyl-CoA hydratase, mitochondrial


NM_021107.1
mitochondrial ribosomal protein S12 (MRPS12), nuclear gene



encoding mitochondrial protein, transcript variant 1


NM_053049.2
Urocortin-3


NM_001545.1
immature colon carcinoma transcript 1 (ICT1)


NM_148571.1
mitochondrial ribosomal protein L27 (MRPL27), nuclear gene



encoding mitochondrial protein, transcript variant 2


NM_001003799.1
TCR gamma alternate reading frame protein (TARP), nuclear gene



encoding mitochondrial protein, transcript variant 1


BC017227.1
phosducin-like (PDCL)


NM_172159.2
potassium voltage-gated channel, shaker-related subfamily, beta



member 1 (KCNAB1), transcript variant 3


NM_000462.2
ubiquitin protein ligase E3A (human papilloma virus E6-associated



protein, Angelman syndrome) (UBE3A), transcript variant 2


XM_210860.4
PREDICTED: Homo sapiens hypothetical LOC283034



(LOC283034)


BC022344.1
twinfilin, actin-binding protein, homolog 1 (Drosophila) (TWF1)


NM_005037.3
peroxisome proliferator-activated receptor gamma (PPARG),



transcript variant 4


NM_022977.1
acyl-CoA synthetase long-chain family member 4 (ACSL4),



transcript variant 2


NM_006217.2
serpin peptidase inhibitor, clade I (pancpin), member 2 (SERPINI2)


NM_024979.2
Guanine nucleotide exchange factor DBS


NM_016286.1
dicarbonyl/L-xylulose reductase (DCXR)


NM_003160.1
Serine/threonine-protein kinase 13


NM_015687.2
filamin A interacting protein 1 (FILIP1)


BC005871.2
chromosome 10 open reading frame 58 (C10orf58)


NM_016216.2
Lariat debranching enzyme


NM_017856.1
gem (nuclear organelle) associated protein 8 (GEMIN8), transcript



variant 3


NM_015869.2
peroxisome proliferator-activated receptor gamma (PPARG),



transcript variant 2


NM_001003397.1
Tumor protein D53


NM_001018061.1
UPF0544 protein C5orf45 [Source: UniProtKB/Swiss-



Prot; Acc: Q6NTE8]


BC013900.1
chromosome 12 open reading frame 41 (C12orf41)


BC022988.1
chromosome 6 open reading frame 65 (C6orf65)


NM_006299.2
zinc finger protein 193 (ZNF193)


BC018847.1
Transaldolase


NM_139355.1
megakaryocyte-associated tyrosine kinase (MATK), transcript



variant 1


NM_207356.1
chromosome 1 open reading frame 174 (C1orf174)


NM_001008737.1
hypothetical LOC401052 (LOC401052)


NM_145109.1
mitogen-activated protein kinase kinase 3 (MAP2K3), transcript



variant B


BC017114.1
oligonucleotide/oligosaccharide-binding fold containing 2A



(OBFC2A)


XM_086879.4
PREDICTED: Homo sapiens hypothetical LOC150371



(LOC150371)


NM_078630.1
male-specific lethal 3-like 1 (Drosophila) (MSL3L1), transcript



variant 2


NM_005197.2
Forkhead box protein N3


NM_004602.2
Double-stranded RNA-binding protein Staufen homolog 1


BC017504.1
Differentially expressed in FDCP 6 homolog


NM_003590.2
cullin 3 (CUL3)


NM_145702.1
tigger transposable element derived 1 (TIGD1)


BC001935.1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)


NM_004965.3
high-mobility group nucleosome binding domain 1 (HMGN1)


BC032508.1
PNMA-like 1, mRNA (cDNA clone MGC: 45422



IMAGE: 5246377), complete cds


BC013966.2
family with sequence similarity 64, member A (FAM64A)


NM_020236.2
mitochondrial ribosomal protein L (MRPL1), nuclear gene encoding



mitochondrial protein


BC043247.2
transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila)



(TLE3)


BC057806.1
insulin-like growth factor binding protein 1 (IGFBP1)


NM_006573.2
tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B)


BC025406.1
phosphodiesterase 4D interacting protein (myomegalin) (PDE4DIP)


BC002559.1
YTH domain family, member 2 (YTHDF2)


NM_052926.1
Paraneoplastic antigen-like protein 5


NM_006254.3
protein kinase C, delta (PRKCD), transcript variant 1


BC022003.1
myotubularin related protein 9 (MTMR9)


BC043348.2
retinitis pigmentosa 2 (X-linked recessive) (RP2)


NM_018010.2
intraflagellar transport 57 homolog (Chlamydomonas) (IFT57)


BC044851.1
vacuolar protein sorting 41 homolog (S. cerevisiae) (VPS41)


BC068094.1
SH3 domain and tetratricopeptide repeats 1 (SH3TC1)


NM_020961.2
KIAA1627 protein (KIAA1627)


PV3757
myosin light chain kinase 2, skeletal muscle (MYLK2)


NM_002451.3
methylthioadenosine phosphorylase (MTAP), mRNA.


NM_000281.1
pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of



hepatocyte nuclear factor 1 alpha (TCF1) (PCBD1)


NM_144982.1
coiled-coil domain containing 131 (CCDC131)


NM_017927.2
mitofusin 1 (MFN1), nuclear gene encoding mitochondrial protein,



transcript variant 2


NM_002150.1
4-hydroxyphenylpyruvate dioxygenase


NM_016267.1
vestigial like 1 (Drosophila) (VGLL1)


BC067299.1
Mdm4, transformed 3T3 cell double minute 4, p53 binding protein



(mouse) (MDM4)


XM_378988.2
PREDICTED: Homo sapiens hypothetical LOC400849 (LOC400849)


NM_006466.1
polymerase (RNA) III (DNA directed) polypeptide F, 39 kDa



(POLR3F)


BC042608.1
family with sequence similarity 90, member A1 (FAM90A1)


NM_025136.1
optic atrophy 3 (autosomal recessive, with chorea and spastic



paraplegia) (OPA3), transcript variant 2


BC012620.1
golgi SNAP receptor complex member 1 (GOSR1)


NM_139244.2
syntaxin binding protein 5 (tomosyn) (STXBP5)


NM_015929.2
lipoyltransferase 1 (LIPT1), transcript variant 1


PV3366
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,



neuro/glioblastoma derived oncogene homolog (avian) (ERBB2),



transcript variant 2


NM_133629.1
RAD51-like 3 (S. cerevisiae) (RAD51L3), transcript variant 4


XM_294794.1
PREDICTED: Homo sapiens similar to putative membrane-bound



dipeptidase 2 (LOC339065)


BC012289.1
KIAA0515 (KIAA0515)


BC029444.1
immunoglobulin kappa constant (IGKC)


BC015109.1
39S ribosomal protein L1, mitochondrial


NM_024578.1
occludin/ELL domain containing 1 (OCEL1)


NM_003908.1
eukaryotic translation initiation factor 2, subunit 2 beta, 38 kDa



(EIF2S2)


BC001726.1
Nucleolar protein 11


BC003666.2
NAD synthetase 1 (NADSYN1)


NM_198491.1
family with sequence similarity 92, member B (FAM92B)


PV3817
WEE1 homolog (S. pombe) (WEE1)


BC000974.2
WDR45-like (WDR45L)


BC053675.1
thymopoietin (TMPO)


BC033292.1
interleukin 20 receptor beta (IL20RB)


BC002509.1
PHD finger protein 23


BC006969.1
dynein, cytoplasmic 2, light intermediate chain 1, mRNA (cDNA



clone MGC: 12166 IMAGE: 3828551), complete cds


BC069491.1
Cerberus


NM_138559.1
B-cell CLL/lymphoma 11A (zinc finger protein) (BCL11A),



transcript variant 3


BC004376.1
annexin A8 (ANXA8L1)


NM_005620.1
S100 calcium binding protein A11 (S100A11)


PV3872
epidermal growth factor receptor (erythroblastic leukemia viral (v-



erb-b) oncogene homolog, avian) (EGFR); see catalog number for



detailed information on wild-type or point mutant status


NM_032214.1
Src-like-adaptor 2 (SLA2), transcript variant 1


NM_002444.1
moesin (MSN)


NM_173796.2
hypothetical protein MGC24125 (MGC24125)


NM_002648.1
pim-1 oncogene (PIM1)


NM_001876.2
Carnitine O-palmitoyltransferase 1, liver isoform


BC014532.1
decapping enzyme, scavenger (DCPS)


NM_001005266.1
Dresden prostate carcinoma protein 2


NM_007172.2
nucleoporin 50 kDa (NUP50), transcript variant 2


NM_018326.1
GTPase, IMAP family member 4 (GIMAP4)


BC033881.1
XRCC6 binding protein 1 (XRCC6BP1)


NM_020168.3
p21(CDKN1A)-activated kinase 6 (PAK6)


NM_014790.3
janus kinase and microtubule interacting protein 2 (JAKMIP2)


NM_032360.1
acyl-Coenzyme A binding domain containing 6 (ACBD6)


NM_006303.2
JTV1 gene (JTV1)


BC017305.1
sirtuin (silent mating type information regulation 2 homolog) 7 (S. cerevisiae)



(SIRT7)


BC051762.1
Uncharacterized protein C20orf96


NM_145010.1
chromosome 10 open reading frame 63 (C10orf63)


NM_206834.1
Uncharacterized protein C6orf201


BC009350.1
Eukaryotic translation initiation factor 2-alpha kinase 4


NM_003720.1
Proteasome assembly chaperone 1


BC067755.1
potassium channel tetramerisation domain containing 18 (KCTD18)


BC005840.2
selenoprotein S (SELS)


BC000934.2
eukaryotic translation initiation factor 2, subunit 2 beta, 38 kDa



(EIF2S2)


NM_020175.1
dihydrouridine synthase 3-like (S. cerevisiae) (DUS3L)


BC014667.1
immunoglobulin heavy constant gamma 1 (G1m marker) (IGHG1)


NM_201403.1
MOB1, Mps One Binder kinase activator-like 2C (yeast) (MOBKL2C),



transcript variant 2


BC010537.1
SUB1 homolog (S. cerevisiae) (SUB1)


NM_170746.2
Selenoprotein H


NM_003092.3
small nuclear ribonucleoprotein polypeptide B′′ (SNRPB2), transcript



variant 1


NM_005105.2
RNA binding motif protein 8A (RBM8A)


BC047411.1
tubulin tyrosine ligase-like family, member 2 (TTLL2)


NM_199188.1
La ribonucleoprotein domain family, member 4 (LARP4), transcript



variant 2


BC003551.1
transglutaminase 2 (C polypeptide, protein-glutamine-gamma-



glutamyltransferase) (TGM2)


BC020647.1
coiled-coil domain containing 59 (CCDC59)


BC011781.2
chromosome 9 open reading frame 37 (C9orf37)


NM_032858.1
maelstrom homolog (Drosophila) (MAEL)


NM_144971.1
hypothetical protein MGC26641 (MGC26641)


BC017440.1
trafficking protein particle complex 2-like (TRAPPC2L)


BC017018.1
DnaJ (Hsp40) homolog, subfamily C, member 12 (DNAJC12)


NM_144767.3
A kinase (PRKA) anchor protein 13 (AKAP13), transcript variant 3


NM_018297.2
N-glycanase 1 (NGLY1)


NM_002307.1
lectin, galactoside-binding, soluble, 7 (galectin 7) (LGALS7)


NM_003939.2
beta-transducin repeat containing (BTRC), transcript variant 2, mRNA.


NM_013242.1
chromosome 16 open reading frame 80 (C16orf80)


NM_152285.1
arrestin domain containing 1 (ARRDC1)


NM_178425.1
histone deacetylase 9 (HDAC9), transcript variant 5


NM_007255.1
xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7



(galactosyltransferase I) (B4GALT7)


NM_205833.1
immunoglobulin superfamily, member 1 (IGSF1), transcript variant 2


BC040457.1
calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha



(CAMK2A)


NM_004732.1
potassium voltage-gated channel, shaker-related subfamily, beta



member 3 (KCNAB3)


NM_004450.1
enhancer of rudimentary homolog (Drosophila) (ERH)


XM_378582.2
PREDICTED: Homo sapiens hypothetical LOC400523



(LOC400523)


NM_001006666.1
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like



3F (APOBEC3F), transcript variant 2, mRNA.


BC041876.1
tau tubulin kinase 2 (TTBK2)


BC036335.1
BTB (POZ) domain containing 12 (BTBD12)


BC036099.1
aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2)


NM_054012.1
argininosuccinate synthetase 1 (ASS1), transcript variant 2


NM_057749.1
cyclin E2 (CCNE2)


PV3839
CDC-like kinase 4 (CLK4)


BC005026.1
sirtuin (silent mating type information regulation 2 homolog) 6 (S. cerevisiae)



(SIRT6)


NM_013975.1
ligase III, DNA, ATP-dependent (LIG3), nuclear gene encoding



mitochondrial protein, transcript variant alpha


NM_181509.1
microtubule-associated protein 1 light chain 3 alpha (MAP1LC3A),



transcript variant 2


BC001709.1
NAD kinase (NADK)


NM_002638.1
peptidase inhibitor 3, skin-derived (SKALP) (PI3)


NM_005901.2
SMAD family member 2 (SMAD2), transcript variant 1


BC046199.1
family with sequence similarity 72, member B (FAM72B)


NM_015417.2
sperm flagellar 1 (SPEF1)


NM_018328.1
methyl-CpG binding domain protein 5 (MBD5)


BC017328.2
angiotensin II receptor-associated protein (AGTRAP)


NM_182739.1
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17 kDa



(NDUFB6), nuclear gene encoding mitochondrial protein, transcript



variant 2


NM_001032293.1
zinc finger protein 207 (ZNF207), transcript variant 2


NM_012227.1
Putative GTP-binding protein 6


BC026039.1
mitochondrial GTPase 1 homolog (S. cerevisiae) (MTG1)


BC072409.1
Serine/threonine-protein phosphatase 4 regulatory subunit 3A


BC066938.1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 (DDX43)


BC000712.1
kinesin family member C1 (KIFC1)


BC000052.1
peroxisome proliferator-activated receptor alpha (PPARA)


NM_004117.2
FK506 binding protein 5 (FKBP5)


NM_002629.2
phosphoglycerate mutase 1 (brain) (PGAM1)


NM_015122.1
FCH domain only 1 (FCHO1)


NM_001021.2
ribosomal protein S17 (RPS17)


NM_013323.1
sorting nexin 11 (SNX11), transcript variant 2


BC002950.1
chromosome 18 open reading frame 8 (C18orf8)


NM_017612.1
Zinc finger CCHC domain-containing protein 8


BC035048.2
neurogenic differentiation 6 (NEUROD6)


BC046117.1
dynein, axonemal, light intermediate chain 1 (DNALI1)


NM_005335.3
Hematopoietic lineage cell-specific protein


NM_144679.1
chromosome 17 open reading frame 56 (C17orf56)


NM_004881.1
tumor protein p53 inducible protein 3 (TP53I3), transcript variant 1


NM_199334.2
thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-



erb-a) oncogene homolog, avian) (THRA), transcript variant 1


NM_201567.1
cell division cycle 25 homolog A (S. pombe) (CDC25A), transcript



variant 2


BC012945.1
Uncharacterized protein C19orf57


BC043394.1
ankyrin repeat domain 17 (ANKRD17)


NM_053005.2
HCCA2 protein (HCCA2)


NM_175065.2
histone cluster 2, H2ab (HIST2H2AB)


NM_004706.3
Rho guanine nucleotide exchange factor (GEF) 1 (ARHGEF1),



transcript variant 2


NM_014346.1
TBC1 domain family, member 22A (TBC1D22A)


NM_133480.1
transcriptional adaptor 3 (NGG1 homolog, yeast)-like (TADA3L),



transcript variant 2


BC048969.1
TSPY-like 1 (TSPYL1)


NM_020319.1
ankyrin repeat and MYND domain containing 2 (ANKMY2)


NM_016046.2
exosome component 1 (EXOSC1)


NM_001003396.1
tumor protein D52-like 1 (TPD52L1), transcript variant 3


NM_005870.3
Histone deacetylase complex subunit SAP18


NM_003403.3
YY1 transcription factor (YY1)


BC036096.2
zinc finger protein 18 (ZNF18)


NM_001010844.1
Interleukin-1 receptor-associated kinase 1-binding protein 1


BC029524.1
Coiled-coil domain-containing protein 46


NM_152387.2
BTB/POZ domain-containing protein KCTD18


BC002369.1
Serine/threonine-protein kinase PLK1


BC092404.1
Rap guanine nucleotide exchange factor 3


NM_004922.2
SEC24 related gene family, member C (S. cerevisiae) (SEC24C),



transcript variant 1


NM_198217.1
Inhibitor of growth protein 1


BC051911.1
chromosome 13 open reading frame 24 (C13orf24)


NM_006205.1
phosphodiesterase 6H, cGMP-specific, cone, gamma (PDE6H)


NM_006439.3
Protein mab-21-like 2


NM_173456.1
phosphodiesterase 8A (PDE8A), transcript variant 4


BC019268.1
Protein arginine N-methyltransferase 1


NM_173642.1
family with sequence similarity 80, member A (FAM80A)


NM_194299.1
Synaptonemal complex protein 2-like


BC062323.1
chromosome 21 open reading frame 25 (C21orf25)


NM_021709.1
Apoptosis regulatory protein Siva


BC100813.1
Putative T-complex protein 1 subunit theta-like 2


BC026317.1
solute carrier family 16, member 1 (monocarboxylic acid transporter



1) (SLC16A1)


BC010956.1
Keratinocyte growth factor


NM_005034.2
polymerase (RNA) II (DNA directed) polypeptide K, 7.0 kDa



(POLR2K)


BC024291.1
BR serine/threonine kinase 2 (BRSK2)


NM_001001568.1
phosphodiesterase 9A (PDE9A), transcript variant 3, mRNA.


NM_014314.3
Probable ATP-dependent RNA helicase DDX58


BC047420.1
UBX domain-containing protein 7


NM_000430.2
platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit



45 kDa (PAFAH1B1)


PV3873
epidermal growth factor receptor (erythroblastic leukemia viral (v-



erb-b) oncogene homolog, avian) (EGFR); see catalog number for



detailed information on wild-type or point mutant status


NM_001328.1
C-terminal binding protein 1 (CTBP1), transcript variant 1


NM_001009959.1
Ermin


BC050387.1
ankyrin repeat and sterile alpha motif domain containing 3 (ANKS3)


NM_007194.1
Serine/threonine-protein kinase Chk2


NM_018492.2
PDZ binding kinase (PBK)


NM_182801.1
EGF-like, fibronectin type III and laminin G domains (EGFLAM),



transcript variant 4


BC016615.1
RAB37, member RAS oncogene family (RAB37)


BC008950.2
Prenylated Rab acceptor protein 1


BC041831.1
transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila)



(TLE3)


NM_003104.2
sorbitol dehydrogenase (SORD)


BC003555.1
nucleolar complex associated 2 homolog (S. cerevisiae) (NOC2L)


NM_001274.2
CHK1 checkpoint homolog (S. pombe) (CHEK1)


NM_153645.1
nucleoporin 50 kDa (NUP50), transcript variant 3


BC017423.1
mesoderm induction early response 1 homolog (Xenopus laevis)



(MIER1)


BC007424.2
PRP4 pre-mRNA processing factor 4 homolog (yeast) (PRPF4)


NM_007107.2
signal sequence receptor, gamma (translocon-associated protein



gamma) (SSR3)


XM_096472.2
hypothetical LOC143678 (LOC143678)


NM_015698.2
G patch domain and KOW motifs (GPKOW)


NM_018111.1
Putative uncharacterized protein FLJ0490


NM_006694.1
jumping translocation breakpoint (JTB)


NM_000045.2
arginase, liver (ARG1)


BC074765.2
POU domain, class 6, transcription factor 1


NM_172028.1
ankyrin repeat and BTB (POZ) domain containing 1 (ABTB1),



transcript variant 3


BC026345.1
Ermin


NM_201262.1
DnaJ (Hsp40) homolog, subfamily C, member 12 (DNAJC12),



transcript variant 2


NM_002966.1
S100 calcium binding protein A10 (S100A10)


BC013352.1
HpaII tiny fragments locus 9c protein


NM_004873.1
BCL2-associated athanogene 5 (BAG5), transcript variant 2


BC009415.1
kinesin family member 26A (KIF26A)


BC012539.1
mediator complex subunit 31 (MED31)


BC021247.1
Phosphatase and actin regulator 4


NM_004414.3
regulator of calcineurin 1 (RCAN1), transcript variant 1


BC028840.1
ankyrin repeat domain 13C (ANKRD13C)


BC025787.1
alkB, alkylation repair homolog 1 (E. coli) (ALKBH1)


NM_000459.1
Angiopoietin-1 receptor


NM_000788.1
Deoxycytidine kinase


NM_173859.1
breast cancer and salivary gland expression gene (RP11-49G10.8)


NM_152382.1
JmjC domain-containing protein C2orf60


NM_002038.2
interferon, alpha-inducible protein 6 (IFI6), transcript variant 1


BC034984.1
Kinesin-like protein KIF16B


NM_014582.1
odorant binding protein 2A (OBP2A)


BC057760.1
MORN repeat-containing protein 3


NM_005595.1
nuclear factor I/A (NFIA)


NM_032726.1
phospholipase C, delta 4 (PLCD4)


NM_153276.1
solute carrier family 22 (organic anion transporter), member 6



(SLC22A6), transcript variant 2


NM_001011538.1
similar to 60S ribosomal protein L21 (LOC402176)


NM_006433.2
granulysin (GNLY), transcript variant NKG5


NM_024800.1
Serine/threonine-protein kinase Nek11


NM_015850.2
Basic fibroblast growth factor receptor 1


NM_006590.2
ubiquitin specific peptidase 39 (USP39)


NM_199054.1
MAP kinase interacting serine/threonine kinase 2 (MKNK2), transcript



variant 2


BC050696.1
chromosome 12 open reading frame 48 (C12orf48)


NM_024563.1
chromosome 5 open reading frame 23 (C5orf23)


NM_004832.1
glutathione S-transferase omega 1 (GSTO1)


NM_003242.2
transforming growth factor, beta receptor II (70/80 kDa) (TGFBR2),



transcript variant 2


BC050444.1
golgi autoantigen, golgin subfamily a, 4 (GOLGA4)


NM_201259.1
Mitochondrial import inner membrane translocase subunit TIM14


NM_032124.3
haloacid dehalogenase-like hydrolase domain containing 2 (HDHD2)


NM_002870.1
RAB13, member RAS oncogene family (RAB13)


BC000337.2
glucose-6-phosphate dehydrogenase (G6PD)


BC060785.1
tripartite motif-containing 40 (TRIM40)


BC030597.1
ATR interacting protein (TREX1)


BC050551.1
BCL2-associated athanogene 5 (BAG5)


NM_004697.3
PRP4 pre-mRNA processing factor 4 homolog (yeast) (PRPF4)


NM_020990.2
creatine kinase, mitochondrial 1B (CKMT1B), nuclear gene encoding



mitochondrial protein


BC039742.1
poly(rC) binding protein 1 (PCBP1)


BC021573.1
GTP-binding protein 10


NM_015068.1
paternally expressed 10 (PEG10), transcript variant 1


NM_001827.1
CDC28 protein kinase regulatory subunit 2 (CKS2)


NM_152876.1
Tumor necrosis factor receptor superfamily member 6


BC015548.1
RAB3A interacting protein (rabin3) (RAB3IP)


BC062359.1
chromosome 8 open reading frame 47 (C8orf47)


BC029424.1
Probable glutathione peroxidase 8


NM_001786.2
cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1


BC000870.1
TIMELESS interacting protein (TIPIN)


NM_004103.2
Protein tyrosine kinase 2 beta


BC022454.2
Transient receptor potential cation channel subfamily M member 3


NM_024046.1
CaM kinase-like vesicle-associated (CAMKV)


BC040521.1
testis expressed 2 (TEX2)


BC003164.1
leukocyte receptor cluster (LRC) member 4 (LENG4)


NM_000402.2
Glucose-6-phosphate 1-dehydrogenase


BC069328.1
Bcl2 modifying factor (BMF)


BC063463.1
coenzyme Q3 homolog, methyltransferase (S. cerevisiae) (COQ3)


NM_000572.2
Interleukin-10


NM_006374.2
serine/threonine kinase 25 (STE20 homolog, yeast) (STK25)


NM_017966.1
vacuolar protein sorting 37 homolog C (S. cerevisiae) (VPS37C)


BC052602.1
carbonic anhydrase XIII (CA13)


BC018063.1
potassium channel tetramerisation domain containing 4 (KCTD4)


NM_031305.1
Rho GTPase activating protein 24 (ARHGAP24), transcript variant 2


BC056401.1
centaurin, delta 2 (CENTD2)


BC022459.1
sulfotransferase family 4A, member 1 (SULT4A1)


XM_373630.2
PREDICTED: Homo sapiens hypothetical protein LOC145842



(LOC145842)


P3049
v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1),



transcript variant a; see catalog number for detailed information on



wild-type or point mutant status


NM_153012.1
Tumor necrosis factor ligand superfamily member 12


NM_018270.3
MRG-binding protein


BC010739.1
COP9 signalosome complex subunit 7b


NM_015002.2
F-box protein 21 (FBXO21), transcript variant 2


BC000497.1
CaM kinase-like vesicle-associated protein


NM_001449.2
four and a half LIM domains 1 (FHL1)


BC065912.1
Tyrosine-protein kinase ABL2


NM_153356.1
TBC1 domain family, member 21 (TBC1D21)


BC032382.1
similar to pleckstrin homology domain containing, family M (with



RUN domain) member 1; adapter protein 162, mRNA, complete



cds.


BC094800.1
Jouberin


NM_003897.2
immediate early response 3 (IER3)


NM_178821.1
WD repeat domain 69 (WDR69)


NM_198219.1
Inhibitor of growth protein 1


NM_024805.1
chromosome 18 open reading frame 22 (C18orf22)


NM_001040633.1
protein kinase, AMP-activated, gamma 2 non-catalytic subunit



(PRKAG2), transcript variant c, mRNA.


NM_130807.1
MOB1, Mps One Binder kinase activator-like 2A (yeast)



(MOBKL2A)


BC008623.1
roundabout, axon guidance receptor, homolog 3 (Drosophila)



(ROBO3)


NM_001004285.1
DNA fragmentation factor, 40 kDa, beta polypeptide (caspase-



activated DNase) (DFFB), transcript variant 3


BC011885.1
eukaryotic translation initiation factor 2A, 65 kDa (EIF2A)









In another preferred embodiment, the substrate and microarrays may contain, as the autoantigen, at least one of the protein antigens of Table 2, or a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the AD diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the AD diagnostic autoantibody. The protein antigens in Tables 2-5 are identified by art-accepted names as well as database identification numbers. The database identification numbers refer to the publically available protein databases of the National Center for Biotechnology Information (NCBI) which are well-known and accessible to those of ordinary skill in the art.








TABLE 2





Database ID
Description







BC030984.1
cDNA clone MGC: 32654 IMAGE: 4701898, complete cds


PHR5001
Recombinant human CTLA-4/Fc


BC016380.1
cDNA clone MGC: 27376 IMAGE: 4688477, complete cds


BC015833.1
cDNA clone MGC: 27152 IMAGE: 4691630, complete cds


BC099907.1
General transcription factor II-I


BC051695.1
FERM domain containing 8 (FRMD8)


BC040106.1
hypothetical protein HSPC111 (HSPC111)


NM_003141.2
tripartite motif-containing 21 (TRIM21)


NM_003384.1
vaccinia related kinase 1 (VRK1)


BC004236.2
ubiquitin-conjugating enzyme E2S (UBE2S)


BC001662.1
MAP kinase-activated protein kinase 3


NM_017588.1
WD repeat domain 5 (WDR5), transcript variant 1


NM_032377.2
elongation factor 1 homolog (S. cerevisiae) (ELOF1)


NM_021032.2
fibroblast growth factor 12 (FGF12), transcript variant 1


NM_000984.2
ribosomal protein L23a (RPL23A)


BC064984.1
additional sex combs like 1 (Drosophila) (ASXL1)


NM_012387.1
peptidyl arginine deiminase, type IV (PADI4)


NM_001641.2
APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1),



transcript variant 1


NM_001896.2
casein kinase 2, alpha prime polypeptide (CSNK2A2)


NM_014481.2
APEX nuclease (apurinic/apyrimidinic endonuclease) 2 (APEX2),



nuclear gene encoding mitochondrial protein


NM_014280.1
DnaJ homolog subfamily C member 8


BC007228.1
CSAG family, member 3A (CSAG3A)


BC021174.1
Small EDRK-rich factor 1


BC033758.1
centaurin, alpha 2 (CENTA2)


BC005248.1
eukaryotic translation initiation factor 1A, Y-linked (EIF1AY)


BC022098.1
cDNA clone MGC: 31944 IMAGE: 4878869, complete cds


NM_024754.2
pentatricopeptide repeat domain 2 (PTCD2)


NM_024316.1
leukocyte receptor cluster (LRC) member 1 (LENG1)


NM_015920.3
40S ribosomal protein S27-like protein


BC048970.1
tubulin tyrosine ligase-like family, member 7 (TTLL7)


NM_003668.2
mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5),



transcript variant 1


NM_007278.1
GABA(A) receptor-associated protein (GABARAP)


NM_006838.1
methionyl aminopeptidase 2 (METAP2)


NM_018439.1
Impact homolog (mouse) (IMPACT)


NM_002013.2
FK506 binding protein 3, 25 kDa (FKBP3)


NM_018956.2
chromosome 9 open reading frame 9 (C9orf9)


NM_004987.3
LIM and senescent cell antigen-like-containing domain protein 1


BC004292.1
PHD finger protein 15 (PHF15)


NM_133494.1
NIMA (never in mitosis gene a)-related kinase 7 (NEK7)


NM_145063.1
chromosome 6 open reading frame 130 (C6orf130)


NM_021104.1
ribosomal protein L41 (RPL41), transcript variant 1


NM_006223.1
protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4



(parvulin) (PIN4)


NM_003135.1
Signal recognition particle 19 kDa protein


NM_015933.1
coiled-coil domain containing 72 (CCDC72)


NM_001031.4
40S ribosomal protein S28


BC022524.1
fibroblast growth factor 12 (FGF12)


NM_001028.2
ribosomal protein S25 (RPS25)


NM_001997.2
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)



ubiquitously expressed (FAU)


NM_080659.1
chromosome 11 open reading frame 52 (C11orf52)









In another embodiment, the substrate and microarrays may contain, as the autoantigen, at least one of the protein antigens of Table 3, or a polypeptide or peptide fragment thereof containing one or more epitopes recognized by the AD diagnostic autoantibodies, or an epitope peptidomimetic that is recognized by the AD diagnostic autoantibody.








TABLE 3





Database ID
Description







BC051695.1
FERM domain-containing protein 8 (FRMD8)


NM_024754.2
Pentatricopeptide repeat-containing protein 2 (PTCD2)


NM_021104.1
60S ribosomal protein L41(RPL41)


NM_032855.1
Hematopoietic SH2 domain-containing protein HSH2D









In another embodiment of one aspect of the present invention, the microarray contains autoantigens consisting of FERM domain-containing protein 8 (FRMD8), 60S ribosomal protein L41(RPL41), pentatricopeptide repeat-containing protein 2 (PTCD2), and hematopoietic SH2 domain-containing protein (HSH2D) or fragments thereof containing one or more epitopes recognized by an AD diagnostic autoantibody, or epitope peptidomimetics that are recognized by the AD diagnostic autoantibody. In another embodiment, the microarray contains autoantigens consisting of FERM domain-containing protein 8 (FRMD8) and hematopoietic SH2 domain-containing protein (HSH2D) or fragments thereof containing one or more epitopes recognized by an AD diagnostic autoantibody.
In one preferred embodiment of the present invention, the substrate and microarrays may contain, as the autoantigen, at least one of the protein antigens of Table 4, or a fragment thereof containing one or more epitopes recognized by an AD diagnostic autoantibody, or an epitope peptidomimetic that is recognized by the AD diagnostic autoantibody. In another preferred embodiment of the present invention, the substrate and microarrays contain all of the protein antigens of Table 4.








TABLE 4





Database ID
Description







BC051695.1
FERM domain containing 8 (FRMD8)


NM_015833.1
adenosine deaminase, RNA-specific, B1 (RED1 homolog rat)



(ADARB1), transcript variant 2


NM_002305.2
lectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1)


NM_001641.2
APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1),



transcript variant 1


NM_024316.1
leukocyte receptor cluster (LRC) member 1 (LENG1)


NM_014280.1
DnaJ homolog subfamily C member 8


PHC1244
chemokine (C-C motif) ligand 19 (CCL19)


BC064984.1
additional sex combs like 1 (Drosophila) (ASXL1)


NM_021104.1
ribosomal protein L41 (RPL41), transcript variant 1


BC004236.2
ubiquitin-conjugating enzyme E2S (UBE2S)


NM_012387.1
peptidyl arginine deiminase, type IV (PADI4)


NM_003384.1
vaccinia related kinase 1 (VRK1)


NM_004113.3
fibroblast growth factor 12 (FGF12), transcript variant 2


BC021174.1
Small EDRK-rich factor 1


NM_001001794.1
family with sequence similarity 116, member B (FAM116B)


NM_032377.2
elongation factor 1 homolog (S. cerevisiae) (ELOF1)


NM_024754.2
pentatricopeptide repeat domain 2 (PTCD2)


NM_000984.2
ribosomal protein L23a (RPL23A)


NM_139016.2
chromosome 20 open reading frame 198 (C20orf198)


NM_024668.1
ankyrin repeat and KH domain containing 1 (ANKHD1), transcript



variant 3









Parkinson's Disease

In another embodiment of the present invention, the microarrays also contain autoantigens that are reactive with autoantibodies diagnostic for Parkinson's Disease (PD) but not for AD, and thus permit differentiation of AD from PD. Autoantigens diagnostic for PD but not AD include, for example, the proteins of Table 5, and fragments thereof containing one or more epitopes recognized by a PD diagnostic autoantibody and epitope peptidomimetics that are recognized by the PD diagnostic autoantibody.








TABLE 5





Database ID
Description







NM_003177.3
Spleen tyrosine kinase (SYK)


BC_019015.2
Mediator of RNA polymerase II transcription subunit 29



(MED29)


BC003551
Protein-glutamine gamma-glutamyltransferase 2 (TGM2)


PV3851
MAP/microtubule affinity-regulating kinase-4 (MAPrk4)


BC001755.1
Leiomodin-1









The following examples serve to further illustrate the present invention.
Example 1
Materials and Methods
Animals
Swiss-Webster mice were obtained from Taconic Farms (Hudson, N.Y.) and used for experiments at 3-6 months of age. Sprague-Dawley rats were also obtained from Taconic Farms and used at 7-9 weeks of age. Both were maintained on ad libitum food and water with 12-hour light/dark cycle in an AALAC-accredited vivarium. Animals use was reviewed and approved by the UMDNJ IACUC.
Human Brain Tissue
Brain tissue from patients with sporadic AD (n=23, age range=71-88) and age-matched, neurologically normal individuals (n=14, age range=69-83) were obtained from the Harvard Brain Tissue Resource Center (Belmont, Mass.), the Cooperative Human Tissue Network (Philadelphia, Pa.), the UCLA Tissue Resource Center (Los Angeles, Calif.) and Slidomics (Cherry Hill, N.J.). Post-mortem intervals were <24 h and pathological confirmation of AD was evaluated according to criteria defined by the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of AD (Hyman and Trojanowski (1997) J Neuropathol Exp Neurol 56, 1095-7). Formalin-fixed tissues were processed for routine paraffin embedding and sectioning according to established protocols. Control tissues exhibited minimal localized microscopic AD-like neuropathology.
Antibodies
Aβ42 antibodies were obtained from Millipore International (Temecula, Calif.,) (polyclonal, Cat. No. AB5078P, dilution=1:50) and Pharmingen (San Diego, Calif.) (polyclonal Cat. No. 4767, dilution=1:50). Biotinylated anti-human IgG antibodies for immunohistochemistry were obtained from Vector Laboratories (Burlingame, Calif.) (host: goat, Cat. No. PK-6103, dilution=1:100). Peroxidase-conjugated anti-human IgG antibodies for western blotting were obtained from Thermo Scientific (Rockford, Ill.) (host: goat, Cat. No. 31410, dilution=1:200,000). The following antibodies were used for treatments of mouse organotypic brain slice cultures: anti-alpha7 nicotinic acetylcholine receptor (C-20, Santa Cruz Biotechnology, Santa Cruz, Calif.); anti-GluR2 (polyclonal N19, Santa Cruz Biotechnology, Santa Cruz, Calif.); anti-beta tubulin (D-10, Santa Cruz Biotechnology, Santa Cruz, Calif.). The specificity of these antibodies was confirmed by western blotting.
Human Sera
Human serum samples [AD (n=52, age range=61-97 years); age-matched controls (n=28, age range=51-86); and younger healthy controls (n=28, age range=19-30 years)] were obtained from Analytical Biological Services Inc (Wilmington, Del.). Samples were numerically coded and included the following information: age and sex of the patient, the presence or absence of a detectable neurological disease and, if present, an indication of disease severity and estimated post-mortem interval. Use of these samples was approved by the UMDNJ IRB.
Immunohistochemistry
Immunohistochemistry was carried out using paraffin-embedded brain tissues as previously described (D'Andrea et al. (2001) Histopathology 38, 120-34; Nagele et al. (2002) Neuroscience 110, 199-211). Briefly, tissues were deparaffinized using xylene and rehydrated through a graded series of decreasing concentrations of ethanol. Antigenicity was enhanced by microwaving sections in citrate buffer. Endogenous peroxidase was quenched by treating sections with 0.3% H2O2 for 30 min. Sections were incubated in blocking serum and then treated with primary antibodies at appropriate dilutions for 1 hr at room temperature. After a thorough rinse in PBS, biotin-labeled secondary antibody was applied for 30 min. Sections were treated with the avidin-peroxidase complex (Vectastain ABC Elite, Vector Laboratories, Inc., Foster City, Calif.) and visualized with 3-3-diaminobenzidine-4-HCL (DAB)/H2O2 (1 mm-Pact-DAB) (Vector). Sections were then lightly counterstained with hematoxylin, dehydrated through increasing concentrations of ethanol, cleared in xylene and mounted in Permount. Controls consisted of brain sections treated with non-immune serum or omission of the primary antibody. Specimens were examined and photographed with a Nikon FXA microscope, and digital images were recorded using a Nikon DXM1200F digital camera and processed and analyzed using Image Pro Plus (Phase 3 Imaging, Glen Mills, Pa.) and Cell Profiler image analysis softwares.
Preparation of Adult Rat Brain Proteins
To prepare rat brain protein fractions, fresh rat brain tissue was removed from storage at −80° C. and placed in a 1 mM phenylmethylsulfonyl fluoride, 50.0 mM Tris-HCL buffer solution, pH 7.4, at a 10.0 ml/g ratio along with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Mo.) at a 0.5 ml/g ratio. Using a pre-cooled Dounce homogenizer (Arrow Engineering Co., Inc., Hillside, N.J.) at a setting of four, brain samples were subjected to homogenization. Brain samples were then centrifuged at 3,000 rpm using a Beckman CS-6R centrifuge (Beckman Coulter Inc, Brea, Calif.) equipped with a swing-rotor at 4° C. for a period of 10 min to remove intact cells and large debris. The supernatant was retained as whole brain protein fraction. Protein concentrations were determined using the Bradford Assay.
Detection of Autoantibody Targets Via Western Blotting
Western blot analysis was performed to determine the brain membrane targets of serum auto-antibodies. First, 12.5% SDS-polyacrylamide separating gels were cast using the Mini PROTEAN 3 System (165-3302, BioRad, Hercules, Calif.) and overlain with stacking gels (4.0%). 100.0 μg of protein sample was added to sample buffer and applied to the gel alongside PageRulerTM Prestained Protein Ladder Plus (SM1811, Fermentas, Glen Burnie, Md.). Proteins were then fractionated at 130V for 7 minutes, followed by 100V for the remainder of the resolving time. Proteins were then transferred to Hybond-ECL Nitrocellulose Membrane (RPN3032D, Amersham, Piscataway, N.J.) for 75 minutes at 180 mA. Blots were blocked in 5.0% non-fat dried milk dissolved in PBS-Tween (PBS-T) then transferred to human serum samples (primary antibody), diluted 1:500 in blocking solution, for overnight incubation at 4° C. The following morning, blots were thoroughly rinsed in PBS-T then placed in the appropriately diluted peroxidase-conjugated secondary antibody and incubated for one hour at 4° C. Blots were then thoroughly rinsed in PBS-T then quickly rinsed in dH2O to remove phosphate buffer. Blots were then developed using the Pierce enhanced chemiluminescence (ECL) substrate (32106, Pierce, Rockford, Ill.) and autoradiography film (XAR ALF 1824, Lab Scientific, Livingston, N.J.). Each western blot for a given serum sample was performed in triplicate.
Mouse Organotypic Brain Slice Cultures and Treatments
Organotypic adult mouse brain slice cultures (MBOCs) were prepared using the technique of Stoppini et al. (1991) J Neurosci Methods. 37, 173-82. Neurons in these cultures have been shown to accumulate exogenous Aβ42 (detectable within 4 h of exposure to 100 nM Aβ42) (Bahr et al., (1998) J Comp Neurol. 397, 139-47; Harris-White et al., (1998) J Neurosci. 18, 10366-74; Malouf, (1992) Neurobiol Aging. 13, 543-51; Stoppini et al. (1991)). Brains from Swiss-Webster mice (3-6 months old) were isolated under sterile conditions and transverse coronal slices (0.5-0.75 mm thick) through desired brain regions were prepared using a Mcllwain tissue chopper, placed on 30 mm Millicell-CM culture inserts (Millicell-CM, Millipore, Bedford, Mass., USA), and allowed to stabilize in serum-free medium (DMEM) briefly (one hour) or in 25% inactivated horse serum, 25% Hanks' BSS, 50% DMEM, 25 mg/l penicillin-streptomycin) overnight prior to treatment. Following stabilization, cultures were exposed to serum-free medium (DMEM alone) or complete medium (25% inactivated horse serum, 25% Hanks' BSS, 50% DMEM, 25 mg/l penicillin-streptomycin) containing Aβ42 peptide (100 nM), anti-GluR2 antibody (diluted 1:250), human serum samples (diluted 1:50), anti-α7nAChR antibody (diluted 1:1000), anti-β-tubulin antibody (diluted 1:200). Control slices received medium only. MBOCs were treated for up to 72 h at 37° C. in a 5% CO2-enriched atmosphere. Aβ42 was solubilized to the monomeric form using the method of (Zagorski et al. (1999) Methods Enzymol. 309, 189-204).
Image Analysis
The extent of Aβ42 accumulation in MBOCs treated with 100 nM Aβ42 with or without human serum or antibodies directed against the α7nAChR or GluR2 was determined using quantitative immunohistochemistry. MBOCs treated as described above were first immunostained with anti-Aβ42 antibodies under identical conditions. Images were then recorded under identical illumination and camera settings using a Nikon FXA microscope equipped with a Nikon CCD camera and image analysis softwares (Image Pro Plus and Cell Profiler). Relative amounts of intracellular Aβ42-positive deposit per Aβ42-positive cell were determined and compared among the different treatment groups. The significance of differences in the amount of intracellular Aβ42 within cells were determined by the Student's t-test. Controls for immunohistochemistry included nonimmune serum or detection antibody only.
Example 2
Brain Reactive Autoantibodies in Human Sera
Sera from AD patients (n=52, age range 61-97 years), age-matched, non-demented control subjects (n=28, age range 51-86 years) and younger healthy individuals (n=28, age range 19-30 years) were tested for the presence of brain-reactive autoantibodies. For western analyses, individual sera were tested for the presence of brain-reactive autoantibodies by probing proteins obtained from whole cell homogenate derived from adult rat brain. Results confirmed the presence of brain-reactive autoantibodies in all sera from the three groups tested. The number of immunoreactive protein bands generated by each serum sample was similar for all three subject groups: mean=5.1+/−3.1 for AD sera (n=52); 7.4+/−4.0 for age-matched control sera (n=28); and 6.0+/−3.8 for younger healthy control sera (n=28). Comparable results were obtained when human sera were used to probe mouse and human brain proteins. Based on apparent molecular weights in western blots, a few potentially common protein bands were noted within and among the three subject groups.
Example 3
IgG-Positive Neurons in Brain Regions Exhibiting AD Pathology
Ig-positive neurons in postmortem AD brains have been reported (Bouras et al. (2005) Brain Res Brain Res Rev. 48, 477-87; Clifford et al. (2007) Brain Res. 1142, 223-36; Deane and Zlokovic (2007) Curr Alzheimer Res. 4, 191-7; Franceschi et al. (1989) J. Gerontol. 44, M128-30; Kalaria (1999) Ann NY Acad. Sci. 893, 113-125; Kulmala et al. (1987) Exp Aging Res 13:67-72; Loeffler et al. (1997) Neurochem Res. 22, 209-14; Mooradian (1988) Neurobiol Aging. 9, 31-9; Nandy et al. (1975) J. Gerontol. 30, 269-74; Stein et al. (2002) J Neuropathol Exp Neurol. 61, 1100-8). In this example, immunohistochemistry using anti-human IgG antibodies was employed to test for the presence of IgG-immunopositive brain components in 23 AD and 14 age-matched control brains. IgG-positive neurons with immunolabeled cell bodies and dendrite trunks were found in all brains that were examined. IgG-positive neurons were far more abundant, widespread and intensely immunostained in AD brains than in corresponding age-matched control brains. In the latter, IgG-positive neurons were most often encountered as scattered individual cells and small cell clusters separated by relatively large expanses of brain tissue that were completely devoid of IgG-positive cells. In AD brains, IgG-positive neurons were particularly abundant in brain regions known to be vulnerable to AD-associated pathological changes (e.g., temporal cortex, entorhinal cortex and hippocampus). In both AD and control brains, IgG immunoreactivity was consistently and preferentially associated with pyramidal neurons, and these cells often showed marked individual variations in the intensity of IgG immunolabeling, sometimes with IgG-positive and -negative neurons present in close proximity. Similar variations in neuronal IgG immunostaining intensity were noted in neurons of the hippocampus. In pyramidal neurons, IgG immunoreactivity was most conspicuous in the cell body and proximal segment of the main dendrite trunk. Most of the smaller neurons, astrocytes and microglia that were interspersed among pyramidal cells were IgG-negative. In three of the 23 AD brains examined, both astrocytes and pyramidal neurons were IgG-positive, but this was not observed in age-matched control brains.
Example 4
Relationship Between IgG Immunoreactivity and Aβ42 Deposition
Sections of post-mortem AD brain tissue were probed with antibodies specific for human IgG and Aβ42. In regions of the cerebral cortex and hippocampus showing mild AD pathology (i.e., regions with sequestered intraneuronal Aβ42 deposits but few amyloid plaques), Aβ42-immunopositive neurons also exhibited intense IgG immunostaining. Two sets of consecutive sections were immunostained to reveal the relative distribution of Aβ42 and IgG in the cerebral cortex of AD brains. In regions exhibiting mild AD pathology, both IgG and Aβ42 were colocalized to the same neurons appearing in both sections. Likewise, in cortical regions showing more advanced pathology (as judged by the increased deposition of Aβ42 within neurons and amyloid plaques), the amount of interstitial and intraneuronal IgG was substantially increased. In addition to the typical large juxtanuclear deposits of Aβ42-rich material in pyramidal neurons, the main dendrite trunks of these cells frequently contained abundant small Aβ42-positive granules of uniform size. These results demonstrate the temporal and spatial coincidence of intraneuronal Aβ42 deposition and IgG immunolabeling within pyramidal neurons.
Example 5
Reactivity of Human Serum Antibodies with Living Neurons
To test for the reactivity (i.e., binding) of human serum antibodies with the surfaces of living neurons, adult mouse brain organotypic (brain slice) cultures (MBOCs) were maintained in medium with or without diluted human serum for up to 72 h. MBOCs retain the adult brain histological architecture for up to several weeks under proper conditions and have been shown to contain neurons that internalize and accumulate exogenous, soluble Aβ42 peptide (Bahr et al. (1998); Harris-White et al. (1998); Malouf (1992); Stoppini et al. (1991). The binding of human IgG to neurons in MBOCs was detected by immunohistochemistry using anti-human IgG antibodies. Addition of human serum to the culture medium resulted in intense and selective IgG immunolabeling of living adult mouse neurons, whereas controls not treated with serum showed no inherent IgG immunoreactivity. The pattern of background IgG immunostaining in human serum-treated MBOCs suggests that dendrites and/or synaptic connections may also be IgG-positive. As was shown in postmortem human AD brains described above, pyramidal neurons of the cerebral cortex of MBOCs were consistently the most intensely immunopositive cells.
Example 6
Effect of Autoantibodies on Internalization of Exogenous Aβ42
This example utilizes the property of cross-reactivity of the antibodies in human serum with rodent brain proteins as demonstrated above in western blots and in brain tissue as shown above in immunohistochemical preparations. MBOCs were treated with 100 nM Aβ42 in the presence or absence of individual human serum samples diluted 1:50 in otherwise serum-free medium for 1, 3, 24, 48 and 72 h and the relative amounts of intraneuronal Aβ42 were quantified using image analysis for MBOCs treated for 24 h. MBOCs treated with 100 nM Aβ42 alone for 24 h showed no human IgG immunostaining and only minimal Aβ42 immunoreactivity. On the other hand, when MBOCs were exposed to human serum autoantibodies and Aβ42 peptide for 24 h, pyramidal neurons selectively showed a dramatic increase in intracellular Aβ42 accumulation over that of controls treated with Aβ42 peptide or serum alone for the same time period. Within these neurons, Aβ42-positive material was localized to dense cytoplasmic granules that were concentrated in the neuronal perikaryon and proximal dendrite trunk. Measurements of the relative amounts of intraneuronal Aβ42 in MBOCs using image analysis after 24 h of treatment revealed that the addition of human serum to medium containing 100 nM Aβ42 caused a many-fold increase in neuronal Aβ42 immunoreactivity over that in cells treated with Aβ42 alone. Morphological evidence of significant cell death and loss of Aβ42-burdened neurons in MBOCs was not observed
Example 7
Effect of Purified Antibodies Targeting Neural Surface Proteins on Internalization of Exogenous Aβ42
MBOCs were treated for 24 h with commercially available antibodies directed against two neuronal receptors that are known to be abundantly expressed on neuronal cell surfaces, the alpha7 nicotinic acetylcholine receptor (α7nAChR) and the glutamate R2 (GluR2) receptor. Both antibodies were found to be effective in increasing intraneuronal Aβ42 accumulation, again selectively in pyramidal neurons and well above levels seen in cultures treated with Aβ42 alone. To explore whether neuronal cell surface reactivity of IgG is required for enhancement of exogenous Aβ42 internalization, MBOCs were also treated with an antibody directed against the common intracellular protein, beta-tubulin, along with 100 nM Aβ42. Treatment with beta-tubulin antibody resulted in levels of neuronal Aβ42 accumulation that were comparable to treatment with 100 nM Aβ42 alone.
Example 8
Identification of Autoantibodies Diagnostic for AD
Western Analysis
As disclosed hereinabove, biochemical confirmation of the presence of brain-reactive autoantibodies in individual human sera was carried out using western analysis. In addition, total rat brain protein, which is immunoreactive to human autoantibodies as shown hereinabove, was used to compare sera from patients with AD, age-matched neurologically normal controls and younger healthy individuals. Based on estimated molecular weights alone, the resulting distributions of molecular weights for individual target proteins were analyzed using the pattern recognition computer program called A.I. Solver (Silversoft Solutions).
Based on the recognition of specific patterns of distribution of molecular weights of autoantibody target proteins, A.I. Solver was able to distinguish western blots derived from AD patient's sera from that of age-matched controls and younger healthy subjects 98% of the time. This example demonstrates the existence of AD-specific protein antibodies in the blood that bind to brain protein target antigens. Next, a protein microarray platform was used identify the specific subset of autoantibodies and their target proteins that are useful to effectively diagnose AD.
Microarray Procedure
The protein microarray platform used to identify diagnostic antibodies and prove the efficacy of a protein microarray diagnostic was Invitrogen's ProtoArray® Human Protein Microarray v5.0. It is a high-density protein microarray containing thousands of purified human proteins for protein interaction screening. Each human open reading frame (ORF) is expressed as an N-terminal GST fusion protein using a baculovirus expression system, purified from insect cells, and printed in duplicate on a nitrocellulose-coated glass slide. The Immune Response Biomarker Profiling application was used as it is best suited the needs of a diagnostic. All reagents and materials were purchased directly through Invitrogen. The recommended Invitrogen Prot® Array® protocol was strictly adhered to at all times and is incorporated herein by reference in its entirety. The array was probed with diluted (1:500) human serum or plasma.
Microarray Scanning
The protein microarrays were scanned using the recommended Axon Genepix 4000b imager. Individual slides were inserted into the imager and then scanned using 100% laser power, 635 nm excitation wavelength, PMT 600, and Sum pixel size. Data was extracted from the image by syncing it with a Genepix Array List (.GAL) file obtained from Invitrogen. GAL files describe the location and identity of all spots on the protein microarray and are used by Genepix Pro software (by Molecular Devices) to generate files that contain pixel intensity information for all features on the array. Genepix Pro then creates a .GPR (Genepix Pixel Results) file that lists all of the pixel intensity data for each protein spot on the microarray in text-only spreadsheet format. It is the GPR file that is imported into Prospector for data analysis.
Normalization
After acquiring the individual microarray data by scanning the microarrays with an Axon Genepix 4000b imager and performing the initial quantification with Genepix Pro software, the resulting data were normalized so as to allow microarray-to-microarray comparison. For this, Invitrogen's proprietary software, Prospector; more specifically, the Immune Response Biomarker Profiling Toolbox application, was used. Each microarray's gpr file was imported into the program, analyzed, and normalized to a linear model.
Fitting the data to a linear model was performed through a robust regression by means of an iteratively re-weighted least-square procedure with an M-estimator, like the median. The linear model uses log-transformed signals to estimate and correct the variations. For each spot replicate r (=1, 2) of protein feature k (=1, . . . , nf) in sub-array j (=1, . . . , 48) on slide i (=1, . . . , ns,) the following model was fit:

yijkr=αi+βj+τk+εijkr 

where yijkr is the observed signal in log 2 scale, α is the slide effect, βj is the sub-array/block effect (including printing pin effect), τk is the “true” signal of the protein feature (different protein content printed in different concentration), and εijkr the error, assuming εijkr ̃N(0,σ2). After the coefficients of these effects were estimated using control proteins, the normalized signal in its original scale for each spot was calculated as:

Sijkr=2^(yijkr−αi−βj)

After normalization, the microarray data was fully adjusted for error and individual variation; formal analysis was begun. It was this adjusted data from which diagnostic significance was determined.
Data Analysis
There are multiple accepted methods of determining the diagnostic significance of microarray fluorescence data. To ensure the reproducibility and accuracy of our results, data were analyzed three separate times using three independent and distinct methods. The methods chosen are among the most reliable and consistent available, and are commonly used in similar studies. The methods are: M-Statistical Prevalence, Nearest Shrunken Centroid Analysis, and Random Forest Decision-Making Trees. To harness each of these unbiased statistical quantification schemes, Prospector, PAM, and R's Random Forest, respectively, were utilized. Each of these programs evaluated the protein microarray data to determine which proteins were most significant to diagnose Alzheimer's Disease. The lists reflected one another almost exactly, thus demonstrating that protein microarrays are useful as a successful diagnostic. The statistical methods, programs involved, and results generated are described below.
M-Statistical Analysis
As well as interpreting and normalizing the raw fluorescence data generated by Genepix Pro, Prospector was used to generate M-Statistics that were, in turn, used to evaluate each protein's diagnostic significance. Briefly, M-statistics were used to determine the number of assays in one group (e.g. Alzheimer's or Control) that have a signal value for a protein greater than the highest observed signal value of this probe in the comparison group. The M order statistic for the group y of size ny compared to group x of size nx is given by the formula:

Myi,above,between=Σ1{yk>x(i)+between}1{yk>above}

where x(i) is the ith largest value of the group x, and above and between are the calculation parameters. A p-value was calculated as the probability of having M value greater or equal than Mi. Prospector selected the M statistic with the lowest p-value and reported this Mmax value and order, as well as a corresponding p-value and protein prevalence estimate. The values were viewed as a spreadsheet in Microsoft Excel Workbook format, and filtered to provide a list of the most effective indicators of group differences, i.e., the proteins that are the best diagnostic markers.

PAM (Prediction Analysis of Microarrays)

Another method of interpreting protein microarray results and yielding protein significance is PAM, or Prediction Analysis of Microarrays. PAM is a statistical technique for class prediction that uses nearest shrunken centroids. It is run as a Microsoft Excel Macro and has been used extensively in characterizing microarray results (Tibshirani et al. (2002) Proc Natl Acad Sci USA 99:6567-6572). The program was used to identify specific subsets of fluorescence data that best characterize each class and thus serve as significant diagnostic indicators. Briefly, the method computed a standardized centroid for each class. This is the average fluorescence for protein in each class divided by the within-class standard deviation for that protein. Centroids were “shrunken”—reduced by a threshold value—to reduce error and outlier effect. The microarray fluorescence of each new sample was then compared to each shrunken class centroid; the class whose centroid that it was closest to, in squared distance, was the predicted class for that new sample. Using this information, PAM generated a list of proteins presented in order of diagnostic significance.
PAM was used to produce a list of the top fifty most important proteins for distinguishing Alzheimer's Disease sera from Control Sera which is shown below in Table 6.










TABLE 6





Protein

AD
Control


database ID
Description
score
score


















BC030984.1
cDNA clone MGC: 32654 IMAGE: 4701898,
0.2132
−0.2665



complete cds


PHR5001
Recombinant human CTLA-4/Fc
0.2108
−0.2635


BC016380.1
cDNA clone MGC: 27376 IMAGE: 4688477,
0.1766
−0.2208



complete cds


BC015833.1
cDNA clone MGC: 27152 IMAGE: 4691630,
0.1621
−0.2026



complete cds


BC099907.1
General transcription factor II-I
−0.156
0.195


BC051695.1
FERM domain containing 8 (FRMD8)
0.1452
−0.1816


BC040106.1
hypothetical protein HSPC111 (HSPC111)
0.1429
−0.1787


NM_003141.2
tripartite motif-containing 21 (TRIM21)
0.1388
−0.1735


NM_003384.1
vaccinia related kinase 1 (VRK1)
0.1268
−0.1585


BC004236.2
ubiquitin-conjugating enzyme E2S (UBE2S)
0.1244
−0.1555


BC001662.1
MAP kinase-activated protein kinase 3
0.1183
−0.1479


NM_017588.1
WD repeat domain 5 (WDR5), transcript variant 1
0.1176
−0.147


NM_032377.2
elongation factor 1 homolog (S. cerevisiae) (ELOF1)
0.1158
−0.1448


NM_021032.2
fibroblast growth factor 12 (FGF12), transcript
0.1144
−0.143



variant 1


NM_000984.2
ribosomal protein L23a (RPL23A)
0.1123
−0.1403


BC064984.1
additional sex combs like 1 (Drosophila) (ASXL1)
0.1106
−0.1383


NM_012387.1
peptidyl arginine deiminase, type IV (PADI4)
0.1082
−0.1353


NM_001641.2
APEX nuclease (multifunctional DNA repair
0.1062
−0.1327



enzyme) 1 (APEX1), transcript variant 1


NM_001896.2
casein kinase 2, alpha prime polypeptide (CSNK2A2)
0.1045
−0.1306


NM_014481.2
APEX nuclease (apurinic/apyrimidinic endonuclease)
−0.1009
0.1261



2 (APEX2), nuclear gene encoding mitochondrial



protein


NM_014280.1
DnaJ homolog subfamily C member 8
0.0993
−0.1242


BC007228.1
CSAG family, member 3A (CSAG3A)
0.0952
−0.119


BC021174.1
Small EDRK-rich factor 1
0.0924
−0.1155


BC021174.1
Small EDRK-rich factor 1
0.0924
−0.1155


BC033758.1
centaurin, alpha 2 (CENTA2)
0.0894
−0.1118


BC005248.1
eukaryotic translation initiation factor 1A, Y-linked
0.0876
−0.1096



(EIF1AY)


BC022098.1
cDNA clone MGC: 31944 IMAGE: 4878869,
0.0853
−0.1066



complete cds


NM_024754.2
pentatricopeptide repeat domain 2 (PTCD2)
0.0845
−0.1057


NM_024316.1
leukocyte receptor cluster (LRC) member 1 (LENG1)
−0.0836
0.1044


NM_015920.3
40S ribosomal protein S27-like protein
0.0798
−0.0997


BC048970.1
tubulin tyrosine ligase-like family, member 7
0.0792
−0.099



(TTLL7)


NM_003668.2
mitogen-activated protein kinase-activated protein
0.0789
−0.0986



kinase 5 (MAPKAPK5), transcript variant 1


NM_007278.1
GABA(A) receptor-associated protein (GABARAP)
0.0787
−0.0984


NM_006838.1
methionyl aminopeptidase 2 (METAP2)
0.0779
−0.0974


NM_018439.1
Impact homolog (mouse) (IMPACT)
0.0772
−0.0965


NM_002013.2
FK506 binding protein 3, 25 kDa (FKBP3)
0.0749
−0.0937


NM_018956.2
chromosome 9 open reading frame 9 (C9orf9)
0.0744
−0.093


NM_004987.3
LIM and senescent cell antigen-like-containing
−0.0741
0.0926



domain protein 1


BC004292.1
PHD finger protein 15 (PHF15)
−0.0709
0.0886


NM_133494.1
NIMA (never in mitosis gene a)-related kinase 7
0.0699
−0.0874



(NEK7)


NM_145063.1
chromosome 6 open reading frame 130 (C6orf130)
0.0646
−0.0808


NM_021104.1
ribosomal protein L41 (RPL41), transcript variant 1
0.0645
−0.0807


NM_006223.1
protein (peptidylprolyl cis/trans isomerase) NIMA-
0.0633
−0.0791



interacting, 4 (parvulin) (PIN4)


NM_003135.1
Signal recognition particle 19 kDa protein
0.0622
−0.0777


NM_015933.1
coiled-coil domain containing 72 (CCDC72)
0.0615
−0.0769


NM_001031.4
40S ribosomal protein S28
0.0606
−0.0758


BC022524.1
fibroblast growth factor 12 (FGF12)
0.0594
−0.0743


NM_001028.2
ribosomal protein S25 (RPS25)
0.0578
−0.0722


NM_001997.2
Finkel-Biskis-Reilly murine sarcoma virus (FBR-
0.0572
−0.0715



MuSV) ubiquitously expressed (FAU)


NM_080659.1
chromosome 11 open reading frame 52 (C11orf52)
0.0566
−0.0707









Random Forest
The third quantitative method that was used to corroborate the results was Random Forest. This is an open-source classification algorithm, run through R, that uses an ensemble of decision-making trees. Each of these classification trees was built using a bootstrap sample of the data, and at each split the candidate set of variables was a random subset. Random Forest directly returned several measures of variable significance, which were related to the relevance of the variable in the classification. Hence, in this case, it provided an evaluation of each protein's relative importance to proper diagnosis.
The most reliable measure was based on the decrease of classification accuracy when values of a variable in a node of a tree were permuted randomly and this was the measure of variable importance. Another estimation of significance of a variable was based on Gini impurity. Every time a split of a node was made on variable m the Gini impurity criterion for the two descendent nodes was less than the parent node. Adding up the Gini decreases for each individual variable over all trees in the forest gave a fast variable importance that is often very consistent with the permutation importance measure.
The Relative Fluorescence Unit value for each protein spot on the microarray, as calculated by Genepix Pro and Prospector, was imported into Random Forest. The prediction model was performed using the R package and all default settings—as is proscribed for the best microarray analysis results. Calculating an average Out-Of-Bag Error of only 6.67%, the algorithm was able to quickly evaluate protein significance based on the evaluation methods described above.
Results
Three different, unbiased statistical methods were used to evaluate the diagnostic significance of individual autoantibodies in the microarray data and they reflected one another almost perfectly. The three resultant lists considered the same autoantibodies diagnostically important, and assigned them similar significance. The shared conclusions of all three lend the results great confidence. The list of all of the protein antigens determined by these methods that have autoantibodies that can be used as indicators for Alzheimer's disease is shown below in Table 7. Included is the protein database identification number, the open reading frame number, the common name for each protein, its disease-state indication, and the relevant p-value as calculated by the M-statistic.











TABLE 7






Ultimate





Database ID
ORF ID
Description
Indication
P-Value



















NM_024754.2
IOH12500
pentatricopeptide repeat domain 2
AD
8.03E−14




(PTCD2)


BC051695.1
IOH26532
FERM domain containing 8
AD
4.06E−13




(FRMD8)


NM_014280.1
IOH42939
DnaJ homolog subfamily C
AD
9.49E−12




member 8


BC064984.1
IOH40665
additional sex combs like 1
AD
6.02E−11




(Drosophila) (ASXL1)


BC030814.1
IOH23035
immunoglobulin kappa variable 1-
Control
7.00E−11




5 (IGKV1-5)


NM_003384.1
IOH41408
vaccinia related kinase 1 (VRK1)
AD
2.03E−10


NM_001544.2
IOH23172
intercellular adhesion molecule 4
AD
2.03E−10




(Landsteiner-Wiener blood group)




(ICAM4), transcript variant 1


NM_001896.2
IOH6369
casein kinase 2, alpha prime
AD
2.51E−10




polypeptide (CSNK2A2)


NM_021104.1
IOH13630
ribosomal protein L41 (RPL41),
AD
4.61E−10




transcript variant 1


BC016380.1
IOH23077
cDNA clone MGC: 27376
AD
5.14E−10




IMAGE: 4688477, complete cds


NM_012387.1
IOH11317
peptidyl arginine deiminase, type
AD
6.53E−10




IV (PADI4)


NM_003135.1
IOH59899
Signal recognition particle 19 kDa
AD
8.77E−10




protein


BC022524.1
IOH10757
fibroblast growth factor 12
AD
8.77E−10




(FGF12)


BC000758.1
IOH3735
Coiled-coil domain-containing
AD
1.45E−09




protein 28A


NM_021032.2
IOH35339
fibroblast growth factor 12
AD
1.45E−09




(FGF12), transcript variant 1


NM_022343.2
IOH59950
Golgi-associated plant
AD
1.49E−09




pathogenesis-related protein 1


BC004236.2
IOH3887
ubiquitin-conjugating enzyme E2S
AD
2.00E−09




(UBE2S)


NM_000983.3
IOH58958
60S ribosomal protein L22
AD
2.05E−09


NM_017588.1
IOH4895
WD repeat domain 5 (WDR5),
AD
2.88E−09




transcript variant 1


NM_018956.2
IOH11209
chromosome 9 open reading frame
AD
3.30E−09




9 (C9orf9)


BC033178.1
IOH23236
immunoglobulin heavy constant
AD
4.07E−09




gamma 3 (G3m marker) (IGHG3)


NM_006628.4
IOH3044
cyclic AMP phosphoprotein, 19 kD
AD
4.19E−09




(ARPP-19)


BC022098.1
IOH14790
cDNA clone MGC: 31944
AD
4.19E−09




IMAGE: 4878869, complete cds


NM_001641.2
IOH5081
APEX nuclease (multifunctional
AD
5.85E−09




DNA repair enzyme) 1 (APEX1),




transcript variant 1


NM_003668.2

mitogen-activated protein kinase-
AD
8.91E−09




activated protein kinase 5




(MAPKAPK5), transcript variant 1


NM_015933.1
IOH3769
coiled-coil domain containing 72
AD
8.91E−09




(CCDC72)


PHC1244

chemokine (C-C motif) ligand 19
AD
9.85E−09




(CCL19)


BC099907.1
IOH62625
General transcription factor II-I
Control
1.09E−08


BC007782.2
IOH6514
immunoglobulin lambda constant
AD
1.09E−08




1 (Mcg marker) (IGLC1)


BC006423.1

Serine/threonine-protein kinase 6
AD
1.34E−08


BC042628.1
IOH27650
serpin peptidase inhibitor, clade E
AD
1.34E−08




(nexin, plasminogen activator




inhibitor type 1), member 2




(SERPINE2)


BC021561.1
IOH14131
FACT complex subunit SPT16
AD
1.34E−08


BC005248.1
IOH7358
eukaryotic translation initiation
AD
1.34E−08




factor 1A, Y-linked (EIF1AY)


NM_006223.1
IOH7192
protein (peptidylprolyl cis/trans
AD
1.34E−08




isomerase) NIMA-interacting, 4




(parvulin) (PIN4)


NM_032377.2
IOH6191
elongation factor 1 homolog (S. cerevisiae)
AD
1.34E−08




(ELOF1)


BC057774.1
IOH29168
RNA (guanine-9-)-
AD
1.52E−08




methyltransferase domain-




containing protein 3


NM_004196.2

Cyclin-dependent kinase-like 1
AD
1.64E−08


BC001662.1

MAP kinase-activated protein
AD
2.32E−08




kinase 3


NM_015920.3
IOH57353
40S ribosomal protein S27-like
AD
2.32E−08




protein


NM_001031.4
IOH58930
40S ribosomal protein S28
AD
2.62E−08


NM_003688.1

Peripheral plasma membrane
AD
2.62E−08




protein CASK


BC048970.1
IOH26893
tubulin tyrosine ligase-like family,
AD
3.23E−08




member 7 (TTLL7)


NM_000984.2
IOH13591
ribosomal protein L23a (RPL23A)
AD
3.23E−08


NM_018439.1
IOH23069
Impact homolog (mouse)
AD
3.76E−08




(IMPACT)


NM_002305.2
IOH3861
lectin, galactoside-binding,
AD
3.76E−08




soluble, 1 (galectin 1) (LGALS1)


BC056508.1
IOH29456
variable charge, Y-linked 1B
AD
4.13E−08




(VCY)


BC090938.1
IOH62696
Ig gamma-1 chain C region
AD
4.45E−08


NM_002013.2
IOH14109
FK506 binding protein 3, 25 kDa
AD
4.51E−08




(FKBP3)


NM_007278.1
IOH41289
GABA(A) receptor-associated
AD
4.51E−08




protein (GABARAP)


BC007228.1
IOH6059
CSAG family, member 3A
AD
4.51E−08




(CSAG3A)


BC033758.1
IOH21879
centaurin, alpha 2 (CENTA2)
AD
5.27E−08


BC092518.1
IOH62695
Ig gamma-1 chain C region
AD
6.86E−08


BC019598.1
IOH10613
Zinc finger matrin-type protein 4
AD
7.00E−08


NM_145909.1
IOH45888
Zinc finger protein 323
AD
7.00E−08


NM_003516.2
IOH4867
histone cluster 2, H2aa3
AD
7.22E−08




(HIST2H2AA3)


NM_006838.1
IOH11106
methionyl aminopeptidase 2
AD
7.36E−08




(METAP2)


BC026038.1
IOH13982
Ig gamma-1 chain C region
AD
1.01E−07


NM_002129.2
IOH3826
high-mobility group box 2
AD
1.01E−07




(HMGB2)


NM_002677.1
IOH27101
peripheral myelin protein 2
AD
1.16E−07




(PMP2)


BC001132.1
IOH3853
DEAD (Asp-Glu-Ala-Asp) box
AD
1.27E−07




polypeptide 54 (DDX54)


NM_001001794.1
IOH27259
family with sequence similarity
AD
1.27E−07




116, member B (FAM116B)


NM_001997.2
IOH1655
Finkel-Biskis-Reilly murine
AD
1.27E−07




sarcoma virus (FBR-MuSV)




ubiquitously expressed (FAU)


BC021174.1
IOH10706
Small EDRK-rich factor 1
AD
1.27E−07


NM_001028.2
IOH5471
ribosomal protein S25 (RPS25)
AD
1.27E−07


NM_003512.3
IOH14485
Histone H2A type 1-C
AD
1.78E−07


NM_002095.1
IOH22963
general transcription factor IIE,
AD
1.97E−07




polypeptide 2, beta 34 kDa




(GTF2E2)


NM_005720.1
IOH3992
actin related protein 2/3 complex,
AD
1.97E−07




subunit 1B, 41 kDa (ARPC1B)


NM_003868.1
IOH42157
fibroblast growth factor 16
AD
1.97E−07




(FGF16)


NM_004214.3
IOH2103
fibroblast growth factor (acidic)
AD
1.97E−07




intracellular binding protein




(FIBP), transcript variant 2


NM_021079.2
IOH14141
N-myristoyltransferase 1 (NMT1)
AD
1.99E−07


NM_015833.1
IOH38242
adenosine deaminase, RNA-
AD
2.62E−07




specific, B1 (RED1 homolog rat)




(ADARB1), transcript variant 2


PHR5001

Recombinant human CTLA-4/Fc
AD
2.62E−07


BC030983.1
IOH23183
immunoglobulin lambda locus
AD
2.62E−07




(IGL@)


BC030984.1
IOH23182
cDNA clone MGC: 32654
AD
2.62E−07




IMAGE: 4701898, complete cds


BC002733.2
IOH5365
chromosome 1 open reading frame
Control
2.62E−07




77 (C1orf77)


NM_133494.1
IOH45126
NIMA (never in mitosis gene a)-
AD
2.65E−07




related kinase 7 (NEK7)


BC010467.1
IOH11119
cDNA clone MGC: 17410
AD
3.42E−07




IMAGE: 4156035, complete cds


NM_014060.1
IOH4208
malignant T cell amplified
AD
3.42E−07




sequence 1 (MCTS1)


NM_016167.3
IOH40609
nucleolar protein 7, 27 kDa
AD
3.81E−07




(NOL7)


BC015833.1
IOH14840
cDNA clone MGC: 27152
AD
4.30E−07




IMAGE: 4691630, complete cds


NM_145063.1
IOH13839
chromosome 6 open reading frame
AD
5.08E−07




130 (C6orf130)


BC040106.1
IOH26285
hypothetical protein HSPC111
AD
5.08E−07




(HSPC111)


BC010947.1
IOH14455
signal recognition particle 19 kDa
AD
5.08E−07




(SRP19)


NM_014065.2
IOH43942
Protein asteroid homolog 1
AD
5.31E−07


BC012760.2
IOH62834
Glycogen synthase kinase-3 beta
AD
5.38E−07


NM_004088.1
IOH11297
deoxynucleotidyltransferase,
AD
6.41E−07




terminal (DNTT), transcript




variant 1


BC019337.1
IOH12297
immunoglobulin heavy constant
AD
7.15E−07




gamma 1 (G1m marker) (IGHG1)


NM_024316.1
IOH12150
leukocyte receptor cluster (LRC)
Control
7.80E−07




member 1 (LENG1)


NM_002938.2
IOH41414
ring finger protein 4 (RNF4)
AD
7.80E−07


NM_006620.2
IOH4029
HBS1-like (S. cerevisiae)
AD
8.79E−07




(HBS1L)


NM_000992.2
IOH1702
60S ribosomal protein L29
AD
1.05E−06


NM_024668.2
IOH46162
ankyrin repeat and KH domain
AD
1.05E−06




containing 1 (ANKHD1),




transcript variant 3


NM_031445.1
IOH5185
AMME chromosomal region gene
AD
1.26E−06




1-like (AMMECR1L)


NM_003517.2
IOH29296
histone cluster 2, H2ac
AD
1.38E−06




(HIST2H2AC)


BC072419.1
IOH62555
Ig gamma-1 chain C region
AD
1.50E−06


NM_145174.1
IOH44767
DnaJ (Hsp40) homolog, subfamily
AD
1.57E−06




B, member 7 (DNAJB7)


BC022361.1
IOH14170
rRNA-processing protein FCF1
AD
1.57E−06




homolog


BC006376.1
IOH6481
N-myristoyltransferase 2 (NMT2)
AD
1.60E−06


NM_001895.1

casein kinase 2, alpha 1
AD
1.60E−06




polypeptide (CSNK2A1),




transcript variant 2


NM_003524.2
IOH58715
Histone H2B type 1-H
AD
1.69E−06


BC027951.1
IOH11889
Cas scaffolding protein family
AD
1.93E−06




member 4


NM_134427.1
IOH45474
regulator of G-protein signaling 3
AD
2.02E−06




(RGS3), transcript variant 4


NM_052969.1
IOH12514
ribosomal protein L39-like
AD
2.02E−06




(RPL39L)


NM_023080.1
IOH13369
chromosome 8 open reading frame
AD
2.17E−06




33 (C8orf33)


NM_138779.1
IOH10711
chromosome 13 open reading
AD
2.17E−06




frame 27 (C13orf27)


BC026030.1
IOH14611
zinc finger protein 239 (ZNF239)
AD
2.32E−06


BC029760.1
IOH22119
OTU domain containing 6B
AD
2.76E−06




(OTUD6B)


PHC1475

C-C motif chemokine 21
AD
3.00E−06


NM_133336.1
IOH42549
Wolf-Hirschhorn syndrome
AD
3.44E−06




candidate 1 (WHSC1), transcript




variant 9


BC034142.1
IOH23177
immunoglobulin kappa variable 1-
AD
3.67E−06




5 (IGKV1-5)


NM_020235.2
IOH44025
bobby sox homolog (Drosophila)
AD
3.67E−06




(BBX)


NM_198829.1
IOH58974
Ras-related C3 botulinum toxin
AD
3.89E−06




substrate 1


BC098112.1
IOH63324
Histone H2B type 1-N
AD
3.89E−06


NM_032359.1
IOH5762
chromosome 3 open reading frame
AD
4.32E−06




26 (C3orf26)


NM_001966.2
IOH62346
Peroxisomal bifunctional enzyme
AD
4.32E−06


BC032451.1
IOH21663
cDNA clone MGC: 40426
AD
4.76E−06




IMAGE: 5178085, complete cds


XM_379117.1
IOH43619
PREDICTED: Homo sapiens
AD
4.98E−06




hypothetical protein LOC150568




(LOC150568)


BC033159.1
IOH23223
DnaJ (Hsp40) homolog, subfamily
AD
4.98E−06




C, member 8 (DNAJC8)


NM_006756.2
IOH42106
transcription elongation factor A
AD
4.98E−06




(SII), 1 (TCEA1), transcript




variant 1


NM_016940.1
IOH12821
RWD domain containing 2B
AD
5.00E−06




(RWDD2B)


NM_177559.2
IOH13704
casein kinase 2, alpha 1
AD
5.00E−06




polypeptide (CSNK2A1),




transcript variant 1


NM_004178.3
IOH45867
TAR (HIV-1) RNA binding
AD
5.13E−06




protein 2 (TARBP2), transcript




variant 3


NM_032338.2
IOH7537
chromosome 12 open reading
AD
5.22E−06




frame 31 (C12orf31)


BC005955.1
IOH7485
chromosome 8 open reading frame
AD
5.50E−06




53 (C8orf53)


NM_001009613.1
IOH58584
Sperm protein associated with the
AD
5.50E−06




nucleus on the X chromosome N4


BC036723.1
IOH22599
Fc fragment of IgG, low affinity
AD
5.50E−06




IIIa, receptor (CD16a) (FCGR3A)


NM_003690.3
IOH57108
Interferon-inducible double
AD
6.84E−06




stranded RNA-dependent protein




kinase activator A


NM_014473.2
IOH9851
DIM1 dimethyladenosine
AD
6.91E−06




transferase 1-like (S. cerevisiae)




(DIMT1L)


NM_032855.1
IOH14623
hematopoietic SH2 domain
AD
7.69E−06




containing (HSH2D)


NM_001167.2
IOH21984
baculoviral IAP repeat-containing
AD
7.69E−06




4 (BIRC4)


NM_178571.2
IOH26524
hypothetical protein MGC51025
AD
7.69E−06




(MGC51025)


NM_003600.1

aurora kinase A (AURKA),
AD
7.69E−06




transcript variant 2


NM_006912.3
IOH29584
Ras-like without CAAX 1 (RIT1)
AD
8.05E−06


NM_005307.1

G protein-coupled receptor kinase 4
AD
8.29E−06


BC001280.1
IOH21165
Serine/threonine-protein kinase 6
AD
8.71E−06


NM_182970.2
IOH43687
regulating synaptic membrane
AD
8.71E−06




exocytosis 4 (RIMS4)


NM_153332.2
IOH27323
three prime histone mRNA
AD
8.71E−06




exonuclease 1 (THEX1)


NM_139016.2
IOH27635
chromosome 20 open reading
AD
8.88E−06




frame 198 (C20orf198)


NM_003677.3
IOH56971
Density-regulated protein
AD
1.15E−05


NM_013293.1
IOH9999
Transformer-2 protein homolog
AD
1.15E−05


NM_014481.2
IOH4887
APEX nuclease
Control
1.17E−05




(apurinic/apyrimidinic




endonuclease) 2 (APEX2), nuclear




gene encoding mitochondrial




protein


BC033856.1
IOH21797
La ribonucleoprotein domain
AD
1.18E−05




family, member 1 (LARP1)


NM_000939.1
IOH40048
proopiomelanocortin
AD
1.18E−05




(adrenocorticotropin/beta-




lipotropin/alpha-melanocyte




stimulating hormone/beta-




melanocyte stimulating hormone/




beta-endorphin) (POMC),




transcript variant 2


BC009348.2
IOH12064
cirrhosis, autosomal recessive 1A
AD
1.29E−05




(cirhin) (CIRH1A)


NM_014508.2
IOH54737
apolipoprotein B mRNA editing
AD
1.46E−05




enzyme, catalytic polypeptide-like




3C (APOBEC3C), mRNA.


NM_080659.1
IOH7410
chromosome 11 open reading
AD
1.48E−05




frame 52 (C11orf52)


NM_022755.2
IOH10937
inositol 1,3,4,5,6-
AD
1.54E−05




pentakisphosphate 2-kinase




(IPPK)


NM_002690.1
IOH41443
polymerase (DNA directed), beta
AD
1.57E−05




(POLB)


BC011668.1

Casein kinase II subunit alpha
AD
1.57E−05


NM_002128.2
IOH2937
high-mobility group box 1
AD
1.62E−05




(HMGB1)


BC012472.1
IOH11069
ubiquitin D (UBD)
AD
1.62E−05


BC030020.2
IOH22410
DEAD (Asp-Glu-Ala-Asp) box
AD
1.62E−05




polypeptide 55 (DDX55)


BC018060.1
IOH11303
Ras-like without CAAX 2 (RIT2)
AD
1.62E−05


NM_003141.2
IOH9948
tripartite motif-containing 21
AD
1.62E−05




(TRIM21)


NM_007054.1
IOH26900
kinesin family member 3A
AD
1.62E−05




(KIF3A)


NM_006924.3
IOH11039
splicing factor, arginine/serine-
AD
1.67E−05




rich 1 (splicing factor 2, alternate




splicing factor) (SFRS1),




transcript variant 1


NM_032563.1
IOH40397
late cornified envelope 3D
AD
1.67E−05




(LCE3D)


NM_173080.1
IOH34934
small proline-rich protein 4
AD
1.67E−05




(SPRR4)


NM_003527.4
IOH58710
Histone H2B type 1-O
AD
1.82E−05


BC009762.2
IOH14113
Tripartite motif-containing protein
AD
1.82E−05




41


NM_006861.2
IOH10011
RAB35, member RAS oncogene
AD
1.83E−05




family (RAB35)


NM_002136.1
IOH3526
heterogeneous nuclear
AD
1.90E−05




ribonucleoprotein A1




(HNRNPA1), transcript variant 1


BC009623.1
IOH9844
nucleophosmin (nucleolar
AD
2.11E−05




phosphoprotein B23, numatrin)




(NPM1)


NM_021063.2
IOH58956
Histone H2B type 1-D
AD
2.11E−05


BC054021.1
IOH29457
pterin-4 alpha-carbinolamine
AD
2.29E−05




dehydratase/dimerization cofactor




of hepatocyte nuclear factor 1




alpha (TCF1) 2 (PCBD2)


NM_012108.1
IOH13463
signal transducing adaptor family
AD
2.63E−05




member 1 (STAP1)


NM_023937.1
IOH4594
mitochondrial ribosomal protein
AD
3.15E−05




L34 (MRPL34), nuclear gene




encoding mitochondrial protein


XM_088679.2
IOH43003
Spermatid nuclear transition
AD
3.33E−05




protein 4


NM_022720.5
IOH52788
DiGeorge syndrome critical region
AD
3.33E−05




gene 8 (DGCR8)


NM_016073.2
IOH10649
hepatoma-derived growth factor,
AD
3.33E−05




related protein 3 (HDGFRP3)


NM_018105.1
IOH10776
THAP domain containing,
AD
3.41E−05




apoptosis associated protein 1




(THAP1), transcript variant 1


NM_005371.2
IOH4172
methyltransferase like 1
AD
3.56E−05




(METTL1), transcript variant 1


BC029427.1
IOH23192
coiled-coil domain containing 23
AD
3.61E−05




(CCDC23)


NM_032476.1
IOH13845
mitochondrial ribosomal protein
AD
3.66E−05




S6 (MRPS6), nuclear gene




encoding mitochondrial protein


NM_014110.3
IOH39485
protein phosphatase 1, regulatory
Control
3.66E−05




(inhibitor) subunit 8 (PPP1R8),




transcript variant 1


NM_003089.4
IOH40192
small nuclear ribonucleoprotein
AD
3.88E−05




70 kDa polypeptide (RNP antigen)




(SNRP70)


BC020972.1

Casein kinase I isoform gamma-2
AD
3.88E−05


BC000381.2
IOH3454
TBP-like 1 (TBPL1)
AD
3.88E−05


NM_007285.5
IOH7450
GABA(A) receptor-associated
AD
3.99E−05




protein-like 2 (GABARAPL2)


NM_004060.2
IOH4393
cyclin G1 (CCNG1), transcript
AD
4.02E−05




variant 1


BC001780.1
IOH4955
Uncharacterized methyltransferase
AD
4.02E−05




WBSCR22


NM_022048.1
IOH21026
casein kinase 1, gamma 1
AD
4.02E−05




(CSNK1G1)


BC035256.1
IOH27660
Putative adenylate kinase 7
AD
4.19E−05


NM_175887.2
IOH27336
proline rich 15 (PRR15)
AD
4.22E−05


BC010919.1
IOH27800
ribosomal protein L35 (RPL35)
AD
4.79E−05


NM_016207.2
IOH14059
cleavage and polyadenylation
AD
5.24E−05




specific factor 3, 73 kDa (CPSF3)


BC000784.1
IOH4711
baculoviral IAP repeat-containing
AD
5.50E−05




5 (survivin) (BIRC5)


NM_002364.1
IOH11315
melanoma antigen family B, 2
AD
5.50E−05




(MAGEB2)


NM_022839.2
IOH1783
mitochondrial ribosomal protein
AD
6.97E−05




S11 (MRPS11), nuclear gene




encoding mitochondrial protein,




transcript variant 1


NM_014370.2
IOH60262
SFRS protein kinase 3 (SRPK3)
AD
6.97E−05


NM_016505.2
IOH6093
zinc finger, CCHC domain
AD
7.25E−05




containing 17 (ZCCHC17)


BC030813.1
IOH23055
cDNA clone MGC: 22645
AD
7.42E−05




IMAGE: 4700961, complete cds


BC020803.1
IOH14817
developmentally regulated GTP
AD
7.42E−05




binding protein 1 (DRG1)


NM_205848.1
IOH43389
synaptotagmin VI (SYT6)
AD
7.94E−05


NM_006398.2
IOH59996
Ubiquitin D
AD
7.94E−05


NM_017646.3
IOH37769
tRNA isopentenyltransferase 1
AD
8.04E−05




(TRIT1)


NM_006925.2
IOH58606
Splicing factor, arginine/serine-
AD
8.04E−05




rich 5


NM_153822.1
IOH41107
proteasome (prosome, macropain)
AD
8.43E−05




26S subunit, non-ATPase, 4




(PSMD4), transcript variant 2


NM_014321.2
IOH39827
origin recognition complex,
AD
0.000103




subunit 6 like (yeast) (ORC6L)


BC012876.1
IOH10177
Ig lambda chain C regions
AD
0.000104


NM_021967.1
IOH45915
small EDRK-rich factor 1A
AD
0.000104




(telomeric) (SERF1A)


NM_003295.1
IOH25767
tumor protein, translationally-
AD
0.000104




controlled 1 (TPT1)


NM_017503.2
IOH12519
surfeit 2 (SURF2)
AD
0.000105


BC018137.1
IOH10369
TATA box binding protein (TBP)-
AD
0.000108




associated factor, RNA




polymerase I, B, 63 kDa (TAF1B)


BC005004.1
IOH4814
family with sequence similarity
AD
0.000114




64, member A (FAM64A)


NM_152373.2
IOH14361
zinc finger protein 684 (ZNF684)
AD
0.000114


NM_000989.2
IOH3809
ribosomal protein L30 (RPL30)
AD
0.000121


NM_000800.2
IOH21917
fibroblast growth factor 1 (acidic)
AD
0.000121




(FGF1), transcript variant 1


NM_000975.2
IOH1740
ribosomal protein L11 (RPL11)
AD
0.000142


BC064144.1
IOH40037
spermatogenesis associated 1
Control
0.000142




(SPATA1)


PHC1695

C—X—C motif chemokine 11
AD
0.000151


NM_022140.2
IOH38016
Band 4.1-like protein 4A
AD
0.000159


NM_016287.2
IOH43530
heterochromatin protein 1, binding
AD
0.000162




protein 3 (HP1BP3)


BC015586.2
IOH46065
laminin, gamma 1 (formerly
AD
0.000162




LAMB2) (LAMC1)


NM_023931.1
IOH3950
zinc finger protein 747 (ZNF747)
AD
0.000168


NM_153207.2
IOH14301
AE binding protein 2 (AEBP2)
AD
0.000168


NM_007079.2
IOH4497
Protein tyrosine phosphatase type
AD
0.000168




IVA 3


NM_004397.3
IOH45655
Probable ATP-dependent RNA
AD
0.000172




helicase DDX6


NM_012424.2

Ribosomal protein S6 kinase
AD
0.000172




delta-1


CCP_1BSA

NA
Control
0.000177


NM_020239.2
IOH21482
CDC42 small effector 1
AD
0.000186




(CDC42SE1), transcript variant 2


BC029378.1
IOH23186
telomeric repeat binding factor
AD
0.000186




(NIMA-interacting) 1 (TERF1)


BC062732.1
IOH62856
Ig kappa chain C region
Control
0.000211


BC000306.1
IOH3456
hydroxyacyl-Coenzyme A
AD
0.000216




dehydrogenase (HADH)


BC031650.1
IOH22742
Putative E3 ubiquitin-protein
Control
0.000221




ligase SH3RF2


NM_182692.1
IOH38187
Serine/threonine-protein kinase
AD
0.000227




SRPK2


NM_032350.3
IOH6347
Uncharacterized protein C7orf50
AD
0.000227


NM_001022.3
IOH4572
ribosomal protein S19 (RPS19)
AD
0.000227


NM_001002913.1
IOH26561
peptidyl-tRNA hydrolase 1
AD
0.000227




homolog (S. cerevisiae) (PTRH1)


BC000535.1
IOH4145
Suppressor of SWI4 1 homolog
AD
0.000227


NM_017692.1
IOH4894
aprataxin (APTX), transcript
AD
0.000233




variant 4


NM_000993.2
IOH14051
ribosomal protein L31 (RPL31),
AD
0.000245




transcript variant 1


NM_152653.1
IOH13176
ubiquitin-conjugating enzyme E2E
AD
0.000245




2 (UBC4/5 homolog, yeast)




(UBE2E2)


NM_014891.1
IOH4282
PDGFA associated protein 1
AD
0.000245




(PDAP1)


NM_012148.1
IOH39321
double homeobox, 3 (DUX3)
AD
0.000252


NM_024046.1

CaM kinase-like vesicle-
AD
0.00028




associated (CAMKV)


NM_022063.1
IOH27864
chromosome 10 open reading
AD
0.00028




frame 84 (C10orf84)


BC036434.1
IOH62212
Serine/threonine-protein kinase
AD
0.00032




VRK2


NM_001396.2

Dual specificity tyrosine-
AD
0.00032




phosphorylation-regulated kinase




1A


NM_004939.1
IOH14578
DEAD (Asp-Glu-Ala-Asp) box
AD
0.00032




polypeptide 1 (DDX1)


NM_001039724.1
IOH63165
Nostrin
AD
0.000331


NM_138551.1
IOH13700
thymic stromal lymphopoietin
AD
0.000332




(TSLP), transcript variant 2


XM_379194.1
IOH43490
PREDICTED: Homo sapiens
AD
0.000332




hypothetical LOC401068




(LOC401068)


BC007401.2
IOH5852
cell division cycle 25 homolog A
AD
0.00034




(S. pombe) (CDC25A)


BC008902.2
IOH46064
GRIP and coiled-coil domain-
AD
0.00034




containing protein 1


BC019039.2
IOH46089
Regulator of G-protein signaling 3
AD
0.000407


NM_016050.1
IOH4903
mitochondrial ribosomal protein
AD
0.000432




L11 (MRPL11), nuclear gene




encoding mitochondrial protein,




transcript variant 1


NM_002927.3
IOH11040
regulator of G-protein signaling 13
AD
0.000432




(RGS13), transcript variant 1


NM_207430.1
IOH59509
FLJ46266 protein (FLJ46266),
AD
0.000432




mRNA.


NM_016508.2
IOH21339
Cyclin-dependent kinase-like 3
AD
0.000432


NM_197964.1
IOH7576
chromosome 7 open reading frame
AD
0.000442




55 (C7orf55)


BC021930.1
IOH13703
KIAA1530 protein (KIAA1530)
AD
0.000442


NM_145043.1
IOH13260
nei like 2 (E. coli) (NEIL2)
AD
0.000442


BC030586.2
IOH22241
signal transducing adaptor
AD
0.000442




molecule (SH3 domain and ITAM




motif) 1 (STAM)


BC004292.1
IOH22899
PHD finger protein 15 (PHF15)
Control
0.000442


BC022378.1
IOH13502
zinc finger with KRAB and SCAN
AD
0.000443




domains 1 (ZKSCAN1)


NM_003792.1
IOH10852
endothelial differentiation-related
AD
0.000448




factor 1 (EDF1), transcript variant




alpha


BC070154.1
IOH63011
Non-histone chromosomal protein
AD
0.000448




HMG-14


BC010074.2
IOH13694
FUS interacting protein
AD
0.000479




(serine/arginine-rich) 1 (FUSIP1)


NM_002201.3
IOH6793
interferon stimulated exonuclease
AD
0.000479




gene 20 kDa (ISG20)


BC033621.2
IOH21688
Pseudouridylate synthase 7
AD
0.000481




homolog-like protein


NM_004114.2
IOH13832
fibroblast growth factor 13
AD
0.00054




(FGF13), transcript variant 1A


NM_016483.3
IOH22255
PHD finger protein 7 (PHF7),
AD
0.00054




transcript variant 1


NM_012420.1
IOH22625
interferon-induced protein with
AD
0.000543




tetratricopeptide repeats 5 (IFIT5)


NM_016203.2
IOH42382
protein kinase, AMP-activated,
AD
0.000543




gamma 2 non-catalytic subunit




(PRKAG2), transcript variant a,




mRNA.


NM_014878.2
IOH10030
Pumilio domain-containing
AD
0.000544




protein KIAA0020


NM_018664.1
IOH44746
Jun dimerization protein p21SNFT
AD
0.000593




(SNFT)


NM_002402.1
IOH3706
mesoderm specific transcript
AD
0.000613




homolog (mouse) (MEST),




transcript variant 1


NM_003769.2
IOH41184
splicing factor, arginine/serine-
AD
0.000613




rich 9 (SFRS9)


NM_018132.3
IOH45979
centromere protein Q (CENPQ)
AD
0.000613


NM_006072.4
IOH40395
chemokine (C-C motif) ligand 26
AD
0.000613




(CCL26)


NM_021029.3
IOH4423
ribosomal protein L36a (RPL36A)
AD
0.000638


NM_000978.2
IOH13951
ribosomal protein L23 (RPL23)
AD
0.000638


NM_001023.2
IOH6083
ribosomal protein S20 (RPS20)
AD
0.000638


BC013366.2
IOH27815
UNC-112 related protein 2
AD
0.000638




(URP2)


BC001327.1
IOH3125
interferon-related developmental
AD
0.000644




regulator 2 (IFRD2)


BC000522.1
IOH3622
serpin peptidase inhibitor, clade F
AD
0.000644




(alpha-2 antiplasmin, pigment




epithelium derived factor),




member 1 (SERPINF1)


NM_019067.1
IOH13693
guanine nucleotide binding
AD
0.000644




protein-like 3 (nucleolar)-like




(GNL3L)


NM_152634.1
IOH21490
TFS2-M domain-containing
AD
0.000644




protein 1 (MGC17403)


BC011842.2
IOH14099
hypothetical protein FLJ11184
AD
0.00065




(FLJ11184)


BC068514.1
IOH40543
NF-kappaB repressing factor
AD
0.00065




(NKRF)


NM_018063.3
IOH44165
helicase, lymphoid-specific
AD
0.000661




(HELLS)


NM_198467.1
IOH40427
round spermatid basic protein 1-
AD
0.000739




like (RSBN1L)


NM_198517.2
IOH25922
TBC1 domain family, member
AD
0.000835




10C (TBC1D10C)


NM_001564.1
IOH22913
inhibitor of growth family,
AD
0.000835




member 2 (ING2)


NM_002930.1
IOH54792
GTP-binding protein Rit2
AD
0.000835


NM_019058.1
IOH6497
DNA-damage-inducible transcript
AD
0.000835




4 protein


NM_020661.1
IOH6382
activation-induced cytidine
AD
0.000868




deaminase (AICDA)


NM_144659.1
IOH21795
t-complex 10 (mouse)-like
Control
0.000868




(TCP10L)


NM_173822.1
IOH27491
family with sequence similarity
AD
0.000898




126, member B (FAM126B)


BC056887.1
IOH29097
chromosome 5 open reading frame
AD
0.000898




5 (C5orf5)


BC070334.1
IOH40810
immunoglobulin kappa constant
AD
0.000898




(IGKC)


NM_004071.1

Dual specificity protein kinase
AD
0.000898




CLK1


XM_378514.1
IOH42688
PREDICTED: Homo sapiens
Control
0.000901




hypothetical protein LOC283663




(LOC283663), mRNA


NM_005801.2
IOH6916
eukaryotic translation initiation
AD
0.000906




factor 1 (EIF1)


BC001487.2
IOH12155
TAR DNA-binding protein 43
AD
0.000906


NM_006790.1
IOH7249
myotilin (MYOT)
AD
0.000906


NM_175923.2
IOH22051
hypothetical protein MGC42630
AD
0.000906




(MGC42630)


NM_000122.1
IOH6320
excision repair cross-
AD
0.000918




complementing rodent repair




deficiency, complementation




group 3 (xeroderma pigmentosum




group B complementing)




(ERCC3)


NM_001819.1
IOH3444
chromogranin B (secretogranin 1)
Control
0.000992




(CHGB)


BC010501.1
IOH10253
Catenin delta-1
AD
0.001011


BC005298.1
IOH7271
cyclin-dependent kinase 7 (MO15
AD
0.001015




homolog, Xenopus laevis, cdk-




activating kinase) (CDK7)


PHC0076

interleukin 7 (IL7)
AD
0.001041


NM_138349.2
IOH45741
Tumor protein p53-inducible
AD
0.001041




protein 13


BC000044.1
IOH4604
Spindlin-2B
AD
0.001041


NM_014747.2
IOH4568
regulating synaptic membrane
AD
0.001117




exocytosis 3 (RIMS3)


NM_001014.2
IOH4063
ribosomal protein S10 (RPS10)
AD
0.001122


NM_005678.3
IOH45840
SNRPN upstream reading frame
AD
0.001122




(SNURF), transcript variant 1


BC010876.1
IOH9862
nei endonuclease VIII-like 1 (E. coli)
AD
0.001122




(NEIL1)


BC025281.1
IOH14071
RNA binding motif protein 9
AD
0.001147




(RBM9)


NM_001013.2
IOH5840
ribosomal protein S9 (RPS9)
AD
0.001147


NM_015414.2
IOH4985
ribosomal protein L36 (RPL36),
AD
0.001201




transcript variant 2


NM_017566.2
IOH11408
kelch domain containing 4
AD
0.001209




(KLHDC4)


BC015818.1
IOH14254
lectin, galactoside-binding,
AD
0.001262




soluble, 8 (galectin 8) (LGALS8)


BC036109.1
IOH27253
SECIS binding protein 2
AD
0.001265




(SECISBP2)


NM_005738.1
IOH5077
ADP-ribosylation factor-like 4A
AD
0.001498




(ARL4A), transcript variant 1


BC022816.1
IOH14672
NA
AD
0.001498


NM_024303.1
IOH5245
zinc finger and SCAN domain
AD
0.001533




containing 5 (ZSCAN5)


BC018823.2
IOH14860
splicing factor, arginine/serine-
AD
0.001533




rich 5 (SFRS5)


NM_024319.1
IOH5397
chromosome 1 open reading frame
AD
0.001533




35 (C1orf35)


PV3359

Ephrin receptor A3 (EPHA3),
AD
0.00166




transcript variant 1


BC006318.1
IOH6433
erythrocyte membrane protein
Control
0.001674




band 4.9 (dematin) (EPB49)


NM_145899.1
IOH6516
high mobility group AT-hook 1
AD
0.001732




(HMGA1), transcript variant 1


NM_021158.1

tribbles homolog 3 (Drosophila)
AD
0.001796




(TRIB3)


NM_005794.2
IOH41302
dehydrogenase/reductase (SDR
AD
0.001796




family) member 2 (DHRS2),




transcript variant 2


BC005807.2
IOH6261
stearoyl-CoA desaturase (delta-9-
AD
0.001796




desaturase) (SCD)


NM_006374.2
IOH6735
serine/threonine kinase 25 (STE20
AD
0.001796




homolog, yeast) (STK25)


NM_152757.1
IOH43336
Putative uncharacterized protein
AD
0.001796




C20orf200


NM_001009880.1
IOH42078
chromosome 22 open reading
AD
0.001796




frame 9 (C22orf9), transcript




variant 2


NM_138558.1
IOH13759
protein phosphatase 1, regulatory
AD
0.001796




(inhibitor) subunit 8 (PPP1R8),




transcript variant 2


BC007852.1

Serine/threonine-protein kinase 25
AD
0.001796


NM_012396.1
IOH12626
pleckstrin homology-like domain,
AD
0.001845




family A, member 3 (PHLDA3)


NM_012437.2
IOH3724
SNAP-associated protein
AD
0.001845




(SNAPAP)


PHC0205

interleukin 20 (IL20)
AD
0.001845


NM_016093.2
IOH14674
ribosomal protein L26-like 1
AD
0.001845




(RPL26L1)


NM_005902.1
IOH27044
SMAD family member 3
AD
0.001845




(SMAD3)


XM_375456.2
IOH43380
Ataxin-7-like protein 3
AD
0.001925


NM_006275.2
IOH3168
splicing factor, arginine/serine-
AD
0.00196




rich 6 (SFRS6)


NM_018037.1
IOH45458
Ral GEF with PH domain and
Control
0.001993




SH3 binding motif 2 (RALGPS2),




transcript variant 1


BC011600.1
IOH13680
cDNA clone IMAGE: 3050953,
AD
0.002095




**** WARNING: chimeric clone




****


NM_014570.2
IOH5693
ADP-ribosylation factor GTPase
AD
0.002095




activating protein 3 (ARFGAP3)


NM_022551.2
IOH41520
ribosomal protein S18 (RPS18)
AD
0.002095


BC063275.1
IOH40423
eukaryotic translation initiation
AD
0.002095




factor 2C, 1 (EIF2C1)


BC062423.1
IOH40739
chromosome 7 open reading frame
AD
0.0021




41 (C7orf41)


NM_170676.2
IOH26710
Meis homeobox 2 (MEIS2),
Control
0.002174




transcript variant d


BC096708.1
IOH63336
Wilms tumor-associated protein
AD
0.002181


NM_199123.1
IOH42083
SET domain containing 3
AD
0.002181




(SETD3), transcript variant 2


BC010907.1
IOH12088
PAK1 interacting protein 1
AD
0.002181




(PAK1IP1)


NM_004217.1

aurora kinase B (AURKB)
AD
0.002181


NM_005737.3
IOH44753
ADP-ribosylation factor-like 4C
AD
0.002186




(ARL4C)


NM_020467.2
IOH3994
small trans-membrane and
AD
0.002186




glycosylated protein (LOC57228),




transcript variant 2


BC021180.2
IOH11041
high-mobility group box 4
AD
0.002209




(HMGB4)


NM_004728.2
IOH46173
DEAD (Asp-Glu-Ala-Asp) box
AD
0.002209




polypeptide 21 (DDX21)


BC030702.1
IOH22356
microcephaly, primary autosomal
AD
0.002281




recessive 1 (MCPH1)


NM_003724.1
IOH26418
jerky homolog (mouse) (JRK),
AD
0.002281




transcript variant 1


NM_016077.1
IOH3153
peptidyl-tRNA hydrolase 2
AD
0.002329




(PTRH2), nuclear gene encoding




mitochondrial protein


BC022362.1
IOH14191
cDNA clone MGC: 23888
Control
0.002364




IMAGE: 4704496, complete cds


NM_014955.2
IOH45543
KIAA0859 (KIAA0859),
AD
0.002364




transcript variant 2


NM_001834.2
IOH43456
clathrin, light chain (Lcb) (CLTB),
Control
0.002495




transcript variant 1, mRNA.


NM_002045.1
IOH6708
growth associated protein 43
Control
0.002495




(GAP43)


NM_003503.2

Cell division cycle 7-related
AD
0.00252




protein kinase


NM_022491.2
IOH62643
Sin3 histone deacetylase
Control
0.002538




corepressor complex component




SDS3


NM_004987.3
IOH55033
LIM and senescent cell antigen-
Control
0.002538




like-containing domain protein 1


BC017212.2
IOH13041
PHD finger protein 11 (PHF11)
AD
0.0027


NM_019069.3
IOH26403
WD repeat domain 5B (WDR5B)
AD
0.00274


BC094719.1
IOH62673
Rho GTPase-activating protein 12
AD
0.002753


BC021187.1
IOH10893
DKFZP434K028 protein
AD
0.00278




(DKFZP434K028)


NM_003948.2

Cyclin-dependent kinase-like 2
AD
0.00278


BC040183.2
IOH27627
Rap guanine nucleotide exchange
AD
0.00278




factor (GEF) 4 (RAPGEF4)


NM_014061.3
IOH10824
melanoma antigen family H, 1
AD
0.00278




(MAGEH1)


BC032587.1
IOH21953
tubby like protein 3 (TULP3)
AD
0.002953


BC005332.1
IOH7177
cDNA clone MGC: 12418
AD
0.003171




IMAGE: 3934658, complete cds


BC033710.2
IOH45968
RAD54 homolog B (S. cerevisiae)
AD
0.003171




(RAD54B)


BC010425.1
IOH27813
acyl-Coenzyme A oxidase 1,
AD
0.003171




palmitoyl (ACOX1)


NM_021138.2
IOH21846
TNF receptor-associated factor 2
AD
0.003171




(TRAF2)


BC093990.1
IOH62017
Sin3 histone deacetylase
AD
0.003185




corepressor complex component




SDS3


NM_014288.2
IOH13691
Centromere protein R
AD
0.003283


NM_024826.1
IOH42194
Microtubule-associated protein 9
AD
0.003283


BC035968.1
IOH27970
chloride intracellular channel 5
AD
0.003283




(CLIC5)


BC096165.1
IOH59027
Troponin I, cardiac muscle
AD
0.003432


BC012105.1
IOH14609
nuclear VCP-like (NVL)
AD
0.003548


BC011924.1
IOH12682
unkempt homolog (Drosophila)-
AD
0.003548




like (UNKL)


NM_001311.2
IOH5361
Cysteine-rich protein 1
AD
0.003548


NM_014445.2
IOH41298
stress-associated endoplasmic
AD
0.003548




reticulum protein 1 (SERP1)


NM_005979.1
IOH1589
S100 calcium binding protein A13
AD
0.003548




(S100A13), transcript variant 2


BC036923.1
IOH25928
chromosome 9 open reading frame
AD
0.003733




150 (C9orf150)


NM_033671.1
IOH43039
cyclin B3 (CCNB3), transcript
AD
0.003733




variant 2


NM_201998.1
IOH56887
Splicing factor 1
Control
0.003827


BC014441.1
IOH13328
NOL1/NOP2/Sun domain family,
AD
0.003841




member 4 (NSUN4)


BC031549.1
IOH21007
CDC-like kinase 1 (CLK1)
AD
0.003841


NM_194290.1
IOH42276
cDNA FLJ42001 fis, clone
AD
0.003841




SPLEN2029912 (LOC153684




protein)




[Source: UniProtKB/TrEMBL; Acc:




Q6ZVW3]


BC053984.1
IOH29361
immunoglobulin heavy variable 4-
AD
0.003841




31 (IGHV4-31)


BC050563.1
IOH26951
hypothetical protein LOC202051
AD
0.003841




(LOC202051)


BC050718.1
IOH27017
polymerase (DNA directed) kappa
AD
0.00385




(POLK)


BC000896.1
IOH3226
RAB10, member RAS oncogene
AD
0.00385




family (RAB10)


NM_006252.2
IOH29876
AMP-activated protein_kinase
AD
0.00385




A2/B1/G1: PRKAA2/B1/G1




sequences are seperated by - (in




protein list file).


BC013630.1
IOH10193
JTV1 gene (JTV1)
AD
0.00385


BC009108.1
IOH10191
cDNA clone IMAGE: 3451214
AD
0.003975




(MCM10)


BC002645.1
IOH5243
syntaxin 5 (STX5)
AD
0.003975


NM_138414.1
IOH10524
coiled-coil domain containing 101
AD
0.004133




(CCDC101)


NM_002740.1

protein kinase C, iota (PRKCI)
AD
0.004133


NM_002822.3
IOH40883
twinfilin, actin-binding protein,
AD
0.004234




homolog 1 (Drosophila) (TWF1)


BC003566.1
IOH4871
zinc finger protein 24 (ZNF24)
AD
0.004412


NM_022756.2
IOH13235
Uncharacterized protein C1orf149
AD
0.004679


NM_153035.1
IOH27410
chromosome 1 open reading frame
AD
0.004754




83 (C1orf83)


NM_177524.1
IOH45900
mesoderm specific transcript
AD
0.004766




homolog (mouse) (MEST),




transcript variant 2


NM_004635.2
IOH3889
mitogen-activated protein kinase-
AD
0.004766




activated protein kinase 3




(MAPKAPK3)


NM_005607.1

Focal adhesion kinase 1
AD
0.004766


BC010697.1
IOH9799
RNA-binding protein 40
AD
0.004766


NM_174942.1
IOH26291
GAS2-like protein 3
AD
0.004766


BC038976.1
IOH28763
Rho GTPase-activating protein 15
AD
0.004867


NM_012117.1
IOH3162
chromobox homolog 5 (HP1 alpha
AD
0.004867




homolog, Drosophila) (CBX5)


NM_013313.3
IOH43282
yippee-like 1 (Drosophila)
AD
0.005052




(YPEL1)


NM_148179.1
IOH23094
chromosome 9 open reading frame
AD
0.0051




23 (C9orf23), transcript variant 2


BC038105.2
IOH27173
membrane protein, palmitoylated
AD
0.0051




7 (MAGUK p55 subfamily




member 7) (MPP7)


BC091489.1
IOH62570
zinc finger, MYND domain
AD
0.0051




containing 11, mRNA (cDNA




clone MGC: 111056




IMAGE: 6186814), complete cds


BC034435.1
IOH21500
zinc finger CCCH-type containing
AD
0.0051




3 (ZC3H3)


NM_152736.2
IOH14153
Zinc finger protein 187
AD
0.0051


NM_015014.1
IOH23193
RNA binding motif protein 34
AD
0.005622




(RBM34)


NM_003137.2

SFRS protein kinase 1 (SRPK1)
AD
0.005622


BC016486.1
IOH21471
lectin, galactoside-binding,
AD
0.005695




soluble, 8 (galectin 8) (LGALS8)


BC000238.1
IOH4394
ankyrin repeat and zinc finger
AD
0.005695




domain containing 1 (ANKZF1)


NM_002904.4
IOH14621
RD RNA binding protein (RDBP)
AD
0.005695


BC009046.1
IOH3394
neurogenic differentiation 1
AD
0.005695




(NEUROD1)


NM_198965.1
IOH44500
Parathyroid hormone-related
AD
0.005695




protein


BC047776.2
IOH26688
coiled-coil domain containing 43
AD
0.005695




(CCDC43)


BC002914.1
IOH5733
WAS/WASL-interacting protein
Control
0.005832




family member 1


NM_001004306.1
IOH40085
similar to hypothetical protein
AD
0.005898




FLJ36492 (MGC87631)


NM_006800.2
IOH45528
male-specific lethal 3-like 1
AD
0.005898




(Drosophila) (MSL3L1), transcript




variant 3


NM_006038.1
IOH14383
spermatogenesis associated 2
AD
0.005898




(SPATA2)


NM_014477.2
IOH22106
chromosome 20 open reading
AD
0.005898




frame 10 (C20orf10)


BC027612.2
IOH11844
EP300-interacting inhibitor of
AD
0.005898




differentiation 3


NM_017411.2
IOH10903
survival of motor neuron 2,
AD
0.005898




centromeric (SMN2), transcript




variant d


BC004876.1
IOH5626
Protein MCM10 homolog
AD
0.005898


NM_201516.1
IOH45833
H2A histone family, member V
AD
0.005917




(H2AFV), transcript variant 4


NM_199290.2
IOH40757
Nascent polypeptide-associated
Control
0.006165




complex subunit alpha-2


BC006273.1
IOH6379
T-cell activation NFKB-like
Control
0.006165




protein (TA-NFKBH)


NM_014012.2
IOH26198
RAS (RAD and GEM)-like GTP-
Control
0.006165




binding 1 (REM1)


BC012499.1
IOH11855
NAD-dependent deacetylase
Control
0.006165




sirtuin-1


NM_022156.3
IOH39856
dihydrouridine synthase 1-like (S. cerevisiae)
AD
0.006165




(DUS1L)


BC015742.1
IOH12050
polymerase (DNA directed), eta
AD
0.006497




(POLH)


NM_001015509.1
IOH54713
Peptidyl-tRNA hydrolase 2,
AD
0.006497




mitochondrial


NM_014366.1
IOH4189
guanine nucleotide binding
AD
0.006531




protein-like 3 (nucleolar) (GNL3),




transcript variant 1


NM_018357.2
IOH6558
La ribonucleoprotein domain
AD
0.006544




family, member 6 (LARP6),




transcript variant 1


BC020221.1
IOH13291
SH3 and cysteine rich domain
AD
0.006912




(STAC)


NM_005307.1

G protein-coupled receptor kinase 4
AD
0.006912


NM_017785.2
IOH12118
coiled-coil domain containing 99
AD
0.006926




(CCDC99)


BC026101.2
IOH10652
nudE nuclear distribution gene E
AD
0.006926




homolog (A. nidulans)-like 1




(NDEL1)


NM_175571.2
IOH44212
GTPase, IMAP family member 8
AD
0.006926




(GIMAP8)


NM_004286.2
IOH14552
GTP binding protein 1 (GTPBP1)
AD
0.006926


BC072461.1
IOH62565
Cysteine and histidine-rich
AD
0.006926




domain-containing protein 1


BC047945.1
IOH26362
tripartite motif-containing 69
AD
0.006926




(TRIM69)


BC005858.1
IOH5967
fibronectin 1 (FN1)
AD
0.006926


NM_001722.2
IOH4103
polymerase (RNA) III (DNA
AD
0.006926




directed) polypeptide D, 44 kDa




(POLR3D)


NM_024333.1
IOH4546
Fibronectin type III and SPRY
AD
0.006926




domain-containing protein 1


NM_144595.1
IOH25832
SLAIN motif family, member 1
AD
0.006926




(SLAIN1), transcript variant 2


NM_002469.1
IOH13806
myogenic factor 6 (herculin)
AD
0.006926




(MYF6)


BC053866.1
IOH28947
endothelin 3 (EDN3)
AD
0.006926


NM_001319.5
IOH10417
casein kinase 1, gamma 2
AD
0.006926




(CSNK1G2)


BC006124.1
IOH6586
IMP (inosine monophosphate)
AD
0.006926




dehydrogenase 2 (IMPDH2)


NM_014667.1
IOH29305
vestigial like 4 (Drosophila)
AD
0.006926




(VGLL4)


NM_031465.2
IOH6623
chromosome 12 open reading
AD
0.006926




frame 32 (C12orf32)


NM_182612.1
IOH42453
Parkinson disease 7 domain
AD
0.006926




containing 1 (PDDC1)


PV4803

epidermal growth factor receptor
AD
0.006926




(erythroblastic leukemia viral (v-




erb-b) oncogene homolog, avian)




(EGFR); see catalog number for




detailed information on wild-type




or point mutant status


NM_152266.1
IOH13579
chromosome 19 open reading
AD
0.006926




frame 40 (C19orf40)


NM_000997.2
IOH1585
ribosomal protein L37 (RPL37)
AD
0.00699


BC001728.1
IOH4430
TCF3 fusion partner
AD
0.00699


BC007015.1
IOH29312
cyclin E2 (CCNE2)
AD
0.00699


NM_022347.1
IOH41552
interferon responsive gene 15
AD
0.00699




(IFRG15)


BC031821.1
IOH22188
Secernin-3
AD
0.007845


NM_016304.2
IOH7552
chromosome 15 open reading
AD
0.007845




frame 15 (C15orf15)


BC069677.1
IOH61907
Regulator of G-protein signaling 8
AD
0.008076


BC013331.1
IOH13858
H2A histone family, member Y
AD
0.008076




(H2AFY)


NM_017838.2
IOH4642
nucleolar protein family A,
AD
0.008076




member 2 (H/ACA small




nucleolar RNPs) (NOLA2),




transcript variant 1


BC013796.1
IOH21478
adaptor-related protein complex 2,
AD
0.008076




mu 1 subunit (AP2M1)


NM_080743.2
IOH10836
serine-arginine repressor protein
AD
0.008076




(35 kDa) (SRrp35)


BC000190.1
IOH4410
zinc finger, C3HC-type containing
AD
0.008141




1 (ZC3HC1)


BC036089.1
IOH27267
myeloid/lymphoid or mixed-
AD
0.008141




lineage leukemia (trithorax




homolog, Drosophila);




translocated to, 3 (MLLT3)


NM_018215.2
IOH40888
hypothetical protein FLJ10781
AD
0.008141




(FLJ10781), transcript variant 1


BC095401.1
IOH62645
AKT-interacting protein
AD
0.008141


BC006456.1
IOH5963
family with sequence similarity
Control
0.008294




21, member C (FAM21C)


BC033777.2
IOH21769
amyotrophic lateral sclerosis 2
Control
0.008368




(juvenile) chromosome region,




candidate 8 (ALS2CR8)


NM_001008572.1
IOH45757
tubulin tyrosine ligase-like family,
AD
0.008509




member 1 (TTLL1), transcript




variant 2


BC103812.1
IOH63363
Alpha-ketoglutarate-dependent
AD
0.008559




dioxygenase alkB homolog 3


BC036365.1
IOH22309
PH domain-containing protein
AD
0.008559




C10orf81


NM_024718.2
IOH40918
chromosome 9 open reading frame
Control
0.009125




86 (C9orf86)


BC013031.1
IOH13433
Pleckstrin homology-like domain
Control
0.009125




family B member 1


NM_022110.2
IOH10458
FK506 binding protein like
Control
0.009125




(FKBPL)


NM_016047.1
IOH11089
splicing factor 3B, 14 kDa subunit
AD
0.009549




(SF3B14)


BC014949.1
IOH13331
DEXH (Asp-Glu-X-His) box
AD
0.009549




polypeptide 58 (DHX58)


BC047690.1
IOH28834
Ras-related protein M-Ras
AD
0.009633


NM_001894.2
IOH21160
casein kinase 1, epsilon
AD
0.009633




(CSNK1E), transcript variant 2


NM_006482.1

Dual specificity tyrosine-
AD
0.009633




phosphorylation-regulated kinase 2


NM_025104.2
IOH59472
Protein DBF4 homolog B
AD
0.009633


BC004410.1
IOH5586
Zinc finger protein castor homolog 1
Control
0.009819


NM_017819.1
IOH45746
RNA (guanine-9-)-
AD
0.009872




methyltransferase domain-




containing protein 1,




mitochondrial


BC029382.1
IOH23139
Angiogenic factor with G patch
Control
0.010166




and FHA domains 1


NM_199139.1
IOH44783
XIAP associated factor-1 (XAF1),
AD
0.010291




transcript variant 2


NM_003910.2
IOH23209
BUD31 homolog (S. cerevisiae)
AD
0.010291




(BUD31)


BC000442.1

Serine/threonine-protein kinase 12
AD
0.010291


BC028711.2
IOH11814
cancer/testis antigen CT45-3
AD
0.010291




(CT45-3)


NM_018158.1
IOH38323
solute carrier family 4 (anion
AD
0.010774




exchanger), member 1, adaptor




protein (SLC4A1AP)


BC034692.1
IOH22176
anillin, actin binding protein
AD
0.010774




(ANLN)


NM_173605.1
IOH21690
potassium channel regulator
AD
0.010774




(KCNRG), transcript variant 1


NM_014047.1
IOH11187
chromosome 19 open reading
AD
0.010774




frame 53 (C19orf53)


BC073791.1
IOH63073
immunoglobulin kappa constant,
AD
0.010774




mRNA (cDNA clone MGC: 88809




IMAGE: 6279986), complete cds


BC014928.1
IOH10102
MYC-induced nuclear antigen
AD
0.010774


BC053656.1
IOH28981
EGF-like repeats and discoidin I-
AD
0.010774




like domains 3 (EDIL3)


XM_378879.2
IOH42915
PREDICTED: Homo sapiens
AD
0.010774




hypothetical LOC400763




(LOC400763)


NM_017817.1
IOH12515
RAB20, member RAS oncogene
AD
0.010774




family (RAB20)


BC031608.1
IOH22796
REST corepressor 3 (RCOR3)
AD
0.010774


BC047722.1
IOH26651
hypothetical protein MGC52110
AD
0.010774




(MGC52110)


BC020726.1
IOH12969
sciellin (SCEL)
AD
0.010774


NM_024039.1
IOH4379
MIS12, MIND kinetochore
AD
0.010774




complex component, homolog




(yeast) (MIS12)


BC026213.1
IOH11042
F-box/WD repeat-containing
AD
0.010774




protein 11


NM_002135.3
IOH10133
nuclear receptor subfamily 4,
AD
0.010822




group A, member 1 (NR4A1),




transcript variant 1


NM_015939.2
IOH3137
tRNA methyltransferase 6
AD
0.010846




homolog (S. cerevisiae) (TRMT6)


NM_018039.2
IOH43857
jumonji domain containing 2D
AD
0.010846




(JMJD2D)


NM_007373.2
IOH26711
soc-2 suppressor of clear homolog
AD
0.010846




(C. elegans) (SHOC2)


BC022996.1
IOH10666
SH3 domain-binding protein 2
Control
0.011036


BC067120.1
IOH40451
protein tyrosine phosphatase
AD
0.011036




domain containing 1, mRNA




(cDNA clone MGC: 70358




IMAGE: 5539182), complete cds


BC027729.1
IOH14530
tetra-peptide repeat homeobox-
Control
0.01201




like (TPRXL)


BC054520.1
IOH28900
myocyte enhancer factor 2D
Control
0.01201




(MEF2D)


NM_015918.2
IOH10987
processing of precursor 5,
AD
0.012016




ribonuclease P/MRP subunit (S. cerevisiae)




(POP5), transcript




variant 1


NM_152677.1
IOH34851
zinc finger and SCAN domain
AD
0.012016




containing 4 (ZSCAN4)


BC008902.2
IOH7022
GRIP and coiled-coil domain-
AD
0.012016




containing protein 1


NM_001008239.1
IOH45708
chromosome 18 open reading
AD
0.012016




frame 25 (C18orf25), transcript




variant 2


NM_183397.1
IOH44678
peroxisomal membrane protein 4,
AD
0.012016




24 kDa (PXMP4), transcript




variant 2


NM_006337.3
IOH12378
microspherule protein 1 (MCRS1),
AD
0.012016




transcript variant 1


NM_203305.1
IOH26383
family with sequence similarity
Control
0.012091




102, member A (FAM102A),




transcript variant 2


BC034401.1
IOH22782
cDNA clone IMAGE: 5172086,
AD
0.012151




partial cds


NM_006755.1
IOH2052
transaldolase 1 (TALDO1)
AD
0.012151


NM_004853.1
IOH9940
syntaxin 8 (STX8)
AD
0.012151


BC036910.1
IOH25910
hypothetical LOC388882
AD
0.012151




(LOC388882)


BC094687.1
IOH62581
Elongation factor 1-alpha 1
AD
0.012151


BC011713.2
IOH22973
tRNA methyltransferase 12
Control
0.013018




homolog (S. cerevisiae)




(TRMT12)


NM_006263.1
IOH3647
proteasome (prosome, macropain)
Control
0.013018




activator subunit 1 (PA28 alpha)




(PSME1), transcript variant 1


NM_144608.1
IOH14178
hexamthylene bis-acetamide
AD
0.013303




inducible 2 (HEXIM2)


NM_024038.2
IOH5926
chromosome 19 open reading
Control
0.013303




frame 43 (C19orf43)


NM_003831.1
IOH20968
RIO kinase 3 (yeast) (RIOK3)
AD
0.013332


BC020555.1
IOH10305
SERPINE1 mRNA binding
Control
0.013333




protein 1 (SERBP1)


BC009250.1
IOH27775
guanine nucleotide binding
AD
0.013333




protein-like 2 (nucleolar) (GNL2)


BC032598.1
IOH21976
NHL repeat containing 2
AD
0.013369




(NHLRC2)


NM_018697.3
IOH37734
LanC lantibiotic synthetase
AD
0.013369




component C-like 2 (bacterial)




(LANCL2)


NM_024104.1
IOH3754
chromosome 19 open reading
AD
0.013369




frame 42 (C19orf42)


BC030665.1
IOH22451
Sulfotransferase 4A1
AD
0.013369


BC004955.1
IOH5528
ATPase inhibitory factor 1
AD
0.013369




(ATPIF1)


BC009010.1
IOH3292
Uncharacterized protein C6orf142
AD
0.013369




homolog


BC012887.1
IOH25768
Nucleolar and spindle-associated
AD
0.013369




protein 1


BC015066.1
IOH13784
core-binding factor, runt domain,
AD
0.013369




alpha subunit 2; translocated to, 2




(CBFA2T2)


BC052303.1
IOH28113
Rho GTPase activating protein 4
AD
0.013369




(ARHGAP4)


NM_080414.1
IOH42243
vacuolar protein sorting 16
AD
0.013369




homolog (S. cerevisiae) (VPS16),




transcript variant 2


NM_001790.2
IOH14569
cell division cycle 25 homolog C
AD
0.013369




(S. pombe) (CDC25C), transcript




variant 1


PHC0045

interleukin 4 (IL4), transcript
AD
0.013369




variant 1


NM_145041.1
IOH13199
transmembrane protein 106A
AD
0.013369




(TMEM106A)


NM_021639.2
IOH10045
GC-rich promoter binding protein
AD
0.013369




1-like 1 (GPBP1L1)


BC028295.1
IOH25815
peptidase D (PEPD)
AD
0.013369


PV3612

aurora kinase A (AURKA),
AD
0.013369




transcript variant 2


NM_032321.1
IOH6608
hypothetical protein MGC13057
AD
0.013369




(MGC13057), transcript variant 4


BC010033.1
IOH27835
quinolinate
AD
0.013369




phosphoribosyltransferase




(nicotinate-nucleotide




pyrophosphorylase




(carboxylating)) (QPRT)


NM_001064.1
IOH61026
Transketolase
AD
0.013369


NM_017572.2
IOH53775
MAP kinase-interacting
AD
0.013967




serine/threonine-protein kinase 2


NM_022650.1
IOH41794
RAS p21 protein activator
AD
0.013967




(GTPase activating protein) 1




(RASA1), transcript variant 2


NM_020781.2
IOH45442
zinc finger protein 398 (ZNF398),
AD
0.013967




transcript variant 2


NM_182597.1
IOH44503
Coiled-coil domain-containing
Control
0.014519




transmembrane protein C7orf53


NM_001008211.1
IOH57143
Optineurin
Control
0.014972


NM_006246.2
IOH29856
protein phosphatase 2, regulatory
Control
0.014972




subunit B′, epsilon isoform




(PPP2R5E)


NM_148912.2
IOH40097
abhydrolase domain containing 11
Control
0.014972




(ABHD11)


BC053617.1
IOH29004
B-cell CLL/lymphoma 10
Control
0.014972




(BCL10)


NM_021643.1
IOH21149
tribbles homolog 2 (Drosophila)
Control
0.014972




(TRIB2)


NM_024313.1
IOH5392
nucleolar protein 12 (NOL12)
Control
0.014972


NM_002735.1
IOH42254
cAMP-dependent protein kinase
Control
0.014972




type I-beta regulatory subunit


NM_032929.1
IOH7540
ubiquitin specific protease 45
Control
0.014972




(USP45)


NM_024692.3
IOH42634
CAP-GLY domain containing
Control
0.015635




linker protein family, member 4




(CLIP4)


NM_002391.1
IOH13794
midkine (neurite growth-
AD
0.015891




promoting factor 2) (MDK),




transcript variant 3


NM_006298.2
IOH34757
zinc finger protein 192 (ZNF192)
AD
0.015891


BC047536.1
IOH27737
sciellin (SCEL)
AD
0.015891


NM_139062.1
IOH23025
casein kinase 1, delta (CSNK1D),
AD
0.015891




transcript variant 2


NM_005639.1
IOH29114
synaptotagmin I (SYT1)
AD
0.015891


BC006811.1
IOH3174
peroxisome proliferator-activated
AD
0.015961




receptor gamma (PPARG)


BC008364.1
IOH5969
heterogeneous nuclear
AD
0.015961




ribonucleoprotein C (C1/C2)




(HNRPC)


NM_032345.1
IOH6625
within bgcn homolog (Drosophila)
AD
0.015961




(WIBG)


BC040949.1
IOH26268
myocyte enhancer factor 2D
Control
0.016176




(MEF2D)


NM_005522.3
IOH21992
homeobox A1 (HOXA1),
Control
0.016176




transcript variant 1


BC016825.1
IOH14707
spire homolog 1 (Drosophila)
AD
0.016623




(SPIRE1)


NM_020664.3
IOH9825
2,4-dienoyl CoA reductase 2,
AD
0.017399




peroxisomal (DECR2)


NM_173547.2
IOH11612
tripartite motif-containing 65
Control
0.017399




(TRIM65)


NM_017542.3
IOH43680
pogo transposable element with
AD
0.017399




KRAB domain (POGK)


NM_003160.1

Serine/threonine-protein kinase 13
AD
0.017399


NM_032550.1
IOH10814
actin filament associated protein
Control
0.017478




1-like 2 (AFAP1L2), transcript




variant 2


NM_004527.2
IOH40231
mesenchyme homeobox 1
Control
0.017478




(MEOX1), transcript variant 1


BC031687.1
IOH21501
drebrin-like (DBNL)
Control
0.017478


BC026346.1
IOH10816
family with sequence similarity
AD
0.017478




84, member A (FAM84A)


BC041037.1
IOH28003
immunoglobulin heavy constant
AD
0.017478




mu (IGHM)


BC028039.1
IOH11511
hypothetical protein MGC39900
Control
0.01748




(MGC39900)


BC033677.1
IOH40219
Uncharacterized protein C9orf114
AD
0.017534


BC055427.1
IOH28811
TRAF2 and NCK interacting
AD
0.017534




kinase (TNIK)


NM_016648.1
IOH41297
La ribonucleoprotein domain
AD
0.017664




family, member 7 (LARP7),




transcript variant 1


BC064145.1
IOH40031
CDK5 regulatory subunit
AD
0.017664




associated protein 1-like 1




(CDKAL1)


NM_138565.1
IOH6227
cortactin (CTTN), transcript
AD
0.017664




variant 2


NM_018441.2
IOH4050
peroxisomal trans-2-enoyl-CoA
Control
0.018299




reductase (PECR)


NM_022823.1
IOH21980
fibronectin type III domain
AD
0.018299




containing 4 (FNDC4)


NM_015871.2
IOH4113
zinc finger protein 593 (ZNF593)
Control
0.01832


NM_024096.1
IOH3203
XTP3-transactivated protein A
Control
0.01863




(XTP3TPA)


BC023546.2
IOH29323
LIM and calponin homology
Control
0.018757




domains 1 (LIMCH1)


NM_015621.2
IOH43603
coiled-coil domain containing 69
Control
0.018757




(CCDC69)


BC006104.1
IOH6588
RIO kinase 1 (yeast) (RIOK1)
AD
0.018757


BC014975.1
IOH14285
family with sequence similarity
AD
0.018844




136, member A (FAM136A)


NM_138730.1
IOH9857
high mobility group nucleosomal
AD
0.018844




binding domain 3 (HMGN3),




transcript variant 2


BC000226.1
IOH4362
ubiquitin specific peptidase 47
Control
0.019006




(USP47)


NM_007242.3
IOH3925
DEAD (Asp-Glu-Ala-As) box
Control
0.019006




polypeptide 19B (DDX19B),




transcript variant 1


NM_025004.1
IOH43200
Coiled-coil domain-containing
AD
0.019314




protein 15


NM_004092.2
IOH54943
Enoyl-CoA hydratase,
AD
0.019314




mitochondrial


NM_021107.1
IOH6073
mitochondrial ribosomal protein
AD
0.019314




S12 (MRPS12), nuclear gene




encoding mitochondrial protein,




transcript variant 1


NM_053049.2
IOH54667
Urocortin-3
AD
0.019314


NM_001545.1
IOH11951
immature colon carcinoma
AD
0.019314




transcript 1 (ICT1)


NM_148571.1
IOH41376
mitochondrial ribosomal protein
AD
0.019314




L27 (MRPL27), nuclear gene




encoding mitochondrial protein,




transcript variant 2


NM_001003799.1
IOH45702
TCR gamma alternate reading
AD
0.019314




frame protein (TARP), nuclear




gene encoding mitochondrial




protein, transcript variant 1


BC017227.1
IOH12094
phosducin-like (PDCL)
AD
0.019314


NM_172159.2
IOH25842
potassium voltage-gated channel,
AD
0.019314




shaker-related subfamily, beta




member 1 (KCNAB1), transcript




variant 3


NM_000462.2
IOH38426
ubiquitin protein ligase E3A
AD
0.019314




(human papilloma virus E6-




associated protein, Angelman




syndrome) (UBE3A), transcript




variant 2


XM_210860.4
IOH44696
PREDICTED: Homo sapiens
AD
0.019314




hypothetical LOC283034




(LOC283034)


BC022344.1
IOH14799
twinfilin, actin-binding protein,
AD
0.019314




homolog 1 (Drosophila) (TWF1)


NM_005037.3
IOH39661
peroxisome proliferator-activated
AD
0.019314




receptor gamma (PPARG),




transcript variant 4


NM_022977.1
IOH42656
acyl-CoA synthetase long-chain
AD
0.019314




family member 4 (ACSL4),




transcript variant 2


NM_006217.2
IOH11838
serpin peptidase inhibitor, clade I
AD
0.019314




(pancpin), member 2 (SERPINI2)


NM_024979.2
IOH23111
Guanine nucleotide exchange
AD
0.019314




factor DBS


NM_016286.1
IOH4017
dicarbonyl/L-xylulose reductase
AD
0.019314




(DCXR)


NM_003160.1

Serine/threonine-protein kinase 13
AD
0.019314


NM_015687.2
IOH38763
filamin A interacting protein 1
AD
0.019314




(FILIP1)


BC005871.2
IOH46098
chromosome 10 open reading
AD
0.019314




frame 58 (C10orf58)


NM_016216.2
IOH57112
Lariat debranching enzyme
AD
0.019314


NM_017856.1
IOH3877
gem (nuclear organelle) associated
AD
0.019314




protein 8 (GEMIN8), transcript




variant 3


NM_015869.2
IOH36704
peroxisome proliferator-activated
AD
0.019314




receptor gamma (PPARG),




transcript variant 2


NM_001003397.1
IOH58745
Tumor protein D53
AD
0.019314


NM_001018061.1
IOH57329
UPF0544 protein C5orf45
AD
0.019314




[Source: UniProtKB/Swiss-




Prot; Acc: Q6NTE8]


NM_173060.1
IOH52621
Calpastatin
Control
0.019703


BC013900.1
IOH27818
chromosome 12 open reading
AD
0.020182




frame 41 (C12orf41)


BC022988.1
IOH22366
chromosome 6 open reading frame
AD
0.020182




65 (C6orf65)


NM_006299.2
IOH12838
zinc finger protein 193 (ZNF193)
AD
0.020182


BC018847.1
IOH14862
Transaldolase
AD
0.020182


BC052805.1
IOH29378
erythrocyte membrane protein
Control
0.020182




band 4.9 (dematin) (EPB49)


NM_139355.1
IOH4506
megakaryocyte-associated tyrosine
AD
0.0209




kinase (MATK), transcript variant 1


NM_207356.1
IOH40044
chromosome 1 open reading frame
AD
0.0209




174 (C1orf174)


NM_001008737.1
IOH42047
hypothetical LOC401052
AD
0.0209




(LOC401052)


NM_145109.1
IOH21715
mitogen-activated protein kinase
AD
0.0209




kinase 3 (MAP2K3), transcript




variant B


BC017114.1
IOH9995
oligonucleotide/oligosaccharide-
AD
0.0209




binding fold containing 2A




(OBFC2A)


XM_086879.4
IOH43381
PREDICTED: Homo sapiens
AD
0.0209




hypothetical LOC150371




(LOC150371)


NM_078630.1
IOH37755
male-specific lethal 3-like 1
AD
0.0209




(Drosophila) (MSL3L1), transcript




variant 2


NM_005197.2
IOH56874
Forkhead box protein N3
AD
0.0209


NM_004602.2
IOH62672
Double-stranded RNA-binding
AD
0.021101




protein Staufen homolog 1


BC017504.1
IOH12256
Differentially expressed in FDCP
AD
0.021101




6 homolog


NM_014763.2
IOH23003
mitochondrial ribosomal protein
Control
0.021448




L19 (MRPL19), nuclear gene




encoding mitochondrial protein


NM_003590.2
IOH26262
cullin 3 (CUL3)
AD
0.021703


NM_145702.1
IOH40861
tigger transposable element
AD
0.021703




derived 1 (TIGD1)


BC001935.1
IOH5068
cyclin-dependent kinase inhibitor
AD
0.022172




1A (p21, Cip1) (CDKN1A)


NM_031472.1
IOH5640
tRNA phosphotransferase 1
Control
0.023801




(TRPT1), transcript variant 2


NM_032141.1
IOH43707
coiled-coil domain containing 55
Control
0.024725




(CCDC55), transcript variant 1


NM_004965.3
IOH4772
high-mobility group nucleosome
AD
0.024725




binding domain 1 (HMGN1)


BC032508.1
IOH62199
PNMA-like 1, mRNA (cDNA
AD
0.025032




clone MGC: 45422




IMAGE: 5246377), complete cds


BC013966.2
IOH12372
family with sequence similarity
AD
0.025523




64, member A (FAM64A)


NM_020236.2
IOH13751
mitochondrial ribosomal protein
AD
0.025523




L1 (MRPL1), nuclear gene




encoding mitochondrial protein


BC043247.2
IOH28730
transducin-like enhancer of split 3
AD
0.025523




(E(sp1) homolog, Drosophila)




(TLE3)


BC057806.1
IOH29150
insulin-like growth factor binding
AD
0.025523




protein 1 (IGFBP1)


NM_006573.2
IOH12947
tumor necrosis factor (ligand)
AD
0.025523




superfamily, member 13b




(TNFSF13B)


BC025406.1
IOH11226
phosphodiesterase 4D interacting
AD
0.025523




protein (myomegalin) (PDE4DIP)


BC002559.1
IOH4053
YTH domain family, member 2
AD
0.025523




(YTHDF2)


NM_052926.1
IOH35779
Paraneoplastic antigen-like protein 5
AD
0.025523


NM_006254.3
IOH26352
protein kinase C, delta (PRKCD),
AD
0.025523




transcript variant 1


BC022003.1
IOH11205
myotubularin related protein 9
AD
0.025523




(MTMR9)


BC043348.2
IOH26348
retinitis pigmentosa 2 (X-linked
AD
0.025523




recessive) (RP2)


NM_018010.2
IOH12676
intraflagellar transport 57 homolog
AD
0.025523




(Chlamydomonas) (IFT57)


BC044851.1
IOH27643
vacuolar protein sorting 41
AD
0.025523




homolog (S. cerevisiae) (VPS41)


BC068094.1
IOH40788
SH3 domain and tetratricopeptide
AD
0.025523




repeats 1 (SH3TC1)


NM_020961.2
IOH6104
KIAA1627 protein (KIAA1627)
AD
0.025523


PV3757

myosin light chain kinase 2,
AD
0.025523




skeletal muscle (MYLK2)


NM_002451.3
IOH54928
methylthioadenosine
AD
0.025523




phosphorylase (MTAP), mRNA.


NM_000281.1
IOH6468
pterin-4 alpha-carbinolamine
AD
0.025523




dehydratase/dimerization cofactor




of hepatocyte nuclear factor 1




alpha (TCF1) (PCBD1)


NM_144982.1
IOH12275
coiled-coil domain containing 131
AD
0.025523




(CCDC131)


NM_017927.2
IOH43690
mitofusin 1 (MFN1), nuclear gene
AD
0.025523




encoding mitochondrial protein,




transcript variant 2


NM_002150.1
IOH14718
4-hydroxyphenylpyruvate
AD
0.025523




dioxygenase


NM_016267.1
IOH2890
vestigial like 1 (Drosophila)
AD
0.025523




(VGLL1)


BC067299.1
IOH40040
Mdm4, transformed 3T3 cell
AD
0.025523




double minute 4, p53 binding




protein (mouse) (MDM4)


XM_378988.2
IOH41598
PREDICTED: Homo sapiens
AD
0.025523




hypothetical LOC400849




(LOC400849)


NM_006466.1
IOH14273
polymerase (RNA) III (DNA
AD
0.025523




directed) polypeptide F, 39 kDa




(POLR3F)


BC042608.1
IOH27462
family with sequence similarity
AD
0.025523




90, member A1 (FAM90A1)


NM_025136.1
IOH6524
optic atrophy 3 (autosomal
AD
0.025523




recessive, with chorea and spastic




paraplegia) (OPA3), transcript




variant 2


BC012620.1
IOH12299
golgi SNAP receptor complex
AD
0.025523




member 1 (GOSR1)


NM_139244.2
IOH44877
syntaxin binding protein 5
AD
0.025523




(tomosyn) (STXBP5)


NM_015929.2
IOH7138
lipoyltransferase 1 (LIPT1),
AD
0.025523




transcript variant 1


PV3366

v-erb-b2 erythroblastic leukemia
AD
0.025523




viral oncogene homolog 2,




neuro/glioblastoma derived




oncogene homolog (avian)




(ERBB2), transcript variant 2


NM_133629.1
IOH43384
RAD51-like 3 (S. cerevisiae)
AD
0.025523




(RAD51L3), transcript variant 4


XM_294794.1
IOH42923
PREDICTED: Homo sapiens
AD
0.025523




similar to putative membrane-




bound dipeptidase 2 (LOC339065)


BC012289.1
IOH11447
KIAA0515 (KIAA0515)
AD
0.025523


BC029444.1
IOH23178
immunoglobulin kappa constant
AD
0.025523




(IGKC)


BC015109.1
IOH14036
39S ribosomal protein L1,
AD
0.025523




mitochondrial


NM_024578.1
IOH23128
occludin/ELL domain containing 1
AD
0.025523




(OCEL1)


NM_003908.1
IOH3554
eukaryotic translation initiation
AD
0.025523




factor 2, subunit 2 beta, 38 kDa




(EIF2S2)


BC001726.1
IOH4820
Nucleolar protein 11
AD
0.025523


BC003666.2
IOH6106
NAD synthetase 1 (NADSYN1)
AD
0.025523


NM_198491.1
IOH41015
family with sequence similarity
AD
0.025523




92, member B (FAM92B)


PV3817

WEE1 homolog (S. pombe)
AD
0.025523




(WEE1)


BC000974.2
IOH3026
WDR45-like (WDR45L)
AD
0.025523


BC053675.1
IOH29030
thymopoietin (TMPO)
AD
0.025523


BC033292.1
IOH26782
interleukin 20 receptor beta
AD
0.025523




(IL20RB)


BC002509.1
IOH3968
PHD finger protein 23
AD
0.025523


BC006969.1
IOH7343
dynein, cytoplasmic 2, light
AD
0.025523




intermediate chain 1, mRNA




(cDNA clone MGC: 12166




IMAGE: 3828551), complete cds


BC069491.1
IOH40249
Cerberus
AD
0.025523


NM_138559.1
IOH43559
B-cell CLL/lymphoma 11A (zinc
AD
0.025523




finger protein) (BCL11A),




transcript variant 3


BC004376.1
IOH5584
annexin A8 (ANXA8L1)
AD
0.025523


NM_005620.1
IOH4079
S100 calcium binding protein A11
AD
0.025523




(S100A11)


PV3872

epidermal growth factor receptor
AD
0.025523




(erythroblastic leukemia viral (v-




erb-b) oncogene homolog, avian)




(EGFR); see catalog number for




detailed information on wild-type




or point mutant status


NM_032214.1
IOH26309
Src-like-adaptor 2 (SLA2),
AD
0.025523




transcript variant 1


NM_002444.1
IOH2457
moesin (MSN)
AD
0.025523


NM_173796.2
IOH23049
hypothetical protein MGC24125
AD
0.025523




(MGC24125)


NM_002648.1

pim-1 oncogene (PIM1)
AD
0.025523


NM_001876.2
IOH52786
Carnitine O-palmitoyltransferase
AD
0.025523




1, liver isoform


BC014532.1
IOH12798
decapping enzyme, scavenger
AD
0.025523




(DCPS)


NM_001005266.1
IOH59477
Dresden prostate carcinoma
AD
0.025523




protein 2


NM_007172.2
IOH40805
nucleoporin 50 kDa (NUP50),
AD
0.025523




transcript variant 2


NM_018326.1
IOH14251
GTPase, IMAP family member 4
AD
0.025523




(GIMAP4)


BC033881.1
IOH22099
XRCC6 binding protein 1
AD
0.025523




(XRCC6BP1)


NM_020168.3
IOH20961
p21(CDKN1A)-activated kinase 6
AD
0.025523




(PAK6)


NM_014790.3
IOH14698
janus kinase and microtubule
AD
0.025562




interacting protein 2 (JAKMIP2)


NM_032360.1
IOH6003
acyl-Coenzyme A binding domain
AD
0.025562




containing 6 (ACBD6)


NM_006303.2
IOH5395
JTV1 gene (JTV1)
AD
0.025562


BC017305.1
IOH12450
sirtuin (silent mating type
AD
0.025562




information regulation 2 homolog)




7 (S. cerevisiae) (SIRT7)


BC051762.1
IOH28838
Uncharacterized protein C20orf96
AD
0.025562


NM_145010.1
IOH10871
chromosome 10 open reading
AD
0.025589




frame 63 (C10orf63)


NM_206834.1
IOH40081
Uncharacterized protein C6orf201
AD
0.027186


BC009350.1
IOH14087
Eukaryotic translation initiation
AD
0.027186




factor 2-alpha kinase 4


NM_003720.1
IOH3819
Proteasome assembly chaperone 1
AD
0.027186


NM_001906.1
IOH7194
chymotrypsinogen B1 (CTRB1)
Control
0.027437


BC037900.2
IOH27758
C-terminal binding protein 2
Control
0.027437




(CTBP2)


NM_138960.3
IOH59763
Homeobox protein TGIF2LX
Control
0.027437


BC067755.1
IOH40120
potassium channel tetramerisation
AD
0.027437




domain containing 18 (KCTD18)


BC005840.2
IOH46093
selenoprotein S (SELS)
AD
0.027437


BC000934.2
IOH2996
eukaryotic translation initiation
AD
0.027601




factor 2, subunit 2 beta, 38 kDa




(EIF2S2)


BC038838.1
IOH28760
Proline-rich protein 16
Control
0.027601


NM_020175.1
IOH13452
dihydrouridine synthase 3-like (S. cerevisiae)
AD
0.027808




(DUS3L)


BC002695.1
IOH5262
AP2 associated kinase 1 (AAK1)
Control
0.028183


NM_032472.3
IOH44558
Peptidyl-prolyl cis-trans
Control
0.028183




isomerase-like 3


NM_016185.1
IOH4078
hematological and neurological
Control
0.028183




expressed 1 (HN1), transcript




variant 1


BC032372.1
IOH21643
Ral GEF with PH domain and
Control
0.028183




SH3 binding motif 1 (RALGPS1)


NM_002994.2
IOH7295
chemokine (C—X—C motif) ligand 5
Control
0.028183




(CXCL5)


NM_176783.1
IOH40962
proteasome (prosome, macropain)
Control
0.028183




activator subunit 1 (PA28 alpha)




(PSME1), transcript variant 2


BC053872.1
IOH28961
copine V (CPNE5)
Control
0.028183


BC017236.1
IOH14401
Casein kinase I isoform gamma-1
Control
0.028183


BC014667.1
IOH14303
immunoglobulin heavy constant
AD
0.028183




gamma 1 (G1m marker) (IGHG1)


NM_201403.1
IOH42184
MOB1, Mps One Binder kinase
AD
0.028996




activator-like 2C (yeast)




(MOBKL2C), transcript variant 2


NM_006640.2
IOH12164
septin 9 (SEPT9)
Control
0.028996


BC010537.1
IOH10170
SUB1 homolog (S. cerevisiae)
AD
0.029607




(SUB1)


NM_170746.2
IOH58679
Selenoprotein H
AD
0.029607


NM_031296.1
IOH43454
RAB33B, member RAS oncogene
Control
0.030052




family (RAB33B)


NM_032459.1
IOH21413
embryonal Fyn-associated
Control
0.030431




substrate (EFS), transcript variant 2


NM_003092.3
IOH21977
small nuclear ribonucleoprotein
AD
0.030431




polypeptide B′′ (SNRPB2),




transcript variant 1


NM_005105.2
IOH10383
RNA binding motif protein 8A
AD
0.030921




(RBM8A)


BC022571.1
IOH22219
prune homolog 2 (Drosophila)
Control
0.031626




(PRUNE2)


NM_002714.2
IOH39632
protein phosphatase 1, regulatory
Control
0.031794




(inhibitor) subunit 10 (PPP1R10)


NM_153450.1
IOH27352
mediator complex subunit 19
Control
0.031794




(MED19)


BC104468.1
IOH63630
Outer dense fiber protein 3-like
Control
0.031794




protein 2


BC047411.1
IOH26516
tubulin tyrosine ligase-like family,
AD
0.031794




member 2 (TTLL2)


NM_199188.1
IOH38224
La ribonucleoprotein domain
AD
0.031794




family, member 4 (LARP4),




transcript variant 2


BC003551.1
IOH4964
transglutaminase 2 (C polypeptide,
AD
0.032518




protein-glutamine-gamma-




glutamyltransferase) (TGM2)


BC020647.1
IOH12765
coiled-coil domain containing 59
AD
0.032518




(CCDC59)


BC048301.1
IOH26612
zinc finger, CCHC domain
Control
0.032529




containing 11 (ZCCHC11)


BC011781.2
IOH13131
chromosome 9 open reading frame
AD
0.032529




37 (C9orf37)


NM_001033551.1
IOH26533
TOM1-like protein 2
Control
0.032802


NM_177973.1
IOH22150
sulfotransferase family, cytosolic,
Control
0.032802




2B, member 1 (SULT2B1),




transcript variant 2


NM_006907.2
IOH59071
Pyrroline-5-carboxylate reductase
Control
0.032802




1, mitochondrial


NM_032858.1
IOH12001
maelstrom homolog (Drosophila)
AD
0.033103




(MAEL)


NM_144971.1
IOH10719
hypothetical protein MGC26641
AD
0.033103




(MGC26641)


BC017440.1
IOH14659
trafficking protein particle
AD
0.033103




complex 2-like (TRAPPC2L)


BC017018.1
IOH11265
DnaJ (Hsp40) homolog, subfamily
AD
0.033103




C, member 12 (DNAJC12)


NM_144767.3
IOH44040
A kinase (PRKA) anchor protein
AD
0.033103




13 (AKAP13), transcript variant 3


NM_018297.2
IOH6809
N-glycanase 1 (NGLY1)
AD
0.033103


NM_031845.1
IOH37776
microtubule-associated protein 2
Control
0.033103




(MAP2), transcript variant 2


NM_002307.1
IOH40009
lectin, galactoside-binding,
AD
0.03362




soluble, 7 (galectin 7) (LGALS7)


NM_003939.2
IOH42069
beta-transducin repeat containing
AD
0.03362




(BTRC), transcript variant 2,




mRNA.


NM_013242.1
IOH5166
chromosome 16 open reading
AD
0.03362




frame 80 (C16orf80)


NM_152285.1
IOH21698
arrestin domain containing 1
AD
0.033955




(ARRDC1)


NM_178425.1
IOH38634
histone deacetylase 9 (HDAC9),
AD
0.033955




transcript variant 5


NM_007255.1
IOH5828
xylosylprotein beta 1,4-
AD
0.033955




galactosyltransferase, polypeptide




7 (galactosyltransferase I)




(B4GALT7)


NM_205833.1
IOH41224
immunoglobulin superfamily,
AD
0.033955




member 1 (IGSF1), transcript




variant 2


BC040457.1
IOH26807
calcium/calmodulin-dependent
AD
0.033955




protein kinase (CaM kinase) II




alpha (CAMK2A)


NM_004732.1
IOH29581
potassium voltage-gated channel,
AD
0.033955




shaker-related subfamily, beta




member 3 (KCNAB3)


NM_004450.1
IOH14288
enhancer of rudimentary homolog
AD
0.033955




(Drosophila) (ERH)


XM_378582.2
IOH43485
PREDICTED: Homo sapiens
AD
0.033955




hypothetical LOC400523




(LOC400523)


NM_001006666.1
IOH58588
apolipoprotein B mRNA editing
AD
0.033955




enzyme, catalytic polypeptide-like




3F (APOBEC3F), transcript




variant 2, mRNA.


BC041876.1
IOH27738
tau tubulin kinase 2 (TTBK2)
AD
0.033955


BC036335.1
IOH25781
BTB (POZ) domain containing 12
AD
0.033955




(BTBD12)


BC036099.1
IOH27225
aryl-hydrocarbon receptor nuclear
AD
0.033955




translocator 2 (ARNT2)


NM_054012.1
IOH14007
argininosuccinate synthetase 1
AD
0.033955




(ASS1), transcript variant 2


NM_057749.1
IOH43526
cyclin E2 (CCNE2)
AD
0.033955


PV3839

CDC-like kinase 4 (CLK4)
AD
0.033955


BC005026.1
IOH6532
sirtuin (silent mating type
AD
0.033955




information regulation 2 homolog)




6 (S. cerevisiae) (SIRT6)


NM_013975.1
IOH40893
ligase III, DNA, ATP-dependent
AD
0.033955




(LIG3), nuclear gene encoding




mitochondrial protein, transcript




variant alpha


NM_181509.1
IOH42908
microtubule-associated protein 1
AD
0.033955




light chain 3 alpha (MAP1LC3A),




transcript variant 2


BC001709.1
IOH4911
NAD kinase (NADK)
AD
0.033955


NM_002638.1
IOH13658
peptidase inhibitor 3, skin-derived
AD
0.033955




(SKALP) (PI3)


NM_005901.2
IOH22138
SMAD family member 2
AD
0.033955




(SMAD2), transcript variant 1


BC046199.1
IOH26969
family with sequence similarity
AD
0.033955




72, member B (FAM72B)


NM_015417.2
IOH11253
sperm flagellar 1 (SPEF1)
AD
0.033955


NM_018328.1
IOH12893
methyl-CpG binding domain
AD
0.033955




protein 5 (MBD5)


BC017328.2
IOH14721
angiotensin II receptor-associated
AD
0.033955




protein (AGTRAP)


NM_182739.1
IOH44393
NADH dehydrogenase
AD
0.033955




(ubiquinone) 1 beta subcomplex,




6, 17 kDa (NDUFB6), nuclear




gene encoding mitochondrial




protein, transcript variant 2


NM_001032293.1
IOH3584
zinc finger protein 207 (ZNF207),
AD
0.033955




transcript variant 2


NM_012227.1
IOH57121
Putative GTP-binding protein 6
AD
0.033955


BC026039.1
IOH40656
mitochondrial GTPase 1 homolog
AD
0.033955




(S. cerevisiae) (MTG1)


BC072409.1
IOH62546
Serine/threonine-protein
AD
0.033955




phosphatase 4 regulatory subunit




3A


BC066938.1
IOH40083
DEAD (Asp-Glu-Ala-Asp) box
AD
0.034253




polypeptide 43 (DDX43)


BC000712.1
IOH4703
kinesin family member C1
AD
0.034253




(KIFC1)


BC000052.1
IOH4650
peroxisome proliferator-activated
AD
0.035152




receptor alpha (PPARA)


NM_199124.1
IOH43439
chromosome 11 open reading
Control
0.035152




frame 63 (C11orf63), transcript




variant 2


NM_004117.2
IOH27424
FK506 binding protein 5 (FKBP5)
AD
0.035152


NM_002629.2
IOH13682
phosphoglycerate mutase 1 (brain)
AD
0.035152




(PGAM1)


NM_015122.1
IOH26137
FCH domain only 1 (FCHO1)
AD
0.035152


NM_001021.2
IOH27847
ribosomal protein S17 (RPS17)
AD
0.035152


NM_013323.1
IOH3822
sorting nexin 11 (SNX11),
AD
0.035152




transcript variant 2


BC002950.1
IOH46164
chromosome 18 open reading
AD
0.035152




frame 8 (C18orf8)


NM_017612.1
IOH11180
Zinc finger CCHC domain-
AD
0.035152




containing protein 8


BC035048.2
IOH27687
neurogenic differentiation 6
AD
0.035152




(NEUROD6)


BC046117.1
IOH26985
dynein, axonemal, light
AD
0.035152




intermediate chain 1 (DNALI1)


NM_005335.3
IOH57089
Hematopoietic lineage cell-
AD
0.035152




specific protein


NM_144679.1
IOH40679
chromosome 17 open reading
AD
0.035152




frame 56 (C17orf56)


NM_004881.1
IOH3658
tumor protein p53 inducible
AD
0.035152




protein 3 (TP53I3), transcript




variant 1


NM_006442.2
IOH14520
DR1-associated protein 1
Control
0.035766




(negative cofactor 2 alpha)




(DRAP1)


BC047733.1
IOH26736
tRNA aspartic acid
Control
0.035766




methyltransferase 1 (TRDMT1)


NM_033122.1
IOH26918
chromosome 4 open reading frame
Control
0.035766




35 (C4orf35)


NM_080423.1
IOH23012
protein tyrosine phosphatase, non-
Control
0.035766




receptor type 2 (PTPN2),




transcript variant 3


BC015665.2
IOH40642
LATS, large tumor suppressor,
Control
0.035766




homolog 1 (Drosophila) (LATS1)


BC001716.1
IOH4447
poly(A) binding protein
Control
0.035766




interacting protein 2 (PAIP2)


NM_138316.2
IOH59336
Pantothenate kinase 1
Control
0.035766


NM_005900.1
IOH4970
SMAD family member 1
Control
0.035766




(SMAD1), transcript variant 1


BC039337.1
IOH62273
Polyadenylate-binding protein-
Control
0.035766




interacting protein 2


NM_001950.3
IOH23241
E2F transcription factor 4,
Control
0.035766




p107/p130-binding (E2F4)


BC008819.1
IOH6323
nuclear receptor subfamily 1,
Control
0.035766




group H, member 3 (NR1H3)


NM_024818.1
IOH9860
ubiquitin-activating enzyme E1-
Control
0.035766




domain containing 1 (UBE1DC1),




transcript variant 1


NM_004838.2
IOH12410
homer homolog 3 (Drosophila)
Control
0.035766




(HOMER3)


NM_012419.3
IOH11052
regulator of G-protein signaling 17
Control
0.035766




(RGS17)


BC042999.2
IOH25869
Putative Polycomb group protein
Control
0.035766




ASXL2


NM_005441.2
IOH13577
chromatin assembly factor 1,
Control
0.035766




subunit B (p60) (CHAF1B)


BC009055.1
IOH3376
Protein FAM184A
Control
0.035766


BC006818.1
IOH3186
1-acylglycerol-3-phosphate O-
Control
0.035766




acyltransferase 1




(lysophosphatidic acid




acyltransferase, alpha), mRNA




(cDNA clone IMAGE: 3448169),




complete cds.


BC053509.1
IOH29394
5,10-methylenetetrahydrofolate
Control
0.035766




reductase (NADPH) (MTHFR)


BC051888.1
IOH27068
tRNA-yW synthesizing protein 1
Control
0.035766




homolog (S. cerevisiae) (TYW1)


NM_001952.2
IOH6989
E2F transcription factor 6 (E2F6)
Control
0.035766


PV3871

dual-specificity tyrosine-(Y)-
Control
0.035766




phosphorylation regulated kinase 4




(DYRK4)


BC012746.1
IOH14565
mesoderm development candidate
Control
0.035766




2 (MESDC2)


NM_003341.3
IOH43236
Ubiquitin-conjugating enzyme E2
Control
0.035766




E1


NM_138499.2
IOH40143
PWWP domain-containing protein
Control
0.035766




2B


NM_032051.1
IOH13231
POZ (BTB) and AT hook
Control
0.035766




containing zinc finger 1 (PATZ1),




transcript variant 4


BC007565.1
IOH6820
phospholipase C, gamma 2
Control
0.035766




(phosphatidylinositol-specific)




(PLCG2)


NM_022083.1
IOH45531
Protein Niban
Control
0.035766


NM_052940.3
IOH10671
leucine rich repeat containing 42
Control
0.035766




(LRRC42)


BC044884.1
IOH26494
KIAA0265 protein (KIAA0265)
Control
0.035766


BC000452.1
IOH3518
peroxiredoxin 2 (PRDX2)
Control
0.035766


NM_018246.1
IOH40864
coiled-coil domain containing 25
Control
0.035766




(CCDC25)


BC005033.1
IOH6631
actinin, alpha 4 (ACTN4)
Control
0.035766


BC000583.1
IOH22887
Thimet oligopeptidase
Control
0.035766


NM_006406.1
IOH7551
peroxiredoxin 4 (PRDX4)
Control
0.035766


BC034488.2
IOH22312
ATP-binding cassette, sub-family
Control
0.035766




F (GCN20), member 1 (ABCF1)


BC020942.1
IOH11137
transmembrane protein 140
Control
0.035766




(TMEM140)


NM_003223.1
IOH9646
transcription factor AP-4
Control
0.035766




(activating enhancer binding




protein 4) (TFAP4)


BC011863.2
IOH14833
DNA helicase HEL308 (HEL308)
Control
0.035766


NM_025057.1
IOH35314
chromosome 14 open reading
Control
0.035766




frame 45 (C14orf45)


NM_031361.1
IOH4674
collagen, type IV, alpha 3
Control
0.035766




(Goodpasture antigen) binding




protein (COL4A3BP), transcript




variant 2


NM_052965.1
IOH56031
tRNA-splicing endonuclease
Control
0.035766




subunit Sen15


NM_199334.2
IOH6734
thyroid hormone receptor, alpha
AD
0.037822




(erythroblastic leukemia viral (v-




erb-a) oncogene homolog, avian)




(THRA), transcript variant 1


NM_201567.1
IOH37812
cell division cycle 25 homolog A
AD
0.037822




(S. pombe) (CDC25A), transcript




variant 2


BC012945.1
IOH25802
Uncharacterized protein C19orf57
AD
0.038115


NM_005663.2
IOH46152
Wolf-Hirschhorn syndrome
Control
0.038115




candidate 2 (WHSC2)


BC025266.1
IOH23199
taspase, threonine aspartase, 1
Control
0.038169




(TASP1)


NM_014487.2
IOH4416
zinc finger protein 330 (ZNF330)
Control
0.038169


NM_197957.2
IOH41003
MYC associated factor X (MAX),
Control
0.038169




transcript variant 6


NM_006695.2
IOH5798
RUN domain containing 3A
Control
0.038169




(RUNDC3A)


NM_144594.1
IOH10942
family with sequence similarity
Control
0.038169




112, member B (FAM112B)


NM_032146.2
IOH10608
ADP-ribosylation factor-like 6
Control
0.038169




(ARL6), transcript variant 1


BC014218.2
IOH12802
THAP domain-containing protein 3
Control
0.038169


BC037845.1
IOH62213
Multiple coagulation factor
Control
0.038169




deficiency protein 2


BC043394.1
IOH26350
ankyrin repeat domain 17
AD
0.040087




(ANKRD17)


NM_053005.2
IOH40119
HCCA2 protein (HCCA2)
AD
0.040087


NM_175065.2
IOH35055
histone cluster 2, H2ab
AD
0.040087




(HIST2H2AB)


NM_004706.3
IOH45526
Rho guanine nucleotide exchange
AD
0.040087




factor (GEF) 1 (ARHGEF1),




transcript variant 2


NM_014346.1
IOH22792
TBC1 domain family, member
AD
0.040087




22A (TBC1D22A)


NM_133480.1
IOH13139
transcriptional adaptor 3 (NGG1
AD
0.040118




homolog, yeast)-like (TADA3L),




transcript variant 2


BC002448.2
IOH4300
actin binding LIM protein 1
Control
0.041317




(ABLIM1)


BC048969.1
IOH26897
TSPY-like 1 (TSPYL1)
AD
0.041317


NM_020319.1
IOH27320
ankyrin repeat and MYND domain
AD
0.041317




containing 2 (ANKMY2)


NM_016046.2
IOH11580
exosome component 1 (EXOSC1)
AD
0.042299


NM_001003396.1
IOH3597
tumor protein D52-like 1
AD
0.042315




(TPD52L1), transcript variant 3


NM_005870.3
IOH53845
Histone deacetylase complex
AD
0.042315




subunit SAP18


NM_003403.3
IOH27684
YY1 transcription factor (YY1)
AD
0.042315


BC036096.2
IOH27280
zinc finger protein 18 (ZNF18)
AD
0.042315


NM_001010844.1
IOH43230
Interleukin-1 receptor-associated
AD
0.043024




kinase 1-binding protein 1


BC029524.1
IOH22562
Coiled-coil domain-containing
AD
0.04393




protein 46


NM_005884.2
IOH2475
p21(CDKN1A)-activated kinase 4
Control
0.04393




(PAK4), transcript variant 1


NM_033642.1
IOH36760
fibroblast growth factor 13
Control
0.045355




(FGF13), transcript variant 1B


BC058900.1
IOH29076
rabaptin, RAB GTPase binding
Control
0.045355




effector protein 2 (RABEP2)


BC015239.1
IOH10789
zinc finger and BTB domain
Control
0.045355




containing 8 (ZBTB8)


NM_001005339.1
IOH13018
regulator of G-protein signaling 10
Control
0.045355




(RGS10), transcript variant 1


NM_006819.1
IOH5061
stress-induced-phosphoprotein 1
Control
0.045355




(Hsp70/Hsp90-organizing protein)




(STIP1)


NM_152387.2
IOH53987
BTB/POZ domain-containing
AD
0.045355




protein KCTD18


BC002369.1

Serine/threonine-protein kinase
AD
0.045355




PLK1


BC092404.1
IOH62574
Rap guanine nucleotide exchange
AD
0.045786




factor 3


NM_004922.2
IOH38664
SEC24 related gene family,
AD
0.046722




member C (S. cerevisiae)




(SEC24C), transcript variant 1


NM_198217.1
IOH59743
Inhibitor of growth protein 1
AD
0.046722


BC051911.1
IOH27047
chromosome 13 open reading
AD
0.046722




frame 24 (C13orf24)


NM_006205.1
IOH40356
phosphodiesterase 6H, cGMP-
AD
0.046722




specific, cone, gamma (PDE6H)


NM_024790.2
IOH13277
centrosome and spindle pole
Control
0.046828




associated protein 1 (CSPP1),




transcript variant 2


NM_006439.3
IOH12221
Protein mab-21-like 2
AD
0.046828


NM_173456.1
IOH45493
phosphodiesterase 8A (PDE8A),
AD
0.048209




transcript variant 4


BC019268.1
IOH13177
Protein arginine N-
AD
0.048209




methyltransferase 1


NM_173642.1
IOH26158
family with sequence similarity
AD
0.048209




80, member A (FAM80A)


NM_194299.1
IOH35431
Synaptonemal complex protein 2-
AD
0.048209




like


BC062323.1
IOH40678
chromosome 21 open reading
AD
0.048209




frame 25 (C21orf25)


NM_021709.1
IOH21450
Apoptosis regulatory protein Siva
AD
0.048209


BC100813.1
IOH63506
Putative T-complex protein 1
AD
0.048209




subunit theta-like 2


BC026317.1
IOH11060
solute carrier family 16, member 1
AD
0.048209




(monocarboxylic acid transporter




1) (SLC16A1)


BC010956.1
IOH13684
Keratinocyte growth factor
AD
0.048209


NM_005034.2
IOH10479
polymerase (RNA) II (DNA
AD
0.048209




directed) polypeptide K, 7.0 kDa




(POLR2K)


BC024291.1
IOH14775
BR serine/threonine kinase 2
AD
0.048209




(BRSK2)


NM_001001568.1
IOH53504
phosphodiesterase 9A (PDE9A),
AD
0.048209




transcript variant 3, mRNA.


NM_014314.3
IOH52971
Probable ATP-dependent RNA
AD
0.048209




helicase DDX58


BC047420.1
IOH26512
UBX domain-containing protein 7
AD
0.048209


NM_000430.2
IOH39940
platelet-activating factor
AD
0.048209




acetylhydrolase, isoform Ib, alpha




subunit 45 kDa (PAFAH1B1)


PV3873

epidermal growth factor receptor
AD
0.048209




(erythroblastic leukemia viral (v-




erb-b) oncogene homolog, avian)




(EGFR); see catalog number for




detailed information on wild-type




or point mutant status


NM_001328.1
IOH12818
C-terminal binding protein 1
AD
0.048209




(CTBP1), transcript variant 1


NM_001009959.1
IOH43447
Ermin
AD
0.048209


BC050387.1
IOH26653
ankyrin repeat and sterile alpha
AD
0.048209




motif domain containing 3




(ANKS3)


NM_007194.1

Serine/threonine-protein kinase
AD
0.048209




Chk2


NM_018492.2
IOH12390
PDZ binding kinase (PBK)
AD
0.048209


NM_182801.1
IOH23237
EGF-like, fibronectin type III and
AD
0.048209




laminin G domains (EGFLAM),




transcript variant 4


BC016615.1
IOH10688
RAB37, member RAS oncogene
AD
0.048209




family (RAB37)


BC008950.2
IOH56909
Prenylated Rab acceptor protein 1
AD
0.048209


BC041831.1
IOH27713
transducin-like enhancer of split 3
AD
0.048209




(E(sp1) homolog, Drosophila)




(TLE3)


NM_003104.2
IOH14671
sorbitol dehydrogenase (SORD)
AD
0.048209


BC003555.1
IOH4980
nucleolar complex associated 2
AD
0.048209




homolog (S. cerevisiae) (NOC2L)


NM_001274.2

CHK1 checkpoint homolog (S. pombe)
AD
0.048209




(CHEK1)


NM_153645.1
IOH11663
nucleoporin 50 kDa (NUP50),
AD
0.048209




transcript variant 3


BC017423.1
IOH12806
mesoderm induction early
AD
0.048209




response 1 homolog (Xenopus




laevis) (MIER1)


BC007424.2
IOH6160
PRP4 pre-mRNA processing
AD
0.048209




factor 4 homolog (yeast) (PRPF4)


NM_007107.2
IOH13133
signal sequence receptor, gamma
AD
0.048209




(translocon-associated protein




gamma) (SSR3)


XM_096472.2
IOH42996
hypothetical LOC143678
AD
0.048209




(LOC143678)


NM_015698.2
IOH3563
G patch domain and KOW motifs
AD
0.048209




(GPKOW)


NM_018111.1
IOH57283
Putative uncharacterized protein
AD
0.048209




FLJ10490


NM_006694.1
IOH2941
jumping translocation breakpoint
AD
0.048209




(JTB)


NM_000045.2
IOH14233
arginase, liver (ARG1)
AD
0.048209


BC074765.2
IOH59064
POU domain, class 6, transcription
AD
0.048209




factor 1


NM_172028.1
IOH42497
ankyrin repeat and BTB (POZ)
AD
0.048209




domain containing 1 (ABTB1),




transcript variant 3


BC026345.1
IOH10790
Ermin
AD
0.048209


NM_201262.1
IOH41260
DnaJ (Hsp40) homolog, subfamily
AD
0.048209




C, member 12 (DNAJC12),




transcript variant 2


NM_002966.1
IOH14651
S100 calcium binding protein A10
AD
0.048209




(S100A10)


BC013352.1
IOH14736
HpaII tiny fragments locus 9c
AD
0.048209




protein


NM_004873.1
IOH26366
BCL2-associated athanogene 5
AD
0.048209




(BAG5), transcript variant 2


BC009415.1
IOH14115
kinesin family member 26A
AD
0.048209




(KIF26A)


BC012539.1
IOH12758
mediator complex subunit 31
AD
0.048209




(MED31)


BC021247.1
IOH22996
Phosphatase and actin regulator 4
AD
0.048209


NM_004414.3
IOH5722
regulator of calcineurin 1
AD
0.048209




(RCAN1), transcript variant 1


BC028840.1
IOH13887
ankyrin repeat domain 13C
AD
0.048209




(ANKRD13C)


BC025787.1
IOH12000
alkB, alkylation repair homolog 1
AD
0.048209




(E. coli) (ALKBH1)


NM_000459.1

Angiopoietin-1 receptor
AD
0.048209


NM_000788.1
IOH42066
Deoxycytidine kinase
AD
0.048209


NM_173859.1
IOH35196
breast cancer and salivary gland
AD
0.048209




expression gene (RP11-49G10.8)


NM_152382.1
IOH39899
JmjC domain-containing protein
AD
0.048209




C2orf60


NM_002038.2
IOH14517
interferon, alpha-inducible protein
AD
0.048209




6 (IFI6), transcript variant 1


BC034984.1
IOH26875
Kinesin-like protein KIF16B
AD
0.048209


NM_014582.1
IOH40248
odorant binding protein 2A
AD
0.048209




(OBP2A)


BC057760.1
IOH29220
MORN repeat-containing protein 3
AD
0.048209


NM_005595.1
IOH12791
nuclear factor I/A (NFIA)
AD
0.048209


NM_032726.1
IOH21106
phospholipase C, delta 4 (PLCD4)
AD
0.048209


NM_153276.1
IOH21851
solute carrier family 22 (organic
AD
0.048209




anion transporter), member 6




(SLC22A6), transcript variant 2


NM_001011538.1
IOH39826
similar to 60S ribosomal protein
AD
0.048209




L21 (LOC402176)


NM_006433.2
IOH27865
granulysin (GNLY), transcript
AD
0.048209




variant NKG5


NM_024800.1

Serine/threonine-protein kinase
AD
0.048209




Nek11


NM_015850.2

Basic fibroblast growth factor
AD
0.048209




receptor 1


NM_006590.2
IOH45672
ubiquitin specific peptidase 39
AD
0.048209




(USP39)


NM_199054.1
IOH37765
MAP kinase interacting
AD
0.048209




serine/threonine kinase 2




(MKNK2), transcript variant 2


BC050696.1
IOH27004
chromosome 12 open reading
AD
0.048209




frame 48 (C12orf48)


NM_024563.1
IOH23059
chromosome 5 open reading frame
AD
0.048209




23 (C5orf23)


NM_004832.1
IOH4381
glutathione S-transferase omega 1
AD
0.048209




(GSTO1)


NM_003242.2

transforming growth factor, beta
AD
0.048209




receptor II (70/80 kDa) (TGFBR2),




transcript variant 2


BC050444.1
IOH26738
golgi autoantigen, golgin
AD
0.048209




subfamily a, 4 (GOLGA4)


NM_201259.1
IOH45586
Mitochondrial import inner
AD
0.048209




membrane translocase subunit




TIM14


NM_032124.3
IOH27146
haloacid dehalogenase-like
AD
0.048209




hydrolase domain containing 2




(HDHD2)


NM_002870.1
IOH3059
RAB13, member RAS oncogene
AD
0.048209




family (RAB13)


BC000337.2
IOH3577
glucose-6-phosphate
AD
0.048209




dehydrogenase (G6PD)


BC060785.1
IOH29158
tripartite motif-containing 40
AD
0.048209




(TRIM40)


BC030597.1
IOH22318
ATR interacting protein (TREX1)
AD
0.048209


BC050551.1
IOH26948
BCL2-associated athanogene 5
AD
0.048209




(BAG5)


NM_004697.3
IOH12861
PRP4 pre-mRNA processing
AD
0.048209




factor 4 homolog (yeast) (PRPF4)


NM_020990.2
IOH5022
creatine kinase, mitochondrial 1B
AD
0.048209




(CKMT1B), nuclear gene




encoding mitochondrial protein


BC039742.1
IOH26173
poly(rC) binding protein 1
AD
0.048209




(PCBP1)


BC021573.1
IOH14848
GTP-binding protein 10
AD
0.048209


NM_015068.1
IOH27074
paternally expressed 10 (PEG10),
AD
0.048209




transcript variant 1


NM_001827.1
IOH5978
CDC28 protein kinase regulatory
AD
0.048209




subunit 2 (CKS2)


NM_152876.1
IOH50154
Tumor necrosis factor receptor
AD
0.048209




superfamily member 6


BC015548.1
IOH10351
RAB3A interacting protein
AD
0.048209




(rabin3) (RAB3IP)


BC062359.1
IOH40676
chromosome 8 open reading frame
AD
0.048209




47 (C8orf47)


BC029424.1
IOH23140
Probable glutathione peroxidase 8
AD
0.048209


NM_001786.2
IOH14583
cell division cycle 2, G1 to S and
AD
0.048209




G2 to M (CDC2), transcript




variant 1


BC000870.1
IOH3246
TIMELESS interacting protein
AD
0.048209




(TIPIN)


NM_004103.2

Protein tyrosine kinase 2 beta
AD
0.048209


BC022454.2
IOH10977
Transient receptor potential cation
AD
0.048209




channel subfamily M member 3


NM_024046.1
IOH21132
CaM kinase-like vesicle-
AD
0.048209




associated (CAMKV)


BC040521.1
IOH27477
testis expressed 2 (TEX2)
AD
0.048209


BC003164.1
IOH46140
leukocyte receptor cluster (LRC)
AD
0.048209




member 4 (LENG4)


NM_000402.2
IOH2390
Glucose-6-phosphate 1-
AD
0.048209




dehydrogenase


BC069328.1
IOH40255
Bcl2 modifying factor (BMF)
AD
0.048209


BC063463.1
IOH39865
coenzyme Q3 homolog,
AD
0.048209




methyltransferase (S. cerevisiae)




(COQ3)


NM_000572.2
IOH29878
Interleukin-10
AD
0.048209


NM_006374.2

serine/threonine kinase 25 (STE20
AD
0.048209




homolog, yeast) (STK25)


NM_017966.1
IOH5829
vacuolar protein sorting 37
AD
0.048209




homolog C (S. cerevisiae)




(VPS37C)


BC052602.1
IOH29373
carbonic anhydrase XIII (CA13)
AD
0.048209


BC018063.1
IOH10722
potassium channel tetramerisation
AD
0.048209




domain containing 4 (KCTD4)


NM_031305.1
IOH38124
Rho GTPase activating protein 24
AD
0.048209




(ARHGAP24), transcript variant 2


BC056401.1
IOH28794
centaurin, delta 2 (CENTD2)
AD
0.048209


BC022459.1
IOH11064
sulfotransferase family 4A,
AD
0.048209




member 1 (SULT4A1)


XM_373630.2
IOH41531
PREDICTED: Homo sapiens
AD
0.048209




hypothetical protein LOC145842




(LOC145842)


P3049

v-abl Abelson murine leukemia
AD
0.048209




viral oncogene homolog 1




(ABL1), transcript variant a; see




catalog number for detailed




information on wild-type or point




mutant status


NM_153012.1
IOH12147
Tumor necrosis factor ligand
AD
0.048209




superfamily member 12


NM_018270.3
IOH14702
MRG-binding protein
AD
0.048209


BC010739.1
IOH9887
COP9 signalosome complex
AD
0.048209




subunit 7b


NM_015002.2
IOH42260
F-box protein 21 (FBXO21),
AD
0.048209




transcript variant 2


BC000497.1

CaM kinase-like vesicle-
AD
0.048209




associated protein


NM_001449.2
IOH13860
four and a half LIM domains 1
AD
0.048209




(FHL1)


BC065912.1
IOH40442
Tyrosine-protein kinase ABL2
AD
0.048209


NM_153356.1
IOH27369
TBC1 domain family, member 21
AD
0.048209




(TBC1D21)


BC032382.1
IOH21661
similar to pleckstrin homology
AD
0.048209




domain containing, family M




(with RUN domain) member 1;




adapter protein 162, mRNA,




complete cds.


BC094800.1
IOH62619
Jouberin
AD
0.048362


NM_207035.1
IOH41684
UPF0471 protein C1orf63
Control
0.048362




homolog


NM_003897.2
IOH6603
immediate early response 3 (IER3)
AD
0.048717


NM_178821.1
IOH22298
WD repeat domain 69 (WDR69)
AD
0.048717


NM_198219.1
IOH59467
Inhibitor of growth protein 1
AD
0.048717


NM_024805.1
IOH13501
chromosome 18 open reading
AD
0.048717




frame 22 (C18orf22)


NM_001040633.1
IOH61663
protein kinase, AMP-activated,
AD
0.048717




gamma 2 non-catalytic subunit




(PRKAG2), transcript variant c,




mRNA.


NM_130807.1
IOH10112
MOB1, Mps One Binder kinase
AD
0.049919




activator-like 2A (yeast)




(MOBKL2A)


BC008623.1
IOH3309
roundabout, axon guidance
AD
0.049919




receptor, homolog 3 (Drosophila)




(ROBO3)


NM_001004285.1
IOH45460
DNA fragmentation factor, 40 kDa,
AD
0.049919




beta polypeptide (caspase-




activated DNase) (DFFB),




transcript variant 3


BC011885.1
IOH14206
eukaryotic translation initiation
AD
0.049919




factor 2A, 65 kDa (EIF2A)









Using a small subset of the identified indicators, it was possible to diagnose AD with great efficiency. The twenty protein microarray fluorescence values depicted in Table 4 were used to classify blinded samples as either Alzheimer's or control. A threshold value was calculated for each diagnostic indicator using the following equation:

Diagnostic Threshold=[(Mean AD Fluorescence Value)−(Mean Control Fluorescence Value)/2]+(Mean Control Fluorescence Value)

A fluorescence value for any given diagnostic indicator over the threshold value for that indicator is scored as a positive result. Using the antigens from Table 4, greater than or equal to four positive results out of the possible twenty diagnostic indicators predicts with high accuracy that the sample is from an Alzheimer's Disease patient. Less than four positive results out of the possible twenty diagnostic indicators on Table 4 predicts with high accuracy that the sample is from a healthy Control. (See FIG. 1.) Initial results with this diagnostic logic were as follows:
Alzheimer's Disease (AD) vs. All Controls
(Using twenty biomarkers from Table 4)
(See FIG. 1)
N=90 (50 AD, 40 Control)
Overall Error Rate: 4.44%












Predicted/True
AD
Control

















AD
50
4


Control
0
36


Error Rate
0.000
0.010









Example 9
Diagnosis of Alzheimer's Disease
Twenty antibodies and their respective antigens were selected that were rated as highly significant by multiple statistical analysis programs (Prospector, PAM, Random Forest) and performed well in a single platform. The antibodies are listed in Table 8.







TABLE 8







Diagnostic Autoantibodies in Alzheimer's Disease













MW




Database ID #:
Name:
(kDa):
Indication:
Reactivity:














BC051695.1
FRMD8
51.2
Alzheimer's
↑ AD, ↓CON


NM_015833.1
ADARB1
80.8
Alzheimer's
↑ AD, ↓CON


NM_002305.2
LGALS1
14.7
Alzheimer's
↑ AD, ↓CON


NM_001641.2
APEX1
35.6
Alzheimer's
↑ AD, ↓CON


NM_024316.1
LENG1
30.5
Control
↓ AD, ↑CON


NM_014280.1
DnaJ 
29.8
Alzheimer's
↑ AD, ↓CON



homolog






subfamily C






member 8





PHC1244
CCL19
11.0
Alzheimer's
↑ AD, ↓CON


BC064984.1
ASXL1
9.5
Alzheimer's
↑ AD, ↓CON


NM_021104.1
RPL41
3.4
Alzheimer's
↑ AD, ↓CON


BC004236.2
UBE2S
23.9
Alzheimer's
↑ AD, ↓CON


NM_012387.1
PADI4
74.1
Alzheimer's
↑ AD, ↓CON


NM_003384.1
VRK1
45.5
Alzheimer's
↑ AD, ↓CON


NM_004113.3
FGF12
27.4
Alzheimer's
↑ AD, ↓CON


BC021174.1
Small
12.4
Alzheimer's
↑ AD, ↓CON



EDRK-rich






factor 1





NM_001001794.1
FAM116B
66.5
Alzheimer's
↑ AD, ↓CON


NM_032377.2
ELOF1
9.5
Alzheimer's
↑ AD, ↓CON


NM_024754.2
PTCD2
43.9
Alzheimer's
↑ AD, ↓CON


NM_000984.2
RPL23A
17.7
Alzheimer's
↑ AD, ↓CON


NM_139016.2
C20orf198

Alzheimer's
↑ AD, ↓CON


NM_024668.1
ANKHD1
269.5
Alzheimer's
↑ AD, ↓CON









With these twenty biomarkers (listed in Table 4 and Table 8) and the simple diagnostic logic explained above, it was possible to differentiate Alzheimer's Disease serum samples from Control serum samples with over 95% efficiency.
It is also possible to accurately diagnose using only the four biomarkers from Table 3. Diagnostic efficiency for these diagnostic indicators was assessed for AD, low Mini-Mental Status Examination (MMSE) AD and high-MMSE AD. The results are shown below.
Alzheimer's Disease (AD) vs. All Controls
Random Forest:
N=90 (50 AD, 40 Control)
Overall Error Rate: 7.78%












Predicted/True
AD
Control

















AD
48
5


Control
2
35


Error Rate
0.040
0.125









Predictive Analysis of Microarrays (PAM):

N=90 (50 AD, 40 Con)

Overall Error Rate: 7.8%













Predicted/True
AD
Control







AD
50   
7   


Control
0   
33   


Error Rate
0.000
0.175









Low-MMSE AD vs. All Controls

(Low-MMSE AD samples have MMSE<15)
Random Forest:
N=55 (15 Low-MMSE AD, 40 Control)
Overall Error Rate: 7.26%












Predicted/True
AD
Control







AD
13   
2   


Control
2   
38   


Error Rate
0.133
0.050









Predictive Analysis of Microarrays (PAM):

N=30 (15 Low-MMSE AD, 15 Control)

Overall Error Rate: 9.9%













Predicted/True
AD
Control







AD
13   
1   


Control
2   
14   


Error Rate
0.133
0.067









High-MMSE AD vs. All Controls

(High-MMSE AD samples have MMSE≧15)
Random Forest:
N=75 (35 High-MMSE AD, 40 Control)
Overall Error Rate: 10.67%












Predicted/True
AD
Control







AD
32   
5   


Control
3   
35   


Error Rate
0.086
0.125









Predictive Analysis of Microarrays (PAM):

N=70 (35 High-MMSE AD, 35 Control)

Overall Error Rate: 12.8%













Predicted/True
AD
Control







AD
28   
2   


Control
7   
33   


Error Rate
0.200
0.057









Using a combination of the biomarkers listed in Tables 3 and 5 (totaling nine diagnostic indicators), the efficiency of distinction between AD and Parkinson's Disease was also assessed. The results are shown below.
Alzheimer's Disease (AD) vs. Parkinson's Disease (PK)
Random Forest:
N=79 (29 AD, 29 PK)
Overall Error Rate: 12.07%












Predicted/True
AD
PK







AD
25   
3   


PK
4   
26   


Error Rate
0.138
0.103









Predictive Analysis of Microarrays (PAM):

N=58 (29 AD, 29 PK)

Overall Error Rate: 12.0%













Predicted/True
AD
PK







AD
24   
2   


PK
5   
27   


Error Rate
0.172
0.069









It was determined that it was possible to differentiate AD and control with over 95% accuracy using the twenty antigens from Table 4 and over 90% accuracy using the four antigens on Table 3, however, the use of only these four indicators did not allow accurate differentiation of Alzheimer's Disease from other neurodegenerative diseases like Parkinson's Disease. Accurate differentiation requires the inclusion of antigens from Table 5. In practice, however, this distinction is often unnecessary, since patients presenting with suspected Alzheimer's disease come with memory and cognitive deficits, whereas patients with early Parkinson's most often show tremors with no complaints of cognitive and/or memory deficits.
All references cited herein are incorporated by reference herein in their entireties.

## Claims

1. A method for detecting neurodegenerative disease diagnostic autoantibodies in a subject in need thereof comprising:
(a) obtaining an immunoglobulin-containing biological sample from the subject, and
(b) performing an assay on said biological sample to determine the presence of autoantibodies in the biological sample, wherein said assay comprises the steps of:
(i) forming immunocomplexes between autoantibodies targeting at least two autoantigens selected from the group consisting of centaurin, alpha 2 (CENTA 2), jumonji domain containing 2D (JMJD2D); pentatricopeptide repeat domain 2 (PTCD2); lectin, galactoside-binding, soluble, 1 (galectin 1)(LGALS1); and regulating synaptic membrane exocytosis 4 (RIMS4); and
(ii) detecting the presence of said immunocomplexes.

2. The method of claim 1, wherein said subject is a human.

3. The method of claim 1, wherein said biological sample is selected from the group consisting of whole blood, serum, cerebrospinal fluid, saliva, and sputum.

4. The method of claim 1 wherein the autoantigens are attached to a substrate and are in the form of an array.

5. The method of claim 4 wherein the array is a microarray.

6. The method of claim 5, wherein said microarray contains up to 882 autoantigens.

7. The method of claim 5, wherein said microarray further contains an additional autoantigen selected from the group consisting of pentatricopeptide repeat domain 2 (PTCD2); FERM domain containing 8 (FRMD8); chromosome 9 open reading frame 9 (C9orf9); lectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1); proopiomelanocortin (adrenocorticotropin/beta-lipotropin/alpha-melanocyte stimulating hormone/beta-melanocyte stimulating hormone/beta-endorphin) (POMC), transcript variant 2; mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5), transcript variant 1; DnaJ homolog subfamily C member 8; ankyrin repeat and KH domain containing 1 (ANKHD1), transcript variant 3; mitochondrial ribosomal protein L34 (MRPL34), nuclear gene encoding mitochondrial protein; tripartite motif-containing 21 (TRIM21); four and a half LIM domains 1 (FHL1); tripartite motif-containing 21 (TRIM21); four and a half LIM domains 1 (FHL1); xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I) (B4GALT7); vacuolar protein sorting 37 homolog C (S. cerevisiae) (VPS37C); myotilin (MYOT); cDNA clone MGC:40426 IMAGE:5178085, complete cds; Rap guanine nucleotide exchange factor 4 (RAPGEF4); Nucleolar and spindle-associated protein 1; tumor protein p53 inducible protein 3 (TP53I3), transcript variant 1; Serine/threonine-protein kinase 12; additional sex combs like 1 (ASXL1); vaccinia related kinase 1 (VRK1); intercellular adhesion molecule 4 (ICAM4), transcript variant 1; casein kinase 2, alpha prime polypeptide (CSNK2A2); ribosomal protein L41 (RPL41), transcript variant 1; cDNA clone MGC:27376 IMAGE:4688477, complete eds; peptidyl arginine deiminase, type IV (PADI4); Signal recognition particle 19 kDa protein; fibroblast growth factor 12 (FGF12); Coiled-coil domain-containing protein 28A; fibroblast growth factor 12 (FGF12), transcript variant 1; Golgi-associated plant pathogenesis-related protein 1; ubiquitin-conjugating enzyme E2S (UBE2S); 60S ribosomal protein L22; WD repeat domain 5 (WDR5), transcript variant 1; immunoglobulin heavy constant gamma 3 (G3m marker) (IGHG3); cyclic AMP phosphoprotein, 19 kD (ARPP-19); cDNA clone MGC:31944 IMAGE:4878869 complete cds; coiled-coil domain containing 72 (CCDC72); chemokine (C-C motif) ligand 19 (CCL19); immunoglobulin lambda constant 1 (IGLC1); Serine/threonine-protein kinase 6; serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 (SERPINE2); FACT complex subunit SPT16; eukaryotic translation initiation factor 1A, Y-linked (EIF1AY); protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) (PIN4); elongation factor 1 homolog (ELOF1); RNA (guanine-9-)-methyltransferase domain-containing protein 3; Cyclin-dependent kinase-like 1; and MAP kinase-activated protein kinase 3.

8. The method of claim 7, further wherein the presence of at least one immunocomplex between the autoantibodies in the biological sample targeting said additional autoantigens is detected.

9. The method of claim 4 wherein the substrate is a nitrocellulose-coated glass slide.

10. The method of claim 1, wherein the presence of immunocomplexes between autoantibodies targeting centaurin, alpha 2 (CENTA 2), and at least two additional autoantigens selected from the group consisting of jumonji domain containing 2D (JMJD2D); pentatricopeptide repeat domain 2 (PTCD2); lectin, galactoside-binding, soluble, 1 (galectin 1 or LGALS1); and regulating synaptic membrane exocytosis 4 (RIMS4) is detected.

11. The method of claim 10, wherein the presence of immunocomplexes between autoantibodies targeting centaurin, alpha 2 (CENTA 2), jumonji domain containing 2D (JMJD2D); pentatricopeptide repeat domain 2 (PTCD2); and lectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1) is detected.

12. The method of claim 10, wherein the presence of immunocomplexes between autoantibodies targeting centaurin, alpha 2 (CENTA 2), jumonji domain containing 2D (JMJD2D); pentatricopeptide repeat domain 2 (PTCD2); and regulating synaptic membrane exocytosis 4 (RIMS4) is detected.

13. A method of generating a subject-specific, neurodegenerative disease-specific autoantibody profile comprising:
(a) obtaining an immunoglobulin-containing biological sample from a subject,
(b) performing an assay on said biological sample to determine the presence of more than one neurodegenerative disease diagnostic autoantibodies in the biological sample, wherein said assay comprises the steps of:
(i) forming immunocomplexes between autoantibodies targeting at least two autoantigens selected from the group consisting of centaurin, alpha 2 (CENTA 2), jumonji domain containing 2D (JMJD2D); pentatricopeptide repeat domain 2 (PTCD2); lectin, galactoside-binding, soluble, 1 (galectin 1)(LGALS1); and regulating synaptic membrane exocytosis 4 (RIMS4);
(ii) detecting the presence of said immunocomplexes, and

(c) generating a subject-specific neurodegenerative disease-specific autoantibody profile of the autoantibodies present in the sample.